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Extracellular vesicle is a wide term that involves many different types of vesicles. Almost 
all the cell types studied secrete vesicles to the extracellular environment related to cell–
cell communication. Extracellular vesicles have been found in different biological fluids, 
such as blood, milk, saliva, tears, urine, and cerebrospinal fluid. These vesicles transport 
different molecules, including mRNA, proteins, and lipids, some of them cell type 
specific that make them ideal biomarkers in both health and disease conditions. However, 
their contribution to different conditions is not well understood. The aim of this book 
is to provide an overview of the extracellular vesicles in the human body, how they are 
internalized, and their participation in several diseases.
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Preface
The study of extracellular vesicles (EVs) is a clear focus of the interest of the scientific
community to understand the communication between cells, and is also being used
in the healthcare system in several ways, from diagnosis to prognosis of a number
of diseases. This new field of study is focused on identifying different types of EVs
that are released by all the cells and their participation in different pathways. Their
content is also different attending to the purpose of the cell. Therefore, they may
represent a useful resource for knowledge in cell biology, cell communication, and
participation in human diseases. Over the last few years, several efforts have studied
the use of EVs as a useful source for diagnostic, prognostic, and therapeutic markers.
The goal of this book is to provide a clear picture of the current knowledge of the
vesicles secreted by cells. The book reviews the field of EVs, including a description
of EVs, the different purification techniques, their use in the medical field, and also
their participation in different diseases. The book includes six chapters, each one
focused on specific aspects. Each chapter provides an overview of EVs in the field of
study and gives the reader a general idea of where the current research is heading. 
The chapters in this book are organized in three sections. Section 1, “Introduction
to the extracellular vesicles,” includes two chapters. Chapter 1 introduces the book
with a general statement of EVs in human health. Chapter 2 is focused on the
identification of EVs in human milk. EVs have been identified in different body
fluids, but the study of milk EVs is not full characterized. The chapter describes a
full characterization of the content of milk EVs (proteins, lipids, and nucleic acids) 
and a discussion of how milk EVs could be useful in medicine and biotechnology. 
The chapter also includes an exhaustive introduction to the isolation, purification, 
and analysis of EVs. The second section, “The biology of extracellular vesicles,” 
is comprised of two chapters. Chapter 3 reviews different types of endocytosis
pathways and how cell type can dictate the mechanisms of exosome internalization. 
EV internalization changes from cell to cell and within the same cell. The use of EVs
for therapeutics could be addressed by the characterization of cell–EV interaction
in the body. In Chapter 4, the author reviews applications of lipid metabolizing 
enzymes, due to analytical results of the kinetic theory of membrane enzymes. 
Three chapters comprise the third and last section of the book, “Extracellular
vesicles in human diseases.” Chapter 5 addresses the current knowledge about the
role of EVs in cancer, focusing primarily on ovarian and breast cancer. The chapter
gives a detailed introduction to the different EVs characterized, including a com-
plete overview and their roles in tumor microenvironment, tumorigenesis, and 
metastasis. Chapter 6 describes the role of EVs in modulating diabetic cardiovascu-
lar diseases. This chapter describes the function of EVs in physiological processes
and immune response and how EVs could be clinical biomarkers and therapeutic
targets in diabetic cardiovascular diseases, including atherosclerosis, coronary
artery disease, cerebrovascular disease, and peripheral arterial disease. Chapter 7 
reviews the participation of EVs in neurodegenerative diseases. The authors present
the biological content of EVs and the methods used for their isolation, analysis, and 
their importance in brain pathology and potential role in the prognosis and diagno-
sis of human health and disease.
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This book is the result of all the experts who have participated in the research of EVs 
over the years, making it possible to achieve a vast degree of knowledge in the field. 
We would like to thank all the authors who have contributed, the reviewers, the 
editorial office, and editors who have assisted with this book. Hopefully, this book 
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Introductory Chapter: An 
Overview to the Extracellular 
Vesicles
Ana Gil-Bona and Jose Antonio Reales-Calderon
1. Extracellular vesicles
Cells are basic structural, functional, and biological units delimited by a plasma 
membrane that contains all the molecules necessaries for living. Cells could be 
a complete organism, such as yeast or bacterium, or form part of a multicellular 
organism which is specialized, such as neurons or adipocytes. The communication 
between cells is very important to react to the environment and to initiate signaling 
cascades in all the organisms, from bacteria to eukaryotes. This communication 
involves the secretion of proteins to the extracellular environment through direct 
secretion (classical secretion pathways) or can be mediated by the secretion of 
extracellular vesicles (EVs). This communication allows cells sending and receiving 
messages about the inside and the outside environment. Different strategies are 
applied for cellular crosstalk. Current studies have emerged as EVs as an important 
mechanism of cell communication [1, 2]. The secretion of EVs is a well conserved 
process through all the organisms, from bacteria to mammals [3].
The term extracellular vesicle includes a heterogeneous group of membrane 
vesicles with diverse origins, sizes, and shapes. EVs are being identified in almost 
all the cells, from prokaryotic to eukaryotic, and not only in healthy conditions but 
also associated with many diseases [4]. The composition, origin, and functions are 
the focus of attention of researchers and clinicians. The number of papers published 
yearly in Pubmed related to EVs has increased exponentially during the last 10 years 
(Figure 1). Despite the enormous amount of data published and because of that, 
there are many new questions unanswered. We still cannot claim the complete 
understanding of the function of these vesicles in the cell.
The release of EVs to the media allows the cell sending and receiving messages 
without direct interaction. The content of EVs could participate in controlling 
important processes, such as growth and differentiation, pathogenesis or metabolic 
processes. The diversity and complexity of EVs are enormous. Each cell can pro-
duce different types of EVs, varying the biogenesis process and the content. The 
term of EVs is a generic term for all types of vesicles. There are different types of 
EVs attending to their function, size, and content [5]. Three EV types are mainly 
accepted: exosomes (30–90 nm), microvesicles (100 up to 1 μm), and apoptotic 
bodies. The EVs are formed by lipid bilayer with integrated proteins. This capsule 
protects the inside content from the proteases and nucleases that can affect their 
content. EVs transport lipids, proteins, growth factors, and RNA. In summary, the 
EVs are able to transfer genetic material and proteins that can contribute to change 
the receiving cell. Although, the main components are the same, different EVs from 
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2. Study of EVs
EVs can be released and interact with the target cell through different mecha-
nisms. Currently, there are several databases that serve as resource for EVs research: 
Vesiclepedia [6, 7], EVpedia [8–10], ExoCarta [11–14], and EVmiRNA [15]. These 
databases include data from different organisms, type of vesicle, and content type 
(protein, mRNA, miRNA, and lipid). The composition of each kind of EV derives 
from the cell and purpose of the vesicle realized to the media. As such, these vesicles 
became an important marker for diseases, including cancer, infectious diseases, 
renal diseases, and diabetes [16–20]. In order to achieve this, EVs must be character-
ized and analyze their confidence to be candidates for those used by humans. The 
isolation and purification of different sets of EVs in a single cell is complicated.
Even though several studies isolate EVs from all kinds of fluids, including 
blood, urine, saliva, tears, semen, and cerebrospinal fluid, there is not a consensus 
to determine the best isolation technique to purify EVs. Several approximations 
have been published to isolate and analyze EVs from different sources [5, 21–23]. 
Differential centrifugation and ultracentrifugation are necessary steps at the begin-
ning of the process to avoid sample contamination with non-EVs contaminants that 
can confound the analysis (ex. cellular debris, protein aggregates or lipoproteins). 
After the centrifugation steps, there are several techniques that can be used to 
isolate and analyze the EVs [24, 25]. Several common techniques are listed below:
• Differential ultracentrifugation
• Density gradient ultracentrifugation
Figure 1. 
Evolution of the number of papers published in PubMed over the past 21 years (1997–2018).
5
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• Size exclusion chromatography
• Filtration
• Immunological separation
• Commercial precipitation kits
• Microfluidic chip
The methods summarized above are the most common. However, there are more 
variations of these methods used to purify EVs. All the methods have different 
advantages and disadvantages. Because of the diversity of the EVs, there is not a 
unique method to purify them. The selection of the method and the adaptation to 
the particular scenario is vital for the success of the isolation. After the EVs isola-
tion, several procedures can be performed to characterize, quantify, and validate 
the correct purification of these organelles [5, 26–30]. The most common methods 
are listed below:
• Transmission electron microscopy (TEM)
• Atomic force microscopy (AFM)
• Nanoparticle tracking analysis (NTA)
• Dynamic light scattering (DLS)
• Single-particle tracking (SPT)





• In vitro functional analyses
• In vivo functional analyses
• Lipidomic analysis
3. The role of the extracellular vesicles in human health
Extracellular vesicles are released by many different cell types and organisms. 
The role of the EVs is mediated by the signals transmitted through them by the pro-
tein, lipids, and nucleic acids that are part of the EVs cargo. The release of the EVs to 
the environment allows the emitting cell to send messages to sites close or even far 
from the origin. These vesicles are able to transport biological information through 
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the system with cell targeting properties, making them as great candidates for drug 
delivery systems [31–33]. EVs are naturally secreted by human cells and they are not 
strange for the system, avoiding the negative response by the immune cells. The use 
of EVs as drug delivery systems is focused on improving their ability to reach the 
target recipient cells and deliver the content, controlling the purity of EV prepara-
tion, and analyzing the best administration routes. The challenges are prolonging 
their circulating and improving targeting. The use of EVs as drug delivery systems 
is being studied for several disorders, including cancer, infectious diseases, brain 
disorders, liver diseases, and among others [34–37]. However, this field is still in 
the early stage of development with great potential for future applications, but also 
with big challenges to attempt [38].
More applications for EVs have been described. The specific cargo of the EVs makes 
them useful in the discovery of biomarkers for clinical diagnosis. Because EVs are 
secreted from almost all cells, they are found in various body fluids, making them easy 
to collect and analyze and playing a critical role in diagnosis of several conditions, 
such as cancer, Alzheimer’s, epilepsy, and liver diseases [37, 39–42]. EVs participate 
in pathogenesis and can also be used as diagnosis or vaccines [33, 35, 43]. Last novel 
applications for EVs include using their signaling properties to repair injured muscle or 
use them as biomarkers for male infertility or pregnancy-related disorders [44–46].
4. Conclusions
This first chapter presents a big picture of the EVs research and application as a 
fast-growing field. There are many EVs studies trying to demonstrate their potential 
critical role in cell communication and their use in many different biomedical appli-
cations. The diversity of biogenesis mechanisms and their cargo content outstand 
many challenges and questions to be addressed. Advances in standardized methods 
for purification and analysis are necessary. The increasing knowledge of the differ-
ent cargo compositions and secretion mechanisms to differentiate the healthy cells 
and the sick cells need to be clarified to use them as biomarkers, vaccines or therapy. 
The combination of knowledge and experts deriving from all the fields together 
with the progress on characterization methods is contributing to use EVs in the 
biomedical field.
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with big challenges to attempt [38].
More applications for EVs have been described. The specific cargo of the EVs makes 
them useful in the discovery of biomarkers for clinical diagnosis. Because EVs are 
secreted from almost all cells, they are found in various body fluids, making them easy 
to collect and analyze and playing a critical role in diagnosis of several conditions, 
such as cancer, Alzheimer’s, epilepsy, and liver diseases [37, 39–42]. EVs participate 
in pathogenesis and can also be used as diagnosis or vaccines [33, 35, 43]. Last novel 
applications for EVs include using their signaling properties to repair injured muscle or 
use them as biomarkers for male infertility or pregnancy-related disorders [44–46].
4. Conclusions
This first chapter presents a big picture of the EVs research and application as a 
fast-growing field. There are many EVs studies trying to demonstrate their potential 
critical role in cell communication and their use in many different biomedical appli-
cations. The diversity of biogenesis mechanisms and their cargo content outstand 
many challenges and questions to be addressed. Advances in standardized methods 
for purification and analysis are necessary. The increasing knowledge of the differ-
ent cargo compositions and secretion mechanisms to differentiate the healthy cells 
and the sick cells need to be clarified to use them as biomarkers, vaccines or therapy. 
The combination of knowledge and experts deriving from all the fields together 
with the progress on characterization methods is contributing to use EVs in the 
biomedical field.
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Abstract
Cells of the multicellular organisms communicate with each other in many 
different ways, among which extracellular vesicles play a unique role. Almost all cell 
types secrete vesicles into the extracellular space and deliver their contents to recipi-
ent cells. Today, one of the groups of extracellular vesicles that is of particular inter-
est for studying is exosomes—membrane vesicles with a diameter of 40–100 nm. 
Exosomes are secreted by cells and found in various biological fluids—blood, tears, 
saliva, urine, cerebrospinal fluid, and milk. Exosomes provide not only targeted 
delivery of molecular signals to recipient cells but also carry unique markers, which 
makes them a promising substrate in diagnostic studies, primarily due to their small 
RNA and protein contents. The milk of cows, horses, humans, and other mammals 
is a unique source of exosomes since these organisms can produce liters of milk per 
day, which is much higher than the volume of exosomes produced in cell culture 
fluid or blood plasma. Unfortunately, milk exosomes are currently much less 
studied than exosomes of blood or culture fluid. This review examines the methods 
of the isolation, biochemical analysis (composition of proteins, lipids, and nucleic 
acids), morphology, and prospects for the use of milk exosomes.
Keywords: milk, exosomes, isolation, milk exosomes, proteins, lipids, nucleic acids, 
miRNA, morphology, electron microscopy
1. Introduction
Exosomes are membrane vesicles with a diameter of 40–100 nm, secreted 
by cells and found in various biological fluids—blood, tears, saliva, urine, 
cerebrospinal fluid, and milk [1]. Exosomes deliver molecular signals to recipi-
ent cells and also carry unique markers of the parental cell, which makes them 
a promising substrate for noninvasive diagnostics (liquid biopsy) and targeted 
drug delivery. The microRNA and protein contents of exosomes are of particular 
interest [2, 3].
Milk contains proteins, lipids, nucleic acids, and its complexes and is not a 
simple source of nutrients. Since vesicles of different size and shapes were described 
in milk and since milking animals can produce liters of milk per day, which is much 
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1. Introduction
Exosomes are membrane vesicles with a diameter of 40–100 nm, secreted 
by cells and found in various biological fluids—blood, tears, saliva, urine, 
cerebrospinal fluid, and milk [1]. Exosomes deliver molecular signals to recipi-
ent cells and also carry unique markers of the parental cell, which makes them 
a promising substrate for noninvasive diagnostics (liquid biopsy) and targeted 
drug delivery. The microRNA and protein contents of exosomes are of particular 
interest [2, 3].
Milk contains proteins, lipids, nucleic acids, and its complexes and is not a 
simple source of nutrients. Since vesicles of different size and shapes were described 
in milk and since milking animals can produce liters of milk per day, which is much 
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higher than the volume of culture fluid or blood plasma, milk is a unique source 
of exosomes. Unfortunately, milk exosomes are currently much less studied than 
exosomes of blood or culture fluid.
Milk exosomes may be used as carriers of drugs and therapeutic nucleic acids 
for delivery to cells. The basis of biological functions of milk exosomes is due to 
their components: lipids, proteins, and nucleic acids. The prospects for the further 
practical use of milk exosomes in medicine and biotechnology largely depend on 
investigations of the fine structure and biological functions of exosomes free of 
various contaminating impurities.
A clear classification of extracellular vesicles is difficult due to their considerable 
variability and, particularly, overlapping sizes. The term “extracellular vesicles” was 
introduced to designate all the vesicles secreted to the biological fluids, and the use 
of the term “exosomes” requires the fulfillment of some conditions [4, 5]. The dis-
tinctive features of exosomes are the size (40–100 nm), floating density in a sucrose 
gradient (1.1–1.19 g/ml), a particular cup-shaped form under electron microscope 
examination, and specific biochemical composition.
Exosomes isolated from human [6], cow [7], horse [8], pig [9], rat [10], and 
camel [11] milk have been described so far. However, it has been shown that the 
molecular composition of human milk exosomes largely depends on the mother’s 
lifestyle, lactation stage, and mother’s contact with allergens [12]. It is known that 
a change in the composition of proteins [13] and nucleic acids [14] of cow milk 
exosomes occurs during the development of inflammation of the mammary gland.
2. Methods of exosome isolation, purification, and analysis
According to the international nomenclature, exosomes include vesicles of 
40–100 nm in size, which are formed by invagination of the membrane of the 
multivesicular bodies and carry a number of specific markers, such as CD9, CD63, 
and CD81. Exosomes are round or cup-shaped.
Most investigations of exosomes confirm their presence using transmission elec-
tron microscopy (TEM) without a detailed analysis of the preparation composition. 
TEM is the best method of analysis of size, morphology, and integrity of exosomes, 
as well as of evaluating sample composition. TEM shows the presence of impurities 
in the preparations of exosomes, which can distort the results and lead to a false 
interpretation. For example, researchers describe samples of cow milk exosomes 
and present images that clearly show vesicles larger than 100 nm in size and other 
particles that do not have an outer membrane. However, when analyzing the results, 
this fact is not discussed [15].
To confirm that the isolated vesicles are exosomes, the International Society for 
Extracellular Vesicles recommends identification of specific exosomal membrane 
proteins—tetraspanins CD9, CD63, and CD81—using Western blotting, flow 
cytometry, or immunoelectron microscopy [4, 16]. However, the first two methods 
fix all particles in a solution that have tetraspanins; therefore, there is no selectivity 
in analyzing membrane and non-membrane structures. The advantage of immuno-
electron microscopy is the ability to detect exosomal markers directly on the surface 
of the vesicles.
When analyzing the literature data on exosomes obtained from the milk of 
human donor or other sources, one should take into account by which methods the 
exosome preparation was isolated and analyzed and what is the potential of these 
approaches in a generation of reliable data. Exosomes from different biological 
liquids including milk may be isolated with various methods such as centrifuga-
tion using special conditions, ultracentrifugation, ultracentrifugation in density 
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gradients, and salting out and with other approaches [17–19]. It should be noted 
that these methods allow obtaining preparations only enriched with exosomes, but 
not pure ones. Different biological fluids including milk contain various proteins 
and their highly stable molecular weight associates, which can be co-isolated with 
various vesicles including exosomes during centrifugations. For example, it was 
recently shown that extract of the placenta and human milk contains very stable 
high-molecular-mass (~1000 kDa) multiprotein complexes, in which the size is 
comparable to some extent with various vesicles [20, 21]. Moreover, some free 
proteins and their complexes can nonspecifically or even specifically interact either 
with vesicle surface or their receptors and coprecipitate with the vesicles during 
centrifugations.
Reliability of literature data is questioned in [22] where more than 200 exosome 
preparations were isolated from various sources using sequential centrifugations; 
this method has been used in many papers. Exosomes’ preparations contained many 
structures with low electron density and having no membranes; these structures 
were named “non-vesicles.” Using TEM, two main types of “non-vesicles” were 
described: of 20–40 nm (up 10–40% of all structures of the preparations) and 
of 40–100 nm. The morphology of the “non-vesicles” allowed referring them to 
lipoproteins of intermediate and low density (20–40 nm) and very low density 
(40–100 nm) [22]. Also, crude exosome preparations after different centrifugations 
without additional purification steps contained impurities of various components, 
including proteins and their complexes. In such types of exosome preparations, up 
to several hundred or thousand different contaminating co-isolating proteins and 
their complexes may be detected.
Recently our data confirmed the findings of [22]: using TEM we have shown that 
crude exosome preparations from human placenta and horse milk after centrifuga-
tion and ultracentrifugation (at 10,000 × g, 16,500 × g, and twice at 100,000 × g) 
contained many large >100 nm membrane vesicles, smaller <100 nm vesicles, and 
20–100 nm non-vesicles [23]. Non-vesicles possessed medium electron density, 
distinct outer membrane, and spherical shape (Figure 1).
We observed a similar situation in the case of crude exosome preparations 
obtained from horse milk. All the same, components were identified in such prepa-
rations except ring-shaped structures of ferritin (Figure 2).
After preparations isolated from placenta [23] and horse milk [8] were enriched 
with exosomes by sequential centrifugation and ultracentrifugation, they were sepa-
rated from co-isolating impurities using gel filtration on Sepharose 4B or Ultrogel 
(Figure 3A and B). The first peak corresponding to exosomes was successfully 
separated from contaminating proteins and other impurities of the second peak.
One can see from Figure 3 that gel filtration can noticeably differ in the A280 
ratio of the first and second peaks. The first peak, corresponding to exosomes, 
can be significantly lower than the second peak, corresponding to coprecipitat-
ing impurities. As it was shown in [8, 23], the second peak may contain various 
proteins. Vesicle preparations of human placenta and horse milk obtained after gel 
filtration contained exosomes of various sizes (30–100 nm) but did not contain 
any visible amorphous protein material (Figures 1 and 2). In contrast to horse 
milk exosomes, preparations of human placenta exosomes even after gel filtration 
contain some supramolecular ring-shaped associates of ferritin (10–14 nm). One 
of the criteria for belonging vesicles to exosomes is the content of CD81 or CD63 on 
the surface [4]. Using TEM with anti-CD63 and anti-CD81 gold-labeled antibodies, 
we analyzed the vesicle preparation obtained with gel filtration (Figure 4C–G). 
Extra-purified exosomes obtained after gel filtration correspond to the exosomes 
in terms of morphology, size, and content of tetraspanins CD81 and CD63 on their 
surface (Figure 4).
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higher than the volume of culture fluid or blood plasma, milk is a unique source 
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surface (Figure 4).
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Thus, various kinds of centrifugation and ultracentrifugation are not enough 
for a full purification of exosome preparations from coprecipitating impuri-
ties. Also, for improved exosome purification, it is necessarily what kind of 
ultracentrifugation was performed and how many times it was performed. The 
relative number of vesicles containing CD9 and CD81 tetraspanins was esti-
mated using flow cytometry after the first and second ultracentrifugation and 
after gel filtration (Figure 5). It was shown that vesicle preparations after first 
100,000 × g ultracentrifugation contain only ~16% of CD9- and CD81-positive 
vesicles (Figure 5A and B). The second 100,000 × g ultracentrifugation led to the 
increase of these markers in ~fivefold (up to 80–87% for CD81 and CD9, respec-
tively; see Figure 5C and D). Thus, the number of impurities in the preparations 
of exosomes not subjected to the second 100,000 × g ultracentrifugation can be 
approximately 4–6 times higher.
Figure 1. 
Exosomes of human placenta after ultracentrifugation. (A) Vesicles <100 nm (black arrows), vesicles >100 nm 
(black squares), non-vesicles (white squares), amorphous aggregates of low electron density (white arrows), 
and particles associated with protein aggregates (white ovals). Individual structures in exosome preparations: 
Clumps of large vesicles (>100 nm) (B), vesicles <100 nm (C), non-vesicles (D, E), ring-shaped structures of 
ferritin (insert to A), clusters of aggregated proteins (F), and shapeless aggregations with low electron density 
(G). Images were obtained using TEM with negative staining. Scale bar corresponds to 100 nm.
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Exosomes of different origins according to literature data may contain varying 
amounts of proteins. For example, crude preparations of exosomes of dendritic cells 
can include more than 150–200 different proteins [24, 25]. An even more improb-
able result was obtained when analyzing proteins of the milk’s exosomes of cows, 
whose preparations were isolated by centrifugation and ultracentrifugation in a 
Figure 2. 
Exosome preparations of horse milk after different steps of purification: Ultracentrifugation (A–D) and gel 
filtration (E–I). (A) Aggregates of vesicles and non-vesicles, (B) exosomes and non-vesicles (oval), (C) non-
vesicles, (D) macromolecular aggregates, (E) aggregates of large and small vesicles, (F) exosomes, (G) exosomes 
and non-vesicles, (H) exosomes labeled with anti-CD81 antibody conjugates with gold spheres, and (I) 
exosomes labeled with anti-CD63 antibody conjugates with gold spheres. The oval shapes denote non-vesicles; 
squares in (A and B)—Exosomes. Scale bar corresponds to 100 nm.
Figure 3. 
Gel filtration of crude exosome preparations on Sepharose 4B (A) and Ultrogel (B). Сrude exosome 
preparations from human placenta (A) and horse milk (B) preparations were obtained by sequential 
centrifugation and ultrafiltration through filter 0.1 μm (—), absorbance at 280 nm (A280).
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sucrose gradient [26]. As a result, 2107 proteins have been identified, which include 
all major protein markers of exosomes previously detected.
We have analyzed a possible number of proteins in extra-purified exosomes 
after gel filtration. Exosome proteins were identified before and after gel filtration 
by MALDI MS and MS/MS spectrometry of protein tryptic hydrolysates after SDS-
PAGE and 2D electrophoresis (Figure 6).
Only 46 major and moderate protein spots were revealed on the gel after stain-
ing. Interestingly, only one of the spots corresponded to human serum albumin, 
lactoferrin, and lactadherin, while nine spots corresponded to different forms 
of beta-lactoglobulin. All other protein spots corresponded to various species 
of milk casein (number of spots): kappa-casein precursor (1), beta-casein (2), 
alpha-S1-casein (7), kappa-casein (10), and alpha-S1-casein precursor (14). Thus, 
the mixture of five relatively crude partially purified preparations of horse milk 
exosomes contains only nine different major and moderate proteins, while five of 
them consist of different caseins and their precursors.
It could be assumed that during gel filtration, the loss of a large part of the 
exosomes may occur, and as a consequence, the number of proteins analyzed in 
these exosomes may be underestimated. However, human placenta vesicles after 
gel filtration (fraction of the first peak) contain ~78% of CD9- and 74% of CD81-
positive vesicles (Figure 5E and F). Thus, the yield of particles after gel filtration 
was relatively high up to ~90%. A similar result was obtained for horse milk exo-
somes. Consequently, the loss of the main part of the exosomes during gel filtration 
does not occur.
Figure 4. 
Preparations of human placenta exosomes after filtration through 100 nm filter and gel filtration on Sepharose 
4B. Vesicles (A) and ferritin ring structures (10–14 nm; inset in A). Exosomes purified by gel-filtration 
(B), labeled with conjugates of gold nanoparticles with monoclonal antibodies against tetraspanin CD81 (C–E) 
and CD63 (F–H). Transmission electron microscopy with negative contrast. Scale bar corresponds to 100 nm.
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After gel filtration, extra-purified exosomes isolated from horse milk contained 
only eight different major proteins, CD81, CD63, beta-lactoglobulin, and lactad-
herin, which were common to all preparations, and actin, butyrophilin, lactoferrin, 
and xanthine dehydrogenase which were found only in some of them [8]. Exosome 
preparations from human placenta contain only ten major proteins: CD81, CD63, 
hemoglobin subunits, interleukin-1 receptor, annexin A1, annexin A2, annexin A5, 
cytoplasmic actin, alkaline phosphatase, and serotransferrin [23].
After 2D electrophoresis, only 28 protein spots were found in human placenta 
exosomes, which corresponded to just nine different proteins and their isoforms. 
Overall, using 2 methods of electrophoretic analysis (1D and 2D electrophoresis), 
12 proteins were identified in 4 exosome preparations: CD81, CD63, hemoglobin 
subunits, annexin A1, annexin A2, annexin A5, cytoplasmic actin, alpha-actin-4, 
alkaline phosphatase, serotransferrin, human serum albumin, and immunoglobu-
lins. Ferritin completely disappears after gel filtration and exosome treatment 
with proteolytic enzymes. After treatment of exosome preparations with trypsin 
and chymotrypsin, the protein bands corresponding to human serum albumin 
and immunoglobulins according to SDS-PAGE data almost wholly disappeared. 
Therefore, it cannot be excluded that human serum albumin and immunoglobulins 
form relatively stable complexes with exosome membrane proteins (i.e., tetraspan-
ins) or interact directly with the surface of exosomes.
Figure 5. 
Flow cytometry analysis of exosome preparations after two stages of ultracentrifugation (A–D) and  
gel-filtration (E, F). The relative amount of vesicles containing CD9 (left) and CD81 (right) are shown.
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Authors of [27, 28] discovered proteins of oxidative phosphorylation in the 
urinary exosomes. It is known that the formation of exosomes occurs in the cell 
cytoplasm. However, oxidative phosphorylation is a typical function of the mito-
chondria. Mitochondrial enzymes of the oxidative phosphorylation and Krebs cycle 
are absent in the cytoplasm. The question may arise how these enzymes could get 
into the cytoplasm and then to exosomes. Mechanism of such a process has not been 
described anywhere. These results may be explained if the authors destroyed cells 
and the mitochondria and then co-isolated proteins of oxidative phosphorylation 
(or fragments of the mitochondria) with exosomes.
Several articles describe casein in milk exosome preparations. Precursors of 
caseins undergo posttranslational processing in the Golgi complex. The cytoplasm 
of mammary gland cells never contains any casein that may get inside the multive-
sicular bodies and exosomes. As one can see from Figure 6, crude horse milk exo-
some preparations include 46 major and moderate protein spots (number of spots) 
including some spots of casein isoforms: kappa-casein precursor (1), beta-casein 
(2), alpha-S1-casein (7), kappa-casein (10), and alpha-S1-casein precursor. Casein 
isomers were found only in crude exosome preparations, obtained by centrifuga-
tion. All forms of caseins have disappeared after gel filtration, and they were found 
just in the second peak containing contaminating proteins. Thus, it is possible that 
hundreds to thousands of proteins described in crude milk exosome preparations, 
in fact, are not intrinsic components of exosomes and are co-isolating impurities.
Figure 6. 
2D gel electrophoresis of horse milk exosome proteins. A mixture of five crude horse milk exosome 
preparations was obtained by centrifugation and ultrafiltration through 100 nm. The sample was separated 
by isoelectrofocusing and then by SDS-PAGE in denaturing conditions. The spots were stained with Coomassie 
R-250 and then cut; proteins were subjected to trypsinolysis for their identification using MALDI MS and MS/
MS spectrometry.
19
Milk Exosomes: Isolation, Biochemistry, Morphology, and Perspectives of Use
DOI: http://dx.doi.org/10.5772/intechopen.85416
In this regard, we could note a critical review by academician Sverdlov, who 
believes that in the case of exosomes, there is an incorrect overestimated quantita-
tive assessment of their internal molecular components, which, in his figurative 
expression, “would certainly make Amedeo Avogadro cry” [29]. We are sure that 
the real number of exosome proteins described previously using crude preparations 
of milk exosomes may be very much overestimated.
It is necessary to note another potential method leading to overestimation of 
the protein content in exosomes. The technique identifies proteins of exosome 
crude preparations by bulk trypsinolysis of proteins with subsequent separation 
of peptides using various HPLC. For example, cow milk exosome preparations 
were isolated by centrifugation and ultracentrifugation [29]. Purified exosomes 
after trypsin treatment were subjected to reverse-phase chromatography and then 
fractionated on a nanoLC column connected to the tandem mass spectrometer. 
This approach generated near 2100 proteins detected in milk exosomes. The ques-
tion is what possible errors in the estimation of protein number might be using 
this approach?
After SDS-PAGE all proteins and peptides with molecular mass 10 kDa and less 
usually leave the gel during the gel staining with Coomassie blue. Exosomal peptides 
and small proteins are still practically not investigated. It was shown that peptides 
and small proteins are easily detected using cyano-hydroxycinnamic acid as a matrix 
for MALDI-TOF MS and MS/MS; these substances may be directly detected even in 
native cells [30–32]. Other low-molecular-mass components (lipids, sugars, oligo-
nucleotides) will appear in the MALDI spectra in these conditions only if its content 
is 100–1000-fold higher than of peptides. Vesicles, eluted from anti-CD81-Sepharose 
with 0.15 M NaCl (Figure 7), contained a mixture of peptides and its complexes.
Small proteins and peptides of the fraction, eluted from anti-CD81-Sepharose 
with 0.15 M NaCl, were analyzed by MALDI mass spectrometry in 2–12 kDa range. 
Figure 7. 
Affinity chromatography of a mixture of five exosome preparations on anti-CD81-Sepharose: (—), absorbance 
at 280 nm (A280). Peak numbers and elution conditions are indicated in the picture.
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with 0.15 M NaCl (Figure 7), contained a mixture of peptides and its complexes.
Small proteins and peptides of the fraction, eluted from anti-CD81-Sepharose 
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Figure 7. 
Affinity chromatography of a mixture of five exosome preparations on anti-CD81-Sepharose: (—), absorbance 
at 280 nm (A280). Peak numbers and elution conditions are indicated in the picture.
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The samples were examined before and after destruction of exosomes with trifluo-
roacetic acid (Figure 8).
Similar results were obtained for horse milk exosomes before and after gel 
filtration and after affinity chromatography on anti-CD81-Sepharose. MALDI mass 
spectra demonstrate many various small proteins and peptides with molecular 
masses in the range 2–9 kDa. The fractions were treated with proteases. Figure 9A 
shows MALDI MS spectra of peptides before the protease treatment. Spectra after 
the incubation with trypsin (Figure 9B), chymotrypsin (Figure 9C), and protein-
ase K (Figure 9D) doesn’t contain any peaks >3 kDa but include peaks correspond-
ing to the shorter products after hydrolysis. Masses of these shorter products do not 
coincide with the ones in Figure 9A.
Exosomes of the horse milk and placenta in addition to proteins >10 kDa contain 
small proteins and peptides. These peptides may be analyzed with highly sensitive 
methods of shotgun ESI-MS/MS analysis and lead to the incorrect number of large 
proteins in the exosome preparations. The structure of these small proteins and 
peptides is not yet established; one cannot exclude that initially they may be frag-
ments of larger proteins. In that case, the identification of large proteins from the 
results of the shotgun analysis of peptides will lead to an incorrect determination of 
many proteins.
Some literature data on the analysis of the various components of milk exo-
somes, including lipids, mRNA, microRNA, and proteins, are described below. 
In most of the published papers, milk vesicles were isolated using only different 
centrifugation, and analysis was done only on crude preparations of exosomes. 
Figure 8. 
MALDI mass spectra of human placenta exosomes obtained with gel filtration (A) and anti-CD81-Sepharose 
before (B) and after (C) trifluoroacetic acid and acetonitrile treatment. The analysis was performed using 
2–12 kDa range of MALDI-TOF mass spectrometer.
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According to our data, the second peaks after gel filtration of exosomes (Figure 3) 
contain many different milk proteins as well as RNA, lipids, and oligosaccharides. 
Thus, the analysis of crude preparations of exosomes without additional purifica-
tion can lead to the overestimation of proteins and other biochemical components 
of exosomes. Therefore, the literature data on milk exosomes described below must 
be analyzed very gingerly and critically, taking into account the above data.
3. Biochemistry of milk exosomes
There is no doubt that the biological functions of milk exosomes are due to the 
proteins, lipids, and nucleic acids that make up their composition. There are differ-
ent estimations of the number of protein and nucleic acid molecules, which may be 
located in exosomes. Up to 16–20 thousands of different mRNA [33, 34] and up to 2 
thousands of proteins [35] are described in cow and human exomes in various works. 
Prof. Sverdlov in [29] shows that no more than 1,6 thousand of mRNA molecules may 
fit in a single exosome, since it sounds very doubtful that such amount of different 
mRNA molecules may be transferred with exosomes. We believe that the papers 
describing thousands of proteins and nucleic acids in the preparations of exosomes 
may be due to the analysis of insufficiently purified preparations of exosomes, co-
isolating with milk proteins and nucleic acids (of fat milk globules or other vesicular 
or non-vesicular particles). This assumption is well supported by the data, described 
Figure 9. 
MALDI mass spectra of <10 kDa extract of horse milk exosomes isolated on anti-CD81-Sepharose before (A) 
and after their treatment with trypsin (B), chymotrypsin (C), and proteinase K (D).
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in [8, 23]. As mentioned above, most papers dedicated to the study of exosomes ana-
lyze very crude preparations. Below we describe the structure and possible biological 
functions of major components of milk exosomes following the data given in various 
papers without critical analysis. However, taking into account the data provided 
above, it is necessary to examine the given information critically.
3.1 Proteins of milk exosomes
Data on the protein composition of milk exosomes significantly varies between 
papers. There is no doubt that proteins play a crucial role in the physiology of milk 
exosomes; the other obvious thing is that most of the proteins, secreting in milk, 
cannot be a natural part of exosomes, due to the mechanism of exosome generation 
in the cell [8]. It was shown that the exosome proteome changes depending on the 
physical activity, nutrition, or various infections, suggesting that protein content 
of milk is an excellent biomarker [13]. Also, the data indicate that the concentration 
of exosomal proteins and the exosomes in milk is significantly lower in mature milk 
than the early stages of lactation [12].
Depending on the method of proteome analysis used, researchers found hun-
dreds of proteins in milk obtained from different mammals: 100 [36], 200 [37], 400 
[38], 600 [33], and even 1900 [35] or 2100 [26] proteins in exosome preparations. 
Such a significant difference may be due both to different levels of purification of 
the exosome preparations and to a substantial difference in the protein content in 
vesicles obtained from various sources. However, it is evident that exosomes cannot 
contain several thousand proteins.
According to literature data, exosomes can contain proteins that control the cyto-
skeleton dynamics and membrane fusion: Rab proteins (GTPase family) [39]; Alix, 
TSG101, and other proteins of the endosomal sorting complex [40]; and proteins 
that participate in the binding and transport of miRNA, target cell recognition, and 
fusion (tetraspanins CD9, CD63, CD81). Members of the tetraspanins family medi-
ate the adhesion of exosomes on the surface of the recipient cell and are essential 
structural components of exosomal membranes [41, 42]. Also, one cannot exclude 
that exosomes may contain various enzymes: proteases and their activators, peroxi-
dases, lipid kinases, and other proteins that exhibit catalytic activity [43]. Exosomes 
may be rich in cytoskeleton proteins (actin, tubulin, cofilin), proteins of membrane 
transport and heat shock (HSP60, HSP70, HSP90), and proteins involved in intra-
cellular signal transduction like Wnt proteins, which activate the Wnt signaling 
pathway [44, 45]. The presence of proteins involved in the formation of vesicles 
(ADP-ribosylation factor) [46] and membrane fusion EHD1 (testilin) [47] confirms 
the endosomal origin of exosomes. The presence of integrins in milk exosomes is 
an essential marker of the internalization and biological activity of extracellular 
vesicles, which can also be used to predict their possible direction of delivery [48]. In 
general, exosomes include proteins that make up the endosome, plasma membrane, 
or cytosol, while proteins from the nucleus, mitochondria, endoplasmic reticulum, 
and Golgi must be absent in exosomes. These observations emphasize the specific-
ity of the formation of these vesicles and demonstrate that exosomes are a special 
subcellular compartment but not random cell fragments [49].
The proteins described above are common to all types of exosomes, including 
milk exosomes, which in addition to these proteins contain specific milk proteins. 
Several milk proteins were characterized in milk exosomes: caseins, lactoglobulin, 
lactoferrin, CD36, and polymeric immunoglobulin receptor precursor [6]. The 
CD36 protein in cells mediates phagocytosis and cell adhesion and binds low-density 
oxidized lipoproteins [50], but its role in milk exosomes requires further establish-
ment. It is worth to say that not all the proteins described in the milk exosomes 
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in literature may be really exosome components. For example, in highly purified 
preparations from horse milk, the caseins were not defined as exosomal components 
but co-isolated with exosomes during the ultrafiltration and ultracentrifugation and 
were separated from exosomal fraction by gel filtration [8]. In this regard, additional 
studies of milk exosomes that do not contain impurities of co-isolating proteins are 
required. Improvement of methods of exosome purification will make it possible to 
determine the protein composition of milk exosomes more accurately and to under-
stand the role of specific proteins in their structure and functions.
Since the formation of the exosomal membrane occurs from the endosomal 
membrane, the exosomes carry similar protein markers as the cells secreting 
them. An example is the peripheral membrane protein MFG-E8 (lactadherin), a 
glycoprotein containing several domains, some of which are necessary for bind-
ing to the membrane, while some others carry integrin binding sites. Expression 
of MFG-E8 in the cells increases the secretion of vesicles since MFG-E8 may play 
a unique role in the secretion of membrane vesicles by budding or splitting the 
plasma membrane or by exocytosis of multivesicular bodies [51]. The expression of 
this protein in mammary gland increases during lactation. Human milk exosomes 
contain TGFb2 protein, the increased expression level of which is associated with 
the development of breast cancer [52].
Compared to cow milk fat globule membrane, the same proteins were the most 
abundant in cow milk exosomes: butyrophilin, xanthine oxidase, adipophilin, 
and lactadherin [26]. During the mastitis caused by Staphylococcus aureus, relative 
concentrations of several proteins were increased 9–20 times in cow milk exosomes: 
protein S100-A12, cathelicidin-2, annexin A3, myeloperoxidase, haptoglobin, 
histone H2A, and H4 [13].
Flow cytometry has shown that human B-cell exosomes, unlike human milk 
ones, give a positive signal to tetraspanins CD40, CD54, and CD80 in addition to 
CD63 and CD81, which are detected in milk exosomes. On the contrary, MUC-1 
protein is present in milk exosomes but absent in B-cell-derived exosomes [6].
In the sediments obtained by the centrifuging of cow’s milk at 35,000 × g and 
100,000 × g, CD9, CD63, and CD81 tetraspanins were found mainly in the sediment 
after 100,000 × g, indicating the presence of exosomes. Also, sediment obtained by 
100,000 × g centrifugation contained a higher number of complement proteins C2, 
C6, and C7 than the 35,000 × g one, which indicates the presence of multiple types 
of extracellular vesicles of this sediment. Complement C8 beta chain, C1GALT1-
specific chaperone 1, cartilage-associated protein, α-mannosidase 2, and procollagen-
lysine 2-oxoglutarate 5-dioxygenase 3 were found only in the 100,000 × g fraction. 
Functional analysis of these proteins revealed three functions: galactosidase, glycosyl-
transferase, and peptidase activities. It cannot be excluded that proteins found in the 
milk exosome fraction are involved in the regulation of translation, protein matura-
tion, and maintenance of the cellular structure. Also, analysis of human cells after 
fusion with milk exosomes has shown some exciting changes in expression of proteins 
responsible for translation (ribosomal subunits, initiation, and elongation), innate 
immunity, vesicular transport, and cell migration [48].
Some data indicate that human milk exosomes have a unique composition of 
proteins, distinct from other milk components. Transmembrane (CD9, CD63, 
CD81, lactadherin, guanine nucleotide-binding protein), cytosolic (annexins A2, 
A4–7, and A11, Ras-related proteins Rab, syntenin), and also intracellular proteins 
(endoplasmin, calnexin) are presented in human milk exosomes. The unique 
combination of proteins with different biological roles, cell growth, inflammation, 
and others indicates that milk exosomes may play a key role in the infant’s intestinal 
immune system. The list of the most represented exosomal proteins according to 
the literature data is combined in Table 1.
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The data on the protein composition of milk exosomes gives new information on 
the structure and biological significance of these vesicles and reveals the potential 
role of exosomes in the physiology of the mammary gland. Investigation of the pro-
teome of highly purified milk exosomes compared to milk proteome can shed light 
on the real protein composition of exosomes; these data may be translated to the 
exosomes obtained from other biological liquids. Results of milk exosome proteome 
analysis will possibly lead to their use in medicine as biocompatible carriers of 
drugs or personal therapy tools.
However, as shown above, not all proteins found in crude vesicle preparations 
are proper exosome proteins. At the same time, it is possible that some proteins 
associated with the surface of the vesicles may also play some unique role in the 
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in the composition of the exosomes seems to us enormously overestimated. Also, 
the diversity of proteins found in exosomes raises questions about whether proteins 
that coprecipitated with these vesicles, as well as possible intrinsic minor proteins 
of exosomes, have an or have no important role in the biological functions of 
exosomes.
3.2 Lipids of exosomes
The exosome membrane is enriched with specific lipids (phosphatidylcholine, 
cholesterol, sphingomyelin, ceramides) and has a unique protein composition that 
characterizes them as independent compartments [53, 54]. The minimum size of 
exosomes depends on the structure of the lipid bilayer, which is about 5 nm thick 
and has sufficient rigidity to form vesicles of 40 nm in size [55]. The lipid com-
position of exosomes greatly varies, due to differences in cell types, conditions of 
cell growth and development, as well as the use of different methods for isolating 
exosomes and analyzing them.
The first works on the lipid composition of exosomes were carried out using 
a thin layer and gas-liquid chromatography. The results obtained using these 
methods cannot be considered fully quantitative, since the phosphatidylcholine, 
phosphatidylserine, phosphatidylinositol, and phosphatidic acids migrate together 
and are presented in the single band after separation. Similarly, sphingomyelin and 
ganglioside GM3 are not separated and, therefore, are taken into account together 
in the quantitative analysis. Today, these methods are considered obsolete for the 
analysis of lipids of exosomes, and most studies use modern mass spectrometry 
technology [56].
It was found that different classes of lipids are asymmetrically distributed in 
the membrane of exosomes, so sphingomyelin and other sphingolipids, as well as 
phosphatidylcholines, are mainly located in the outer layer of the membrane, while 
the different classes of lipids are located in the inner layer [57]. However, the estab-
lished asymmetry of the membrane bilayer can be altered by the action of particular 
enzymes, such as flippases, floppases, and scramblases [58, 59].
Phosphatidylserine in exosomes, as in the plasma membrane, is located in the 
inner lipid layer [57], but several studies have shown its presence also in the outer 
layer together with annexin 5. It is known that the presence of phosphatidylserine 
in the outer lipid layer activates blood cells and acts as a signal to macrophages to 
capture [60].
The composition of certain classes of lipids in the exosomal membranes secreted 
by different cell types may be similar or not to the parental cells. Exosomes contain 
up to 2–3 times more cholesterol, sphingomyelin, glycosphingolipids, serine, and 
saturated fatty acids. In addition, GM3 ganglioside [56, 61], ceramides, and their 
derivatives [57, 62, 63] are also present in exosomes in significant amounts. In most 
cases, exosomes contain fewer phosphatidylcholines than their parent cells, and no 
noticeable differences in the content of phosphatidylserine in exosomes and parent 
cells were found [64].
The bis(monoacylglycero)phosphates (BMP) are present in the membranes of 
the intraluminal vesicles of multivesicular bodies and, as stated in [57], can also be 
contained in the exosomes. It was shown that BMP are not transferred to exosomes 
but, with high probability, are included in the intraluminal vesicles of those mul-
tivesicular bodies that are associated with lysosomes. In this regard, it is believed 
that the primary purpose of the BMP is to promote the stability and integrity of the 
lysosomes. Also, it is a necessary cofactor in the process of catabolism of sphingolip-
ids in lysosomes [65].
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saturated fatty acids. In addition, GM3 ganglioside [56, 61], ceramides, and their 
derivatives [57, 62, 63] are also present in exosomes in significant amounts. In most 
cases, exosomes contain fewer phosphatidylcholines than their parent cells, and no 
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The bis(monoacylglycero)phosphates (BMP) are present in the membranes of 
the intraluminal vesicles of multivesicular bodies and, as stated in [57], can also be 
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The stiffness of exosomal membranes increases with the transition from 
acidic to neutral pH values, suggesting that during the secretion of the exosomes 
from the multivesicular bodies, some reorganization of the membrane occurs. At 
neutral pH, the packaging of lipids on the surface of exosomes is dense, but the 
transmembrane movement of lipids increases. Such a flip-flop effect (the transi-
tion of an individual molecule from one layer to another) disrupts the asymmetric 
distribution of lipids between the membrane layers. A uniform distribution of 
phosphatidylethanolamine between the two layers of the exosomal membrane [66] 
was shown; on the contrary, in the plasma membrane, it is located mainly in the 
inner lipid layer [67].
The lipids of the exosomal membranes are not inert molecules but participate 
in the biogenesis of vesicles and affect their biological activity. Besides, exosomes 
carry carbohydrate groups on the outer surface; the presence of mannose, polylac-
tosamine, α-2,6 sialic acid, and complex N-linked glycans was shown [68].
Lipids form the basis of the exosome membrane; the composition of exo-
somal lipids significantly differs from the composition of lipids of non-vesicular 
structures.
The above data reflect the content of lipids and oligosaccharides in the com-
position of mainly crude preparations of exosomes. However, as noted above, the 
second peak after gel filtration of exosome preparations also contains various lipids 
and oligosaccharides. Therefore, it cannot be excluded that part of the lipids and 
polysaccharides found in the vesicles will be attributed in the future to the high-
molecular complexes co-isolating with exosomes during different centrifugations.
3.3 Nucleic acids of milk exosomes
Several works show that milk exosomes contain different types of nucleic acids, 
including functional mRNA with a poly(A) tract at the 3′-end [33, 34, 41] and 
microRNA [34, 69, 70]. Currently the composition of nucleic acids in milk exo-
somes is described in the case of human [71, 72], cow [73, 74], porcine [33, 75], and 
rat [10] milk.
As we have noted above, the number of individual RNA molecules in some 
papers may be overestimated due to various reasons. For example, it has been 
shown that exosomes of porcine milk contain up to 16,304 mRNA. Most of these 
molecules may be involved in the development of the immune system, cell prolifer-
ation, and intercellular signal transduction. Protein products of identified mRNAs 
might be involved in the regulation of metabolism and the growth of the piglet’s 
intestines [33].
Among the 19,230 mRNAs found in cow milk exosomes, the most common 
mRNA molecules are various isoforms of the mRNA of milk and ribosomal pro-
teins: inositol 1,4,5-triphosphate receptor type 1; α-lactalbumin; β-lactoglobulin; 
caseins β, κ, and α; ribosomal proteins S28, S3, P0, L32, L21, and H1 histone; 
and many others. Since the expression level of most of the 50 most represented 
transcripts in exosomes exceeds the standard in supernatants obtained by ultra-
centrifugation, the authors of the [34] conclude that the mRNAs are concentrated 
in the exosomes of milk. Unfortunately, it is difficult to agree with this statement, 
since the process of enrichment of exosomes with mRNA transcript molecules 
during their biogenesis is entirely unclear, as well as it is difficult to suggest a 
mechanism by which this unimaginable number of mRNA molecules can fit into an 
exosome with a diameter of 40–100 nm. At the same time, human and porcine milk 
exosomes contain little or no 18S and 28S rRNA [41, 70], which correlate with the 
mechanism of exosome biogenesis.
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It is shown that miRNA is ubiquitous in tissues and biological fluids and was 
previously isolated from and associated with exosomes formed from various bio-
logical fluids (serum, saliva, urine) and homogenates of body tissues, including the 
mammary gland [76]. Some studies have shown that the exclusion of milk exosomes 
and their contents, including exosomal miRNAs, from nutrition in newborns leads 
to impaired purine metabolism, as well as impaired spatial learning and memory 
in humans and mice [72, 77]. These data indicate the undesirability of feeding 
newborns with infant formulas since their content of microRNAs is absent or much 
lower than breast milk [78].
Analysis of nucleic acids isolated from human milk exosomes revealed about 
452 pre-miRNAs, which is approximately 32% of 1424 miRNAs described for 
humans. These 452 pre-miRNAs lead to the generation of 639 mature miRNAs, 
many of which are involved in the regulation of immune responses. At the 
same time, the distribution of different miRNAs in human milk exosomes is 
irregular; some miRNAs are represented in a million copies and others in single 
molecules. Ten miRNAs compose up to 62% of the total number of miRNA; the 
most represented miRNAs are miR-30b-5p, miR-141-3p, miR-148a-3p, miR-
182-5p, miRs let-7a-5p and let-7f-5p, miR-29a-3p, miR-146b-5p, miR-182-5p, 
miR-200a-3p, and miR-378a-3p [79]. Interestingly miR-148a-3p may comprise 
up to 35% of the total number of miRNAs of human milk exosomes. miR-148a 
specifically controls the expression of several genes, including the TGIF2, which 
encodes a transcription factor, inducing the expression of various transporters and 
drug-metabolizing enzymes [80], and the DNMT3B gene, which encodes DNA 
methyltransferase [81].
Transcriptome of cow milk exosomes contain various miRNAs, the most com-
mon of which are bta-miR-320a-1, bta-miR-193a, bta-miR-2284x, bta-mir-181b-1, 
bta -miR-19b-2, bta-miR-135a-1, bta-miR-200c, bta-miR-142, bta-miR-2887-1, 
bta-miR-30b, bta-miR-let7i, and bta-miR-6522 [72]. It was shown that cow milk 
exosomes penetrate intestinal and choroidal epithelial cells [82, 83] and macro-
phages [34], accumulate in peripheral tissues [84, 85], and transfer miRNA to the 
recipient cells [86]. Analysis of exosome bioavailability between species showed 
that microRNA of cow milk exosomes, after oral delivery to other organisms, is 
protected under the low pH, RNase, and other factors of the gastrointestinal tract 
[78, 87, 88].
Analysis of miRNA content in porcine milk exosomes revealed 366 pre-
miRNAs, which can give rise to 315 mature miRNAs, and 176 of them were 
described in other sources. Functional analysis of porcine milk miRNA indicates 
their role in immune responses, and 14 of 20 of most represented miRNAs may 
be involved in the regulation of milk IgA production [69]. Also, it was shown 
that miR-148a, widely represented in the exosomes of human [71] and cow 
[89] milk, is also highly expressed during lactation in exosomes of porcine 
milk [70]. Other highly expressed miRNAs of porcine milk are miR-181 family 
(181a/181b/181c/181d), miR-30 family (b/c/d/e), let-7 family (a/b/d/f), and miR-
98 family. Thus, miRNAs included in these families can participate in the develop-
ment of the digestive tract in piglets [69].
Nucleic acids play an essential role in biological functions of milk exosomes. The 
further investigations of milk exosome miRNA and mRNA variety will significantly 
expand the prospects of their practical use. However, when analyzing different 
RNA in exosomes, it should not be forgotten that exosomal preparations used in 
most of the papers described above were crude. Therefore, some of the detected 
RNA may be in the fraction with co-isolating proteins and their complexes, which 
may be separated from exosomes with gel filtration.
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4. Milk exosomes: perspectives of use
The first paper describing human milk exosomes was published in 2007 [6] 
and dedicated to the interaction of exosomes with blood cells in cell cultures. 
Preparations of human milk vesicles inhibited interleukin-2, γ-interferon, and 
tumor necrosis factor α production by peripheral blood mononuclear cells and 
stimulated the increase of Foxp3+ cell proportion in vitro.
Exosomes are natural vesicles with very promising perspectives for drug 
therapeutic nucleic acid delivery into the cells. One of the unresolved problems so 
far is the development of universal sources for isolation of preparative amounts 
of exosomes. The use of milk allows researchers to obtain exosome prepara-
tion several liters of milk at once that makes milk a cheap and unique source of 
exosomes.
Milk exosomes can be used for targeted drug delivery to cells. It is shown that 
exosomes of cow [83] and human [88] milk penetrate intestinal crypt-like cells. The 
possibility of milk exosomes to be used as agents for delivery of proteins, nucleic 
acids, and drugs makes the subject of its investigation extremely relevant. Since the 
components of cow milk can be used for therapy with significant limitations, since 
in this case the transmission of prion diseases cannot be excluded [90], analysis of 
exosomes isolated from other milk sources is very actual.
Encapsulation of curcumin in buffalo milk exosomes increased its stability in 
salivary, gastric, pancreatic secrets as well as in bile juice. Also, curcumin encap-
sulated in milk exosomes was successfully uptaken and trans-epithelial trans-
ported in Caco-2 cells [91]. Since curcumin is a hydrophobic and water-insoluble 
molecule, it binds to the exosomes and probably incorporates in exosomal 
membranes. Hydrophobic drug molecules (paclitaxel [92], doxorubicin [93], 
and others) can also be delivered via milk exosomes with the same mechanism. 
Similar results were obtained in the case of chemically synthesized siRNA [86]. 
Transfection of siRNA in cow milk exosomes protects it from the activity of 
digestive juices and increases delivery to Caco-2 cells compared to the control 
samples.
According to several works, milk exosomes contain antibody molecules on the 
surface. Transport of IgG molecules in the intestine occurs as a result of binding 
to neonatal Fc receptor (FcRn). Cow milk-derived exosomes were success-
fully delivered to the mice liver, heart, spleen, lungs, and kidneys after the oral 
administration [94].
Auspicious work shows the possibility of transfer of bovine leukemia virus 
proteins Env (gp51) and Gag (p24), but not viral DNA with milk exosomes obtained 
from infected cattle [95]. This route of viral protein delivery doesn't require 
viral infection since that may have the potential of use for immunization and/or 
vaccination.
Incubation of human milk exosomes, but not the blood plasma exosomes with 
monocyte-derived dendritic cells, results in DC-SIGN inhibition of HIV infection 
of dendritic cells and protects from HIV transfer to CD4+ T lymphocytes [96]. 
These results may partially explain why some breastfeed infants do not get infected 
from HIV-infected mothers.
Yak milk exosomes facilitate survival of intestine cells in hypoxic conditions 
in vitro and have significantly higher activity than cow milk exosomes. Yak milk-
derived exosomes also decrease the expression of p53, increase the expression 
of oxygen-sensitive prolyl hydroxylase, and decrease the expression of vascular 
endothelial growth factor via the hypoxia-inducible factor-α in cell cultures [97]. 
Human milk exosomes protect intestinal epithelium cells in vitro from oxidative 
stress and probably defend newborns from enterocolitis [98].
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It should be noted that the correct use of vesicles for medicine still requires 
extra-purified exosome preparation and analysis of the functioning of such exo-
somes. Also, it cannot be excluded that any proteins and other biologically active 
molecules firmly connected with the surface of vesicles can also be necessary for 
the manifestation of exosome biological functions. However, this issue also requires 
further research.
5. Conclusions
Milk is more than a source of nutrients and vitamins for newborn [99]; it contains 
different proteins and protein complexes [100] with very diverse functions. Milk is a 
biological liquid containing vesicles of different size and shapes. Exosomes are natural 
vesicles with a diameter of 40–100 nm and are found in milk obtained from human, 
cow, horse, camel, mice, rat, swine, and some other mammalian species. There is no 
doubt that milk obtained from any source contains such structures. Many biologi-
cal effects are attributed to exosomes, and researchers are particularly interested in 
milk exosomes, since they can be used as carriers of drugs and therapeutic nucleic 
acids for delivery to cells. The physicochemical properties and biological functions of 
exosomes are primarily determined by their biochemical composition—the structure 
of lipids, proteins, and nucleic acids. The prospects for the further practical use of 
milk exosomes in medicine and biotechnology largely depend on investigations of 
the fine structure and biological functions of exosomes free of various contaminating 
impurities.
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Abstract
The extracellular environment exhibits a potent effect on cellular growth and 
development. Exosomes secreted into this milieu carry functional proteins and 
nucleic acids from the cell of origin to recipient cells, facilitating intercellular 
communication. This interaction is particularly influential in the tumor microenvi-
ronment, transporting oncogenes and oncoproteins within a tumor and to distant 
sites. The mechanisms by which cells internalize exosomes vary greatly and the 
factors dictating this process are still unknown. Most cancers show evidence of 
exosomal transfer of material, but differences in cell type can dictate the effective-
ness and extent of the process. Improving therapeutics requires addressing specific 
cellular functions, illustrating the need to better understand the forces involved in 
exosome-cell interactions. This review summarizes what is known about the differ-
ent types of cells that play a role in exosome internalization.
Keywords: exosome, endocytosis, receptors, internalization, uptake
1. Introduction
Intercellular communication is essential to homeostasis and is largely dependent 
on the cellular secretome [1]. An emerging awareness of the role that the extracellu-
lar environment plays is evident in the field of secreted vesicles. The vesicular con-
tribution to the tumor microenvironment (TME) has furthered our understanding 
of the communication between cells and the surrounding stroma [2]. This relation-
ship has also elucidated many potential therapeutic targets and possible transport-
ers of chemotherapeutics [3, 4]. There are multiple extracellular vesicle types, 
characterized by biogenesis, size, and common protein markers [5, 6]. Of these, 
exosomes are the smallest, with sizes ranging from 30 to 150 nm [6]. These vesicles 
have the most complex synthesis, emerging from the endocytic pathway. They arise 
from intraluminal invaginations into a multivesicular body (MVB) and are released 
from the cell when the MVB fuses with the plasma membrane. Exosomes consist 
of intracellular material surrounded by a lipid membrane that reflects the cellular 
membrane of the host cell [7]. These specific vesicles have demonstrated promise 
in several fields of research, including rheumatoid arthritis [8, 9] and neurode-
generative disease [10], but primarily in cancer [11, 12]. Tumor-derived exosomes 
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(TEX) contain oncoproteins and oncogenes from the cell of origin and thus are 
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very influential in intercellular communication. Numerous studies have used these 
luminal proteins and genes to better understand tumor growth and metastasis, as 
well as for improving diagnostic, prognostic, and therapeutic methods [13, 14].
While there has been an exponential growth in research focused on exosome 
biology, clarification on the mechanisms of transport between the cell of origin and 
the recipient cell is essential to maximizing on exosome potential in treating and 
diagnosing disease. The methods by which exosomes influence the cells with which 
they interact are still under review. Some exosomes have been shown to fuse to 
the recipient cell [15, 16], while others are internalized by specific receptor-ligand 
interactions [17, 18] or by stimulating an indirect uptake by macropinocytosis [19]. 
Exosome binding to cells has been seen both as a mechanism of transferring luminal 
contents [15, 16] and as an initial step in the endocytosis process [17, 20]. The 
significance of the effects of cell-exosome binding in comparison to internalization 
is still unknown. Most types of endocytosis have been described in the process of 
exosome uptake [21], but which factors determine the specific mechanism used, 
are still unclear. Previous reviews have clearly identified a number of ligands and 
receptors involved in exosome trafficking [21–23], but little is known about the 
dependence of uptake mechanism on cell-type. This review presents the current 
understanding of the endocytosis process utilized by specific cells involved in 
exosomal internalization.
2. Endocytosis pathways
Endocytosis is a basic cellular function that is performed by all cell types in the 
process of maintaining homeostasis. Many of the molecules essential for cellular 
function are small enough to cross the cell membrane either passively or actively, 
however, other structures, such as exosomes, are too large and require a more 
complicated process. This general process of internalization is called endocytosis 
and is separated into various types based on the shape [24] and the size of particles 
internalized [25]. There are many well-written reviews covering the specifics of 
the endocytic pathways [25, 26], but here we will address them only superficially. 
Classification under the umbrella of endocytosis varies, but the major methods 
include phagocytosis, macropinocytosis, clathrin-mediated endocytosis, caveolin-
mediated endocytosis, and clathrin/caveolin-independent or lipid raft-mediated 
endocytosis [25, 26]. Receptor-mediated endocytosis (RME) is an additional type 
that is often considered to be a subcategory under several of those previously 
mentioned (Figure 1).
2.1 Phagocytosis
Phagocytosis is the mechanism by which specialized cells (such as macrophages 
and monocytes) engulf large particles (>0.5 μm) by way of receptor/ligand interac-
tions [25, 27] (Figure 1A). Promiscuous receptors allow for a broad range of ligand 
recognition and binding, facilitating a key role phagocytes play in clearing apoptotic 
cells [27]. Exosomes, derived from a diverse population of cells, present a vast 
array of available ligands that make phagocytes ideal recipient cells. This process of 
phagocytosis is designed to not only internalize extracellular material by envelop-
ing it, but also to regulate the immune response by presenting degraded proteins 
as antigens on the phagocyte surface [25]. Tumor-derived exosomes influence 
immune involvement in the tumor [28, 29] which may be facilitated by this mecha-
nism of endocytosis. Other non-phagocytic cells, such as epithelial cells, Sertoli, 
liver endothelial, astrocytes, and cancer cells have also been shown to perform 
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phagocytosis [27], potentially expanding the impact of exosomal communication. It 
is therefore important to define how the process of phagocytosis influences exo-
some function and if that influence is cell type dependent.
2.2 Macropinocytosis
While phagocytosis or “cell eating” involves ingestion of large molecules, 
macropinocytosis (“cell drinking”) internalizes slightly smaller particles (>1 μm) 
[25] (Figure 1B). This method is a way for cells to sample the external environ-
ment without specific receptors or ligands. It is a constitutive process in specialized 
antigen presenting cells, but is stimulated by growth factors in most others [30]. 
Macropinocytosis has a unique membrane ruffling process caused by projections 
from the cell surface encircling extracellular fluid and fusing to the membrane [25], 
resulting in an increased membrane surface area and volume of engulfed mate-
rial. Nakase et al., showed that stimulation of the epidermal growth factor (EGF) 
Figure 1. 
Endocytosis pathways involved in exosome uptake: (A) Phagocytosis, (B) Macropinocytosis, (C) Clathrin-
mediated endocytosis, (D) Caveolin-mediated endocytosis, (E) Lipid Raft-dependent or clathrin−/caveolin-
independent endocytosis, (F) Receptor-mediated endocytosis.
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receptor, either by soluble EGF or exosome-bound, increased exosome internaliza-
tion 27-fold through the activation of macropinocytosis [19].
2.3 Clathrin-dependent endocytosis
The next three mechanisms, clathrin-dependent, caveolae-dependent, and 
clathrin/caveolae-independent, are facilitated by specific membrane proteins/
structures: clathrin, caveolae, and lipid rafts. Clathrin is an intracellular protein that 
forms a coat around an invaginating vesicle facilitating formation and internaliza-
tion [31] (Figure 1C). These vesicles internalize material around 120 nm [25], 
which is within the exosome size range. Stimulation can occur through receptor/
ligand mediation or can be constitutive, depending on cell-type and receptor 
presence, but clathrin-mediated endocytosis (CME) occurs in all cell types [31]. 
Data continues to show that the extracellular cargo of these clathrin-coated vesicles 
can drive the specific mechanisms and protein interactions of internalization [32], 
giving way for exosome surface proteins to influence uptake. Two proteins used 
extensively to describe the details of CME are transferrin (Tf) and low density 
lipoprotein (LDL) and their respective receptors [25], which are all (except LDL) 
found on the surface of exosomes [33, 34]. Overexpression of transferrin receptors 
on cancer cells [35] may also contribute to increased exosomal uptake and clathrin-
mediated endocytosis in tumors, as there have been shown to be 50–80 percent 
more receptors on the cancer cell compared to the non-cancer cell [36].
2.4 Caveolin-dependent endocytosis
Caveolin is similar to clathrin, as it forms a coat around membrane invaginations 
called caveolae and facilitates the entry of extracellular material  
(Figure 1D). These are particularly prevalent on endothelial cells but have been 
found on a wide distribution of cell types [25]. Caveolae are about half the size 
of clathrin-coated vesicles, limiting their cargo to smaller structures [25] but still 
covering some of the exosome size range. This type of endocytosis as well as lipid 
raft-dependent uptake, plays a key role in lipid transport and homeostasis [25]. One 
of the defining factors of the exosome membrane is its slightly altered lipid profile, 
which has been shown to influence internalization [37]. Two proteins commonly 
active in caveolae-dependent endocytosis, which have also been identified on the 
surface of exosomes, are the insulin receptor and albumin [34, 38, 39]. The cellular 
insulin receptor itself has also recently been found to influence exosome uptake [18].
2.5 Lipid raft dependent or clathrin-/caveolin-independent endocytosis
Lipid dependence is not only characteristic of caveolae-dependent endocytosis, 
but also clathrin/caveolae-independent processes. Lipid raft-dependent (or clathrin/ 
caveolae-independent) endocytosis is similar to caveolae-dependent, except for the 
absence of the protein cav-1. Lipid rafts are 40-50 nm sections of the membrane 
with a high percentage of glycosphingolipids and cholesterol, and are anchoring 
points for many membrane proteins [40]. Lipid rafts are involved in exosome bio-
genesis and trafficking [41–43] and exosome uptake has been reduced by blocking 
lipid raft endocytosis [44] (Figure 1E).
2.6 Receptor mediated endocytosis
As mentioned previously, RME is an endocytosis pathway that can fit under 
several of the other categories (Figure 1F). The term and pathway were originally 
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considered to be interchangeable with CME, but it is now understood that not 
all RME is dependent on clathrin [25]. Receptor-ligand interactions play a role in 
phagocytosis [25, 27], macropinocytosis [19], and lipid raft-dependent endocytosis 
[40]. Exosome internalization has been linked to multiple receptor-ligand interac-
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Endocytosis pathways involved in exosome internalization in various cell types.
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identified in the exosome internalization process (Table 1) but additional research 
is needed to determine the driving factors behind the specific mechanisms. One 
hypothesized factor is that the recipient cell type may determine the specific type of 
internalization.
3. Cell type-specific internalization of exosomes
3.1 Phagocytes
As introduced previously, some cells are uniquely designed to internalize 
extracellular material through phagocytosis. Those cells generally considered 
“professional” phagocytes are monocytes, macrophages, and neutrophils [25] with 
dendritic cells, osteoclasts, and eosinophils occasionally included [27]. Phagocytosis 
is dependent on receptor/ligand interactions, relying on a vast array of different 
receptors and ligands. Some of the established receptors include Fc receptors, integ-
rins, pattern-recognition receptors, phosphatidylserine (PS) receptors, and scav-
enger receptors [45]. Macrophage uptake of exosomes has been shown to involve 
many of these receptors including scavenger receptors [46–48], PS/PS receptors 
[20, 48–51], lectins [17, 52, 53] and Fc receptors [54].
However, internalization of extracellular material by phagocytes does not always 
fit perfectly with the hallmarks of phagocytosis. Some phagocytic receptors, such 
as integrins (αvβ3), scavenger receptors (CD68 and CD36), and CD14, facilitate the 
tethering of apoptotic cells to the phagocyte surface, but then are unable to initiate 
internalization without other means, such as PS and PS receptor binding [55]. The PS/
PS receptor interaction also stimulates membrane ruffling and vacuole appearance—
classic hallmarks of macropinocytosis [55]. Phagocytes are primarily involved in 
phagocytosis, but this evidence supports the idea that multiple modes of endocytosis 
are operational in the same cell. This is not unique to apoptotic cell uptake, but has 
been seen with exosome internalization by microglia (phagocytic cells in the brain) 
exhibiting a dependence on PS in a macropinocytic manner [49, 56]. Cooperation 
between multiple receptors appears to be an important characteristic of endocytosis in 
phagocytic cells. Plebenak et al., showed that the scavenger receptor SR-B1 on macro-
phages, when blocked, reduces exosome uptake, but with further testing on melanoma 
cells this blocking was dependent both on the receptor as well as on cholesterol flux 
in the lipid rafts [46], broadening the endocytosis landscape of phagocytes to include 
lipid raft-dependent endocytosis.
The dependence of phagocytosis on extracellular- facing PS, which on healthy cells 
is expressed only on the cytosolic side of the membrane, is evidence that the material 
to be ingested influences the endocytic pathway of phagocytes. Further support of 
this interaction is found in the hypothesis that exosomes “target” specific recipient 
cells [48, 57]. Macrophage uptake (Figure 2A) of TEX is dependent on the presence of 
cellular scavenger receptors or exosomal PS [20, 46, 48, 51, 56], while non-tumor cell-
derived exosomes require the presence of a heterogeneity of receptors. When internal-
ized by macrophages and monocytes, hepatic stellate cell-derived exosomes require Fc 
receptors [54]; B cell, dendritic cell and reticulocyte-derived exosomes use lectins  
[52, 53]; trophoblast-derived exosomes bind to integrins [58]; and T cell-derived 
exosomes need scavenger receptors [50] (Table 2). Costa-Silva et al., showed that 
when comparing TEX to normal cell-derived exosomes, Kupffer cells, liver-specific 
macrophages, preferentially internalized TEX [57]. The significance of the exosome 
surface topography is therefore influential in directing a specific endocytosis pathway. 
Phagocytes are responsible for internalization of extracellular material and are so 
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considered to be interchangeable with CME, but it is now understood that not 
all RME is dependent on clathrin [25]. Receptor-ligand interactions play a role in 
phagocytosis [25, 27], macropinocytosis [19], and lipid raft-dependent endocytosis 
[40]. Exosome internalization has been linked to multiple receptor-ligand interac-
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identified in the exosome internalization process (Table 1) but additional research 
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named based on the primary use of phagocytosis, but as seen above, other endocytic 
pathways are utilized, especially in the context of exosomal internalization.
3.2 Antigen presenting cells
The antigen presenting cells (APCs) include primary phagocytes such as mac-
rophages, but also B cells and dendritic cells [59]. The immune response is heavily 
dependent on the recognition of foreign structures, such as peptides, for activation. 
These APCs sample the extracellular environment, digest and display peptides on 
their surface, and then present these peptides to immune cells that can execute the 
response. The intercellular trafficking of immune regulating proteins, such as the 
major histocompatibility complexes (MHC) [28], by exosomes has the potential to 
either stimulate or block the immune response, dependent on the exosomal con-
tents [17]. Uptake of exosomes plays an important role in B cell and DC cell prolif-
eration, protein presentation, and interactions with other immune cells [17].
B cells perform multiple functions as an immune cell, including presenting 
antigens to T cells in order to stimulate additional immune responses. B cells 
traditionally operate though clathrin-mediated endocytosis, relying heavily on the 
B-cell receptor [60]. However, when it comes to exosome internalization, B cells 
have shown a greater dependence on lipid rafts and various receptors, such as adhe-
sion molecules and tetraspanins [17] than on clathrin, indicating a preference for 
clathrin-independent and receptor-mediated endocytosis (Figure 2B). In analyzing 
B cell uptake of exosomes, using the mantle cell lymphoma (mutated immature B 
cell) cell line, Jeko-1, Hazan-Halevy et al., found dynamin, epidermal growth factor 
receptor (EGFR), and cholesterol to be involved in exosome internalization instead 
of clathrin [61]. EGFR is a well-established target in cancer therapy, particularly 
with lung cancer [62] and its role in exosome internalization may lend clarity and 
power to multiple existing and future chemotherapeutics. Additional exosomal 
surface proteins, with receptor functions, have been identified as participants in  
Figure 2. 
Cell-specific internalization of exosomes by antigen presenting cells: (A) macrophage, (B) B cell and  
(C) Dendritic cells each employ multiple endocytic pathways in the uptake of exosomes. Macrophages utilize 
multiple endocytic pathways in the uptake of exosomes. B Cells and dendritic cells (DC) both employ multiple 
endocytic pathways in the uptake of exsomes. Lipid rafts, integrins and adhesion molecules are used by B cells 
while tetraspanins and adhesion molecules are the more common receptors found in DC-exosome interactions. 
Intercellular adhesion molecule 1 (ICAM-1), Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin (DC-SIGN).
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Protein Cell type Exosome origin References
Scavenger receptor Macrophage Hek293 (embryonic 
kidney cells)
[47]
Phosphatidylserine (PS) Macrophage, microglia Neuron, melanoma, 
oligodendrocytes
[49–51, 56]
PS receptor Macrophage Activated T cells [50]
TIM4 Macrophage K562, MT4 (leukemia 
cell lines)
[20]
Lectins Lymph node cells, splenic cells, 
pancreatic adenocarcinoma, 
lung fibroblast, macrophage, 
dendritic cell, hCMEC/
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[17]
CD44 Lymph node cells/splenic cells Pancreatic 
adenocarcinoma cells
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CD49d/CD106 Lymph node cells/splenic cells Pancreatic 
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[16, 17, 37, 65, 
69, 89]
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(bladder cancer cells)
U-87 cells, myeloma 
cells, SW780 cells
[63, 99, 100, 
101]
Cad-11 PC3-mm2 (prostate cancer 
cells)
Osteoblasts [104]
Syncytin Choriocarcinoma cells Trophoblasts [105]
SNAP 25 Neuron Mesenchymal stromal 
cells
[116]
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B cell internalization of TEX, including integrins (CD49) and cell adhesion mol-
ecules (intercellular adhesion molecule 1—ICAM-1/CD54 and CD62L) [17].
These protein interactions between the cell and the exosomal membranes are 
essential steps in the influence the exosome has on the recipient cell. Exosomes 
derived from myeloma cells, cancerous plasma (mature B) cells, are dependent 
on the interaction between exosomal fibronectin and cellular heparan sulfate 
in order to form a bond between cell and exosome, resulting in modification of 
intracellular signaling [63]. As seen with these cells, the effects caused by the 
exosomes are not entirely dependent on uptake, even though the standard opera-
tion of APCs requires internalization. Some exosome-cell binding (as opposed to 
internalization) may be sufficient, or specifically designed, to alter intracellular 
processes, including signaling, as is also seen with dendritic cell-derived exosomes 
and T cell function [16]. While the influence of heparan sulfate on internalization 
in B cells is still unclear, there is evidence linking heparan sulfate proteoglycans 
to exosomal internalization which indicates that while it wasn’t assessed in these 
cells, the uptake may still be present [21–23]. Whether these differing mecha-
nisms and protein participants of uptake in the B cell population are dependent 
on normal versus oncologic physiology of recipient cells, or on the origin of the 
exosome population (tumor-derived versus non-tumor derived) is yet to be 
determined.
These heterogeneous protein profiles are specific to each cell type and contribute 
to the comparative ability of each cell to internalize exosomes. In line with the 
role of B cells, it was found that they readily take in exosomes, in contrast to other 
immune cells such as T cells and natural killer cells [61, 64]. This suggests that 
certain immune cells are more effective at endocytosing exosomes than others, 
consistent with the primary functions of these specific cell types. Additional groups 
have shown that while B cells internalize exosomes, the uptake is significantly less 
than that of macrophages and dendritic cells, but similar to T cells [17]. This was 
shown in non-mutated mouse cells and may also illustrate important differences 
between cancer cell and normal cell internalization mechanisms.
Dendritic cells (DC) can be classified as both APCs and as phagocytes since 
internalization of extracellular material is a crucial part of their role in the immune 
system. Endocytosis pathways involved in exosome uptake in these cells have been 
tested with various endocytic blockers, including cytochalasin D (inhibits actin 
polymerization), EDTA (chelates calcium), and decreased temperature (reducing 
active cellular processes) [15, 37, 65, 66]. As dendritic cells mature, their mode of 
endocytosis changes; starting first with macropinocytosis, and then in the mature 
cell, receptor-mediated endocytosis and phagocytosis prevails [67] (Figure 2C). 
Despite the evidence of phagocytosis in mature DCs, it was demonstrated that 
immature DCs are more adept at exosomal uptake [37, 68]. Developmental prefer-
ence for exosome uptake may shed light on why cancer cells, which often have 
Protein Cell type Exosome origin References
Galectin 5 Macrophage Reticulocyte [52]
CD169/ α2,3-linked sialic 
acid
Lymph node cells, splenic cells B cell [53]
C-type lectin/C-type 
lectin receptor
Dendritic cell, brain 
endothelial cell (hCMEC/D3)
Macrophage [65, 89]
P-selectin/PSGL-1 Platelet Macrophage [72]
Table 2. 
Proteins involved in exosomal uptake.
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similar profiles to developing cells and are subject to continuous proliferation, are so 
responsive to modification by exosomes. Also, immature DCs play a role in immu-
nologic tolerance and so are less likely to activate T cells, while mature DCs activate 
T cell immunity [15]. This down-regulation of the adaptive immune response by 
immature DCs would be advantageous for tumors and so TEX may specifically 
target immature DCs, explaining the increase in uptake. While the mechanism is 
still unknown, dendritic cells are also more likely to take up TEX or DC-derived 
exosomes than B and T cells, as seen with fluorescent staining in vitro and in vivo 
in a rat model of pancreatic adenocarcinoma [17] and flow cytometry analysis of 
mouse bone marrow derived cells [15]. The CD11c membrane protein present on 
the DC and not on the other cells, was found to be involved in the internalization 
of TEX, as uptake decreased in the presence of an antibody to CD11c. The expres-
sion of this protein unique to DCs may contribute to the disparity in uptake among 
the immune cell types [17]. Recipient cell specificity in exosome uptake and DC 
interconnection with immune effector cells is another potential area of immune-
therapeutic manipulation.
Many of the studies of exosome internalization by DCs have revealed 
dependence on various adhesion molecules. The ubiquity of these proteins on 
exosomes, leukocytes, and endothelial cells promotes the non-specific inter-
nalization characteristic of DCs. The involvement of ICAM-1 and/or its ligand, 
lymphocyte function-associated antigen (LFA-1), in DC-exosome interaction has 
been shown both in vitro and in vivo [16, 17, 37, 65, 69]. These interactions are not 
unique to exosome uptake as DCs regularly depend on a wide range of adhesion 
molecules, including a dendritic cell-specific intercellular adhesion molecule-3 
grabbing non-integrin (DC-SIGN) [70]. This particular adhesion molecule has 
been shown to be more effective at exosome uptake by DCs, when looking at 
breast milk-derived exosomes, than the ICAM-1/LFA-1 binding [71]. In addition 
to adhesion molecules, C-type lectin and its receptor have also been identified in 
DC-exosome binding [65]. These glycan binding proteins have also been identi-
fied as exosome uptake mediators in other cell types, including macrophages [52] 
and platelets [72].
In addition to binding to membrane receptors, dendritic cell endocytosis is 
dependent on lipid rafts and the lipid components of the cell membrane, particu-
larly with viral or bacterial uptake [73, 74]. As viruses and exosomes are similar in 
size, endocytosis mechanisms are often common between these two structures [22]. 
Lipid-dependent endocytosis is evident in exosome uptake by DCs as illustrated 
with DC- and T-cell derived exosomes [15, 75]. While proteins have been the most 
common structure analyzed in connection with exosomal uptake, the membrane 
cholesterol concentration of recipient cells [15] as well as the lipid profile of the 
exosomal membrane [75] both play a role in uptake of exosomes by dendritic cells 
and need further clarification.
3.3 Circulating cells
In addition to the previously mentioned cells, two other circulating cells/struc-
tures have also been found to endocytose exosomes, platelets and T cells. Platelets 
are cell fragments involved in blood coagulation that are unique in their formation 
as they are devoid of a nucleus and some organelles. Despite a reduced intracel-
lular load, they are involved in binding extracellular vesicles. They do so through 
the interaction of cellular P-selectin and vesicular P-selectin glycoprotein ligand-1 
(PSGL-1) as well as PS [72]. Data suggests that binding facilitates fusion of the 
exosomes to the platelets, transferring of material and enhancing platelet coagula-
tion activity [72]. This speaks to the impact of these exosomes on intracellular 
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similar profiles to developing cells and are subject to continuous proliferation, are so 
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nologic tolerance and so are less likely to activate T cells, while mature DCs activate 
T cell immunity [15]. This down-regulation of the adaptive immune response by 
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sion of this protein unique to DCs may contribute to the disparity in uptake among 
the immune cell types [17]. Recipient cell specificity in exosome uptake and DC 
interconnection with immune effector cells is another potential area of immune-
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been shown both in vitro and in vivo [16, 17, 37, 65, 69]. These interactions are not 
unique to exosome uptake as DCs regularly depend on a wide range of adhesion 
molecules, including a dendritic cell-specific intercellular adhesion molecule-3 
grabbing non-integrin (DC-SIGN) [70]. This particular adhesion molecule has 
been shown to be more effective at exosome uptake by DCs, when looking at 
breast milk-derived exosomes, than the ICAM-1/LFA-1 binding [71]. In addition 
to adhesion molecules, C-type lectin and its receptor have also been identified in 
DC-exosome binding [65]. These glycan binding proteins have also been identi-
fied as exosome uptake mediators in other cell types, including macrophages [52] 
and platelets [72].
In addition to binding to membrane receptors, dendritic cell endocytosis is 
dependent on lipid rafts and the lipid components of the cell membrane, particu-
larly with viral or bacterial uptake [73, 74]. As viruses and exosomes are similar in 
size, endocytosis mechanisms are often common between these two structures [22]. 
Lipid-dependent endocytosis is evident in exosome uptake by DCs as illustrated 
with DC- and T-cell derived exosomes [15, 75]. While proteins have been the most 
common structure analyzed in connection with exosomal uptake, the membrane 
cholesterol concentration of recipient cells [15] as well as the lipid profile of the 
exosomal membrane [75] both play a role in uptake of exosomes by dendritic cells 
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3.3 Circulating cells
In addition to the previously mentioned cells, two other circulating cells/struc-
tures have also been found to endocytose exosomes, platelets and T cells. Platelets 
are cell fragments involved in blood coagulation that are unique in their formation 
as they are devoid of a nucleus and some organelles. Despite a reduced intracel-
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tion activity [72]. This speaks to the impact of these exosomes on intracellular 
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communication, both in the variability and specificity of recipient cells, since bind-
ing and fusion occurred preferentially in the activated platelets [72] (Figure 3A).  
The exosomes in this study came from monocytes, suggesting this interaction could 
be a key player in coagulation at a site of injury.
T cells are the effector cells of the immune system and intercellular com-
munication is essential for activation. Endocytosis, while not a primary function 
of T cells, is important to T cell receptor signaling [76] as well as other func-
tions. Dynamin-dependent endocytosis [76], phagocytosis [77], and RME [78] 
are some of the mechanisms involved in T cell interaction with its surrounding 
environment. In relation to exosomes, T cells operate through RME [17, 79, 80] 
and lipid raft-dependent endocytosis [75]. However, T cells do not always read-
ily uptake exosomes as was found in a comparison with other blood cell types. 
In a peripheral blood mononuclear cell culture, when uptake by monocytes was 
blocked, internalization by T-cells increased [47], suggesting that T cell uptake 
may be an adaptive response to increased exosome concentration. When exosome 
uptake was compared to multiple splenic leukocytes [15] or peripheral blood 
leukocytes [64], T cells showed minimal internalization. T cell activity is often 
regulated by surface interactions with other cells, such as with the T cell receptor 
and the MHC II/antigen interaction with APCs. Exosomal influence on T cells may 
therefore operate similarly with surface interaction instead of exosome internal-
ization (Figure 3B). When cultured with DC or DC-derived exosomes, T cells 
acquired functional surface molecules including MHC II from exosomes through 
direct exosome interaction with the T cell membrane, while still showing little 
evidence of internalization [81]. Mouse T cells do not express MHC II and after 
incubation with these exosomes, this protein was identified on the surface of the 
T cell, suggesting the binding of exosomes to cellular membranes is sufficient to 
transfer material, without internalization [81]. Further research into the transfer 
of material between exosomes and immune cells may elucidate the role exosomes 
play in immune regulation in the tumor microenvironment. Depending on the cell 
Figure 3. 
Cell-specific internalization of exosomes: (A) Platelet-exosome interactions have been linked to fusion as well 
as the binding to PSGL-1 and phosphatidylserine, (B) T cell are influenced through their surface interactions 
with exosomes.
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type involved, exosome-mediated communication and manipulation may not be 
entirely dependent on endocytosis.
3.4 Epithelial and endothelial cells
Epithelial and endothelial cells are responsible for lining most of the organs, 
spaces, and blood vessels in the body. They are in a prime position to be exposed to 
and actively endocytose a wide variety of extracellular material. Due to this broad 
selection, the specific mechanisms utilized are dependent on the cell subtype as well 
as the character of the endocytosed material [82–84]. With such variability, it is no 
surprise that exosome uptake by epithelial and endothelial cells is just as diverse 
(Figure 4). Cellular location of these cells is crucial in cancer biology as most of the 
TEX will be in close proximity to epithelial and endothelial cells either in the cir-
culatory system or during paracrine spread in solid tumors. While there have been 
many studies on cell-exosome interaction in these cells, there is still much work 
needed to clearly understand all of the factors that dictate the endocytic mechanism 
of epithelial and endothelial cells from different tissues.
A unique finding in exosome studies with epithelial and endothelial cells is the 
dependence of uptake on intracellular signaling. Svensson et al., discovered that 
exosome internalization is dependent on the proper functioning of the signaling 
pathway, ERK1/2-HSP27 [43]. The promotion of endocytosis through intracellular 
signaling has been shown previously with EGFR-cSrc-ERK1/2 pathways in epi-
thelial cells [85] and the Ras-PI3K pathway with virus uptake by fibroblasts [86]. 
However, little is known about how these pathways facilitate exosome internaliza-
tion. The ability of exosomes to cross the blood–brain barrier and be endocytosed 
by the microvascular endothelial cells in the brain is also dependent on signaling. 
Tumor necrosis factor (TNFα) signaling, as is seen in stroke models, enhances 
exosome uptake [87]. Intracellular signaling may provide a regulatory mechanism 
Figure 4. 
Cell-specific internalization of exosomes: (A) epithelial and (B) endothelial cells. Epithelial cells and 
endothelial cells show the most diversity in exosome uptake of all the cell types. Multiple receptor involved in 
the internalization process are expressed on both cell types, including tetraspanins, adhesion molecules, and 
heparan sulfate peptidoglycans (HSPG). Intercellular adhesion molecule 1 (ICAM-1).
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communication, both in the variability and specificity of recipient cells, since bind-
ing and fusion occurred preferentially in the activated platelets [72] (Figure 3A).  
The exosomes in this study came from monocytes, suggesting this interaction could 
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direct exosome interaction with the T cell membrane, while still showing little 
evidence of internalization [81]. Mouse T cells do not express MHC II and after 
incubation with these exosomes, this protein was identified on the surface of the 
T cell, suggesting the binding of exosomes to cellular membranes is sufficient to 
transfer material, without internalization [81]. Further research into the transfer 
of material between exosomes and immune cells may elucidate the role exosomes 
play in immune regulation in the tumor microenvironment. Depending on the cell 
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to control exosome internalization. Some studies described previously have 
shown that fusion of exosomes to the cell membrane, without endocytosis, can 
influence intracellular signaling [63], but these are the first to show how intracel-
lular signaling specifically impacts the endocytosis mechanism of exosomes. 
These results illustrate the complexity of exosome-cell interactions and where 
additional research is needed. The interdependence of exosome-cell interactions 
and intracellular signaling are unexplored areas with vast therapeutic potential 
and are necessary to better understand how extracellular vesicles influence their 
environment.
Other characteristics are influential in directing endocytosis in epithelial 
cells including vesicle size, lipid profile, and protein profile (Figure 4A). In 
epithelial cells, particle size dictates entry mechanism with macropinocytosis 
as one of the pathways operative at a size range that corresponds with exosomes 
[88]. This pattern is supported by multiple studies where exosome internal-
ization was decreased when key aspects of macropinocytosis were targeted. 
Macropinocytosis was blocked with an inhibitor of Na+/H+ exchange (which 
affects Rac1 activation and actin reorganization) in human cerebral micro-
vascular endothelial cells (hCMEC/D3) [89] and HeLa cells, as well as with an 
inhibitor of phosphoinositide 3-kinase (PI3K) (influences membrane ruffling 
and macropinosome formation) [19, 90] with concomitant decreases in exosome 
internalization. Assessing the same pathway but from an activating instead of 
inhibiting direction, exosome internalization was stimulated by activation of 
epidermal growth factor receptor (which activates Rac family members) in HeLa 
cells [19]. Membrane extensions, or filopodia, that facilitate the formation of the 
macropinosome and are regulated by Rac1 activation have also been shown to 
influence exosome internalization in hepatocyte (Huh7) and kidney (Hek293) 
cells [91], furthering the support that exosomes utilize macropinocytosis in 
multiple epithelial cell lines.
The lipid profile of the exosomes and membrane integrity of the cell are also 
important contributors to vesicle uptake in several different types of epithelial and 
endothelial cells. While macrophages readily recognize external-facing PS, these 
cells can also utilize exosomal PS in the process of internalization, as was shown 
when pre-incubating exosomes with Annexin V inhibited uptake by HeLa cells (cer-
vical cancer epithelial cells), A375 and A431 cells (squamous skin cancer cells) [92] 
and in human umbilical vein endothelial cells (HUVEC) [93]. Disruption of cellular 
lipid raft integrity through cholesterol depletion or sequestration reduced exosome 
uptake in U87 human glioblastoma epithelial cells [43], hCME/D3 human cerebral 
microvascular cells [89], HeLa cells [43, 90], HUVECs [43, 46], and A375 cells [46]. 
Lipid rafts play a key role in many of the functions of epithelial cells, including 
the protein binding interactions between cell and extracellular environment. Also, 
some of the most central components to epithelial cell function are proteins that 
interact closely with the environment such as integrins and adhesion molecules, and 
are anchored into lipid rafts.
Protein interactions are essential to epithelial and endothelial function and are 
closely tied to several of the most common endocytosis pathways used by these 
cells. Clathrin-dependent endocytosis has been shown in gastric [94], nasopha-
ryngeal [95], breast [96], ovarian cancer epithelial cells [97] and HUVECs [98]. 
Caveolin-dependence was seen in breast [96] and nasopharyngeal cancer [95], 
however, caveolin-1 showed negative regulation in glioblastoma cell lines [43] 
(Figure 4B). General receptor-mediated uptake has been shown with several 
proteins including heparan sulfate peptidoglycan (HSPG) in glioblastoma cells 
and HUVECs [99, 100] and in the transitional epithelial cells of the bladder [101]; 
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intercellular adhesion molecule (ICAM1) in hCMEC/D3 cells [89], rat aortic endo-
thelial cells [48], and HUVECs [102]; lectins in cervical cancer [103], HUVECs 
[102], rat aortic endothelial cells [48] and hCMEC/D3 cells [89]; cad-11 in prostate 
cancer [104]; syncytin proteins in choriocarcinoma [105] and tetraspanins in an 
in vivo rat model of pancreatic cancer [48, 106]. The nature of cellular research 
has limited most of the epithelial endocytosis studies to cell lines, which consist 
entirely of transformed cells, and it is still unknown whether these trends are 
translatable to normal healthy epithelial and endothelial cells. While the mecha-
nisms remain unknown, cultured primary normal epithelial cells take up TEX 
[107] highlighting a role for exosome intercellular communication in normal cell 
physiology.
3.5 Fibroblasts
The extracellular matrix (ECM) and stroma are important contributors to cellular 
homeostasis and function. This is particularly evident in tumors when evaluating the 
role of the tumor microenvironment (TME) on the survival and progression of the 
tumor cells. Fibroblasts are the major component of this extracellular environment. 
In normal physiology, they promote stromal stability, while in cancer, they contrib-
ute to altered ECM, increased angiogenesis, and metastasis [108]. These cells are 
in a pivotal position to interact with circulating exosomes and their internalization 
can have a compounding effect on the surrounding environment. Fibroblasts have 
been shown to participate primarily in clathrin-mediated endocytosis [109, 110] and 
occasionally receptor-mediated endocytosis [111]. Interestingly, RME [48, 106] and 
macropinocytosis [91] are the mechanisms by which fibroblasts have been shown to 
internalize exosomes (Figure 5). Tetraspanins are important proteins in fibroblast 
function and migration [112]. This protein family is well represented on the exo-
somal surface and is key to the uptake in many different cell types [48]. Additionally, 
evidence shows that the smaller the size of the vesicle, the more likely the fibroblast 
is to use receptors to internalize particles [111]. These three qualities lend support to 
the evidence of RME as a key pathway for fibroblasts to endocytose exosomes.
Figure 5. 
Cell-specific internalization of exosomes: fibroblasts. Fibroblasts take up exosomes with tetraspanins and 
utilize multiple endocytic pathways.
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vascular endothelial cells (hCMEC/D3) [89] and HeLa cells, as well as with an 
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Lipid rafts play a key role in many of the functions of epithelial cells, including 
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however, caveolin-1 showed negative regulation in glioblastoma cell lines [43] 
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[102], rat aortic endothelial cells [48] and hCMEC/D3 cells [89]; cad-11 in prostate 
cancer [104]; syncytin proteins in choriocarcinoma [105] and tetraspanins in an 
in vivo rat model of pancreatic cancer [48, 106]. The nature of cellular research 
has limited most of the epithelial endocytosis studies to cell lines, which consist 
entirely of transformed cells, and it is still unknown whether these trends are 
translatable to normal healthy epithelial and endothelial cells. While the mecha-
nisms remain unknown, cultured primary normal epithelial cells take up TEX 
[107] highlighting a role for exosome intercellular communication in normal cell 
physiology.
3.5 Fibroblasts
The extracellular matrix (ECM) and stroma are important contributors to cellular 
homeostasis and function. This is particularly evident in tumors when evaluating the 
role of the tumor microenvironment (TME) on the survival and progression of the 
tumor cells. Fibroblasts are the major component of this extracellular environment. 
In normal physiology, they promote stromal stability, while in cancer, they contrib-
ute to altered ECM, increased angiogenesis, and metastasis [108]. These cells are 
in a pivotal position to interact with circulating exosomes and their internalization 
can have a compounding effect on the surrounding environment. Fibroblasts have 
been shown to participate primarily in clathrin-mediated endocytosis [109, 110] and 
occasionally receptor-mediated endocytosis [111]. Interestingly, RME [48, 106] and 
macropinocytosis [91] are the mechanisms by which fibroblasts have been shown to 
internalize exosomes (Figure 5). Tetraspanins are important proteins in fibroblast 
function and migration [112]. This protein family is well represented on the exo-
somal surface and is key to the uptake in many different cell types [48]. Additionally, 
evidence shows that the smaller the size of the vesicle, the more likely the fibroblast 
is to use receptors to internalize particles [111]. These three qualities lend support to 
the evidence of RME as a key pathway for fibroblasts to endocytose exosomes.
Figure 5. 
Cell-specific internalization of exosomes: fibroblasts. Fibroblasts take up exosomes with tetraspanins and 
utilize multiple endocytic pathways.
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3.6 Neurons and glial cells
The nervous system is a uniquely isolated environment with limited con-
nection to the systemic circulation. This characteristic has long impeded ther-
apeutic delivery for brain pathologies. The potential of exosome transport, 
however, is particularly poignant, as exosomes have been observed selectively 
targeting neurons and glial cells, successfully crossing the blood brain bar-
rier [113]. Improving our understanding of endocytosis mechanisms involved 
in these particular cells is essential to therapeutic progression. Clathrin-
mediated endocytosis is the most commonly observed pathway with exosomal 
trafficking between neurons and glial cells [114, 115]. However, some neurons 
also utilize macropinocytosis [114] and specific receptors, such as SNAP25 
(a SNARE family protein) [116], to take up exosomes (Figure 6). Microglia 
performs phagocytosis similar to their counterparts in the extra-neuronal 
environment [117]. Using exosomes from two different sources, Chivet et al., 
illustrated the specificity of exosome targeting seen elsewhere in the body, is 
also evident in the nervous system. Exosomes from a neuroblastoma cell line 
(N2a) were preferentially internalized by astrocytes and oligodendrocytes, 
whereas exosomes from cortical neurons were primarily taken up by hip-
pocampal neurons [118]. It was also shown that pre-synaptic regions were 
the primary site of internalization of these exosomes [118]. Endocytosis is an 
important process in the pre-synaptic membrane to recycle released synaptic 
vesicles [119], indicating that the exosomes may capitalize on this constitutive 
process for entrance to the neuron. Whether exosomes primarily utilize the 
specific clathrin-mediated endocytosis in this region [119] or are simply taken 
by chance with the constant bulk endocytosis [120] still remains unclear. 
Exosome uptake is a developing area of neuro-research, but with significant 
potential for therapeutics, it is growing rapidly.
Figure 6. 
Cell-specific internalization of exosomes: neurons. Neurons use similar pathways but receptor/ligand binding 
has less variability. Synaptosomal associated protein 25 (SNAP25).
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4. Conclusion
Exosomes are internalized by a multitude of cell types and play an important 
role in cellular physiology. Our grasp of the mechanisms of this internalization is 
growing as we are better able to identify characteristics of the cell and the vesicles 
that facilitate uptake. Pathologic states, such as cancer, have played an integral role 
in our understanding of how the cellular-exosomal interaction proceeds. Clarity is 
still needed to better understand the mechanisms by which exosome internaliza-
tion is so varied from cell to cell and within the same cell. As we have seen with 
fibroblasts, the vesicle size can dictate mechanism of uptake [111]. The presence or 
abundance of specific proteins such as scavenger receptors on macrophages [46–48] 
and lipid profiles in several types of cells, such as external-facing phosphatidylser-
ine [20, 48, 49, 56] all contribute to the specificity of uptake. As has been discussed, 
cell type can dictate uptake mechanism, particularly with phagocytic cells and pro-
fessional antigen presenting cells, but even within these specialized cells, differing 
mechanisms occur regularly and further evaluation is needed to parse the primary 
determinants.
Various types of endocytosis have been identified as possible mechanisms of 
intercellular transport of exosomal contents to include macropinocytosis [19, 
56, 114], phagocytosis [20], clathrin-mediated [52, 114], caveolin-dependent 
[95], lipid raft-dependent [43, 46], and clathrin- /caveolin-independent [61] 
endocytosis. Though much about these processes is unique, there are some aspects 
where functional overlap exists between them. Macropinocytosis is a form of 
endocytosis that consists of membrane ruffles forming intracellular vesicles to 
internalize large amounts of extracellular fluid [30]. This varies from other forms 
of endocytosis in its formation of separate and distinct intracellular vesicles (mac-
ropinosomes) and the internalization of material that is considered non-specific 
exosomal has been recorded in microglia [56], human epidermoid carcinoma-
derived A431 cells stimulated by endothelial growth factor receptor (EGFR) 
and by the pancreatic cancer MiaPaCa-2 cell line [19]. Macropinocytosis is not 
selective in which molecules are internalized from the extracellular environment, 
and so uptake may be dictated simply by proximity to the cells and not targeted by 
the exosome specifically [121]. However, it has been shown that some exosomes 
naturally induce macropinocytosis internalization [90] and others, through 
manipulation of exosomal content, can selectively activate this mechanism in 
order to increase uptake [122]. Phagocytosis is a much more common method of 
taking up exosomes, especially with phagocytic cells of the immune system. Feng 
et al., showed that two leukemia cell lines, K562 and MT4, solely utilized phago-
cytosis for exosome internalization [20, 121].
Four other general categories of endocytosis focus on specific cellular proteins 
that facilitate the uptake of particles. Clathrin and caveolin are both cytosolic 
proteins that form specific pits with which to internalize various substances 
[25]. The exact reasons why and when a cell uses clathrin, caveolin, or neither, 
is still incompletely understood but particle size and cell type seem to play a 
role [43, 115, 121]. Caveolin-dependent endocytosis is important in albumin 
uptake, cholesterol transport, and intracellular signaling. Due to the small size 
of the caveolae, its endocytosed material tends to be smaller than 60 nm [25]. 
Clathrin-dependent mechanisms however can internalize particles up to 120 nm. 
The size restrictions may indicate, with further investigation into which uptake 
mechanism is utilized by which cells, a possible functional difference between 
vesicle sizes within the current exosome size range [121]. The clathrin-dependent 
process is involved in many different cell types and functions ranging from vesicle 
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where functional overlap exists between them. Macropinocytosis is a form of 
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internalize large amounts of extracellular fluid [30]. This varies from other forms 
of endocytosis in its formation of separate and distinct intracellular vesicles (mac-
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selective in which molecules are internalized from the extracellular environment, 
and so uptake may be dictated simply by proximity to the cells and not targeted by 
the exosome specifically [121]. However, it has been shown that some exosomes 
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taking up exosomes, especially with phagocytic cells of the immune system. Feng 
et al., showed that two leukemia cell lines, K562 and MT4, solely utilized phago-
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uptake, cholesterol transport, and intracellular signaling. Due to the small size 
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recycling in the neuronal synapse to organ development and ion homeostasis [25]. 
Many of the common, well-known endocytosis receptors utilize clathrin coated 
pits, such as low-density lipoprotein receptor (LDLR) and transferrin recep-
tor (TfR). One of the most commonly used ways to determine which of these 
mechanisms is in operation is through inhibitory drugs or knocking down certain 
key players [121]. Dynamin, a GTPase, facilitates the fission of the intracellular 
clathrin coated vesicle [25, 123]. Dynasore, an inhibitor of dynamin, has been 
utilized to effectively block endocytosis of extracellular vesicles and establish 
clathrin-mediated endocytosis as a mechanism of uptake for these vesicles [21, 52, 
56]. Following siRNA downregulation of caveolin-1 (the primary protein involved 
in caveolae-dependent endocytosis), exosome internalization was significantly 
reduced in B cells [95, 121]. Inhibitory drugs have also been useful in the deter-
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Chapter 4
Effects of Vesicular Membranes




The activity of membrane enzymes could be highly determined by the order of
the lipid of the membrane and the enzyme distribution. Particularly, the reordering
of phospholipid substrates and the local fluctuations of the lipid phases have been
included in mathematical models to explain the modulation of the activity of mem-
brane enzymes in extracellular vesicles, liposomes, or microvesicles. The applied
principles are different to those derived from the classic considerations such as 3D
environment, aqueous, and homogeneous media. Instead, the lateral diffusion of
enzyme and substrate and highly nonhomogeneous 2D environment determine
fluctuations of enzymatic activity capable to explain metabolic effects, such as in
case of peptide-induced membrane components reordering. In this chapter, we
review some applications to lipid metabolizing enzymes, due to analytical results of
the kinetic theory of membrane enzymes.
Keywords: phospholipid domain, substrate reordering, lipolytic enzyme,
phospholipase, enzyme kinetics, lipid phase, micelle, membrane
1. Introduction
The so-called extracellular vesicles (EVs) are either exosomes or microvesicles,
which are formed from intracellular multivesicular bodies or plasma membrane,
respectively [1, 2]. The lipid content of EVs plays a key role in various pathophys-
iological processes [3] as well as the native proteins on their surface, many of them
having functions in cellular metabolism and signal transductions, such as phospho-
lipases [4]. Interestingly, some membrane protein-related human diseases arise
from dysregulation of signal transduction pathways [2]. Moreover, some phospho-
lipases are very important for biogenesis of EVs and there are many phospholipases
in EVs [5–7]. About the lipid phase of EVs, lipid exchange between vesicles has been
described [8], exosomes can vectorize some lipids acting as transport, and the lipid
composition can be modified by in vitro manipulation [7]. On the other hand,
microdomains of EVs could be transferred to a target membrane cells by means of
membrane fusion, and as a consequence, the lipid substrate redistribution could be
able to affect the activity of lipid metabolizing enzymes.
Taking into account all the abovementioned causes and effects of the EVs related
to both lipid substrate reordering and their metabolizing enzymes, the understand-
ing of the effect of lipid-substrate reordering over the enzyme activity could be
71
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essential to the development of therapeutic purposes as well as to insight the
carcinogenesis and to perform enzyme kinetics experiments. We hope that this
purpose of understanding the enzyme kinetics in the lipid phase will be fulfilled at
least partially in the remainder of this chapter.
Numerous processes associated with the cell membranes are mediated by the
action of lipid metabolizing enzymes. Knowing how the changes of membrane
properties affect the activity of these enzymes allows us to explain disease mecha-
nisms and pharmacological activities. Specifically, the knowledge about the mecha-
nisms of the reactions catalyzed by these lipid metabolizing enzymes can contribute
to the understanding of several regulation and signaling phenomena in cells. Thus,
the enzymes of the phospholipase C family (PLC) [9] are involved in lipid signaling
pathways affecting levels of free calcium and protein phosphorylation [10, 11],
regulating secretion, transport, metabolism, gene expression, and protein transla-
tion. Since phospholipases react in a lipid-water interface, different kinetic experi-
mental systems have been developed using phospholipid vesicles, phospholipid and
detergent mixed micelles, or phospholipid monolayers. As a first step, the water-
soluble enzyme would bind to the lipid phase, then having many catalytic cycles
with the lipid substrate before the enzyme returns to the aqueous solution.
To study the kinetic measurements of phospholipases, the theory known as
surface dilution kinetics [12] has been applied. This theory allows to estimate the
main enzyme kinetic parameters considering the effects of the substrate staying
into the lipid phase (“surface dilution”) on the enzyme activity. Similar to the most
enzyme kinetic models, in this theory, the mass action law and the steady-state
assumption for enzyme intermediaries are applied. In the calculations with regard
to molecules in water phase, their concentrations are used. Instead, in the case of
calculations of molecules dissolved in lipid phase, their mole fractions are used.
Using this theory and its associated experiments, it has been proposed that many
lipid metabolizing enzymes follow a mechanism composed by two binding steps of
the enzyme on the lipid phase: a first binding step to the lipid phase followed by a
second binding step to the substrate. More specifically, depending on the first
binding step, there are two possible kinetic models: in the phospholipid-binding
model, first the enzyme binds specifically to the phospholipid substrate; n the
surface-binding model, first the enzyme binds to any lipid phase region. In homoge-
neous substrate distribution conditions, these are the kinetic equations derived for
the phospholipid-binding model (Eq. 1) and the surface-binding model (Eq. 2) [12, 13]:




þ km f þ f 2
(1)
V ¼ kCET  fkmks
CL
þ km þ f
(2)
where V is the rate of product formation (mol/[volume�time]), f is the mole
fraction of the substrate (dimensionless), CET is the total enzyme concentration
(mol/volume), CL is the total lipid concentration (mol/volume), k is the catalytic
time constant (time�1), ks is the dissociation constant (mol/volume), and km is the
interfacial Michaelis constant (dimensionless).
A more complex approach must consider that phospholipids can be reordered in
lateral domains [14–16] because of their interactions with either phospholipids,
cytoskeleton, or charged soluble molecules, and then more adequate mathematical
expressions are necessary involving phospholipid reordering. For example,
phosphatidylinositol 4,5-biphosphate (PIP2) and phosphatidylserine (PS) can be
reordered in lateral domains because of the direct interactions with Ca2+ or basic
72
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molecules such as the protein myristoylated alanine-rich C kinase substrate
(MARCKS) or pentalysine (Lys5, one of the first five amino acid residues of the
region of bovine MARCKS) [17]. In biological membranes, the microdomain
structure and dynamics are widely diverse, considering the scaffolding of cell
proteins [18].
In order to find the effects of lipid substrate domain formation on enzyme
activities, it is necessary for an extended mathematical formulation starting for
similar principles to those of the original surface dilution kinetics theory. That is
because the total activity could be integrated by each one of these substrate
domains, i.e., whenever there is a phospholipid substrate (e.g., Figure 1), and
therefore, the formation of domains enriched in a phospholipid substrate could
either increase (inside the enriched domain) or decrease (outside the enriched
domain; i.e., inside the nonenriched domain) the total enzymatic activity on the
membrane. For this reason, it is useful to propose a comprehensive quantitative
model that explicitly takes into account the enzyme activity in the different phos-
pholipid phases, which here are frequently called substrate domains or simply
“domains,” to distinguish them from the eventual thermodynamic phases on mem-
branes. Below, a theoretical frame for lipid binary membrane systems is shown, and
then the theoretical frame is extended to a more realistic lipid phases with any
number of domains, including continuous gradient of phospholipid substrate
(thereby, considering an infinite number of infinitesimal domains).
2. Changes in the lipolytic enzyme activity due to substrate reordering
In the calculations of the lipase activities in membranes, it is assumed that
whatever the structure of the lipid phase (micelle, liposome, or monolayer), all the
lipids in the lipid-water interface expose the same area to the aqueous phase. As a
consequence, the area of the lipid phase surface is proportional to the amount of
lipid molecules. Then, at the beginning of the reaction, the lipid area will be
Figure 1.
A generalization of the surface dilution kinetics theory applied to lipolytic enzymes has been necessary for cases
of nonhomogeneous substrate distribution. This is because the reordering of the phospholipid substrate could
have important effects on the activity of lipolytic enzymes. In the figure, for the nonhomogeneous substrate
distribution, two domain phases can be distinguished: enriched substrate domain and nonenriched substrate
domain (named elsewhere as nondomain phase) depending on whether the domain phase corresponds to the
lipid phase with the largest substrate molar fraction or not, respectively.
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constant regardless of any substrate reordering. However, depending on the enzy-
matic model, the substrate reordering effectively could change the enzyme activity,
having many differences between homogenous or nonhomogeneous substrate
distributions.
To understand how the substrate lateral reordering might affect the enzyme
kinetics, a mathematical approach has been developed for the models having two
steps binding between the enzyme and the lipid phase. First, the simple
nonhomogeneous case of a binary condition is considered where the substrate can
be distributed in two coexisting lateral phases: an enriched domain and a
nonenriched domain (usually named nondomain). Finally, a more general expres-
sion corresponding to any gradients of substrate molar fraction will be shown.
As in the case of homogenous distribution of substrate on lipid phase [12], in
the simple nonhomogeneous distribution given by a binary substrate distribution
(i.e., two mixed lipid molecules, one of them being the substrate), the kinetics
surface dilution theory is applied to the surface-binding model and to the
phospholipid-binding model [19]:
1. For the phospholipid-binding model (Figure 2A), the enzyme activity (V)
depends on the substrate reordering in according to
V ¼ kCET a1 f
2




þ km f þ a1 f 2S1 þ a2 f 2S2
(3)
Figure 2.
A and B represent two different Lipolytic enzyme kinetic models for a lipid phase with two substrate domains:
enriched substrate domain and nonenriched substrate domain. L, lipid molecule; S, phospholipid substrate; E,











�2). In the text: km � k�2  þ kk2 and ks � k�1k1 . The association of symbols
and parameters to a particular domain is indicated by mean of primed or nonprimated signs in each case.
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where f Siand ai are the substrate molar fraction and the fraction of the total lipid
area in the ith phase (i = 1 or 2), respectively, and such that
a1 f S1 þ a2 f S2 ¼ f (4)
and
a1 þ a2 ¼ 1 (5)
According to Eq. (4), f is the average of the substrate molar fraction weighed by
the domain areas.
In Eq. 3, we can see that V depends hyperbolically on
 f 2Si
  � a1 f 2S1 þ a2 f 2S2 (6)
the average of the square of the substrate mole fraction weighted by the phase
area. These mean values have minimal and maximal values equal to f 2 and f ,





L þ km f þ f 2
(7)
We can see that Vmin corresponds to V for a lipid homogeneous phase (Eq. 1)
[12, 13]
Vmax ¼ ETkfkmks
L þ km f þ f
(8)
Curiously, in spite of Eq. 8 deduced for the phospholipid-binding model with
any substrate distribution, this equation is equal to Eq. 2, which corresponds to the
case of surface-binding model with homogeneous substrate distribution on the
membrane.
According to Eq. 3, if the homogeneous distribution of the substrate on the
membrane is broken (i.e., substrate reordering such that 〈 f 2Si〉. f
2), then the
enzyme activity will increase. In particular, the total enzyme activity increases
when the recruitment of substrate to the enriched-substrate domain (e.g., phase 1)
increases, due to an increase of either the domain mol fraction ( f S1 ) or the exten-
sion of the domain (a1).
2.On the other hand, for the surface-binding model (Figure 2B), the enzymatic
activity in a two-phase membrane equals to the enzyme activity in a
homogeneous lipid phase, following the equation:
V ¼ CETkfkmks
CL
þ km þ f
(9)
and applying the same restrictions given by Eqs. 4 and 5.
The differences between the behaviors of both enzymatic models are much more
than the differences between the corresponding equations for the enzymatic activ-
ities (Eqs. 3 and 9). Following this theory, important differences exist in both the
ratio of the substrate regarding the two substrate domains and the total enzyme
binding to membrane.
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According to Eq. (4), f is the average of the substrate molar fraction weighed by
the domain areas.
In Eq. 3, we can see that V depends hyperbolically on
 f 2Si
  � a1 f 2S1 þ a2 f 2S2 (6)
the average of the square of the substrate mole fraction weighted by the phase
area. These mean values have minimal and maximal values equal to f 2 and f ,





L þ km f þ f 2
(7)
We can see that Vmin corresponds to V for a lipid homogeneous phase (Eq. 1)
[12, 13]
Vmax ¼ ETkfkmks
L þ km f þ f
(8)
Curiously, in spite of Eq. 8 deduced for the phospholipid-binding model with
any substrate distribution, this equation is equal to Eq. 2, which corresponds to the
case of surface-binding model with homogeneous substrate distribution on the
membrane.
According to Eq. 3, if the homogeneous distribution of the substrate on the
membrane is broken (i.e., substrate reordering such that 〈 f 2Si〉. f
2), then the
enzyme activity will increase. In particular, the total enzyme activity increases
when the recruitment of substrate to the enriched-substrate domain (e.g., phase 1)
increases, due to an increase of either the domain mol fraction ( f S1 ) or the exten-
sion of the domain (a1).
2.On the other hand, for the surface-binding model (Figure 2B), the enzymatic
activity in a two-phase membrane equals to the enzyme activity in a
homogeneous lipid phase, following the equation:
V ¼ CETkfkmks
CL
þ km þ f
(9)
and applying the same restrictions given by Eqs. 4 and 5.
The differences between the behaviors of both enzymatic models are much more
than the differences between the corresponding equations for the enzymatic activ-
ities (Eqs. 3 and 9). Following this theory, important differences exist in both the
ratio of the substrate regarding the two substrate domains and the total enzyme
binding to membrane.
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The ratio between the enzymes binding into the two domains (indicated as
primed and nonprimed) is described as follows:
for the phospholipid-binding model:
ES þ ESS
E´S þ E´SS
¼ f d km þ f d
� �
f n km þ f n
� � (10)
for the surface-binding model:
ES þ ESS
E´S þ E´SS
¼ km þ f d
km þ f n
(11)
Furthermore, there are different expressions for the molar concentration of total
enzyme binding to the lipid phase, EB½ �:
Naming the molar concentration of total enzyme binding to the lipid phase EB½ �,
we have:
EB½ � � La ES þ ESSð Þ þ L 1� að Þ E´S þ E´SS
� �
¼ ET











for the phospholipid-binding model,
and
EB½ � � La ES þ ESSð Þ þ L 1� að Þ E´S þ E´SS
� �
¼ ET km þ fkmks
L






for the surface-binding model.
Then, due to the difference between Eqs. 12 and 13, the two enzymatic models
could be easily distinguishable by means of the observed change in the total lipid
metabolizing enzyme binding to the lipid phase under substrate reordering:
phospholipid-binding model predicts changes in total membrane enzyme upon
domain formation, unlike the surface-binding model, in which there are no changes
in total membrane enzyme, whatever the distribution of the substrate is.
3. Redistribution effect versus competitive effect of a lipid-inducing
domain peptide
Similar to the enzyme, again we will not consider the substrate dilution due to
the protein insertion in the bilayer. That is because the number of molecules bind-
ing to the lipid phase is much smaller than the number of the phospholipid substrate
molecules, and besides, the domain-inducing peptide either would not penetrate the
lipid phase or its interface concentration can be considered negligible.
As seen before, depending on the enzymatic model, substrate redistribution
such as the transitions from homogeneous distribution to nonhomogeneous
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distribution could change the enzyme activity. However, another effect must be
considered when there are domains that have been induced by soluble peptides
(e.g., basic peptides such as pentalysine), which interact directly with the phos-
pholipid substrate of the membrane (i.e., acidic phospholipid such as PIP2). In this
case, such interaction could be enough to consider a competitive effect over the
enzyme activity; i.e., in the lipid-water interface, the domain-inducing peptide
would compete with the enzyme for the substrate, because there would be less free
substrate to bind to the enzyme. Then, we have proposed that the superposition of
both redistribution and competitive effects may explain some results in the litera-
ture that appear as contradictory. [19]
3.1 The kinetic effects of peptide induction of phospholipid domains
In order to calculate the effects on the PLC-β activity (a lipolytic enzyme) on
PIP2 (lipid substrate) due to pentalysine-induced domain formation, it has been
assumed that the stoichiometry of binding is one lipid substrate per one domain-
inducing peptide [19]. In case of larger stoichiometry for the phospholipid binding
to the peptide (as Kim et al. describes [20]), this would imply that the competitive
effect from peptides tends to decrease the enzyme activity more dramatically at low
substrate molar fractions in the 1:1 stoichiometric case. Then, to estimate the
amount of substrate bound to all the domain-inducing peptides in any lipid phase, it
was assumed that the domain-inducing peptide near the surface of the lipid phase is
in equilibrium with the phospholipid substrate, obeying a Langmuir isotherm, and
this peptide concentration was determined by the electrochemical equilibrium in
according with a Boltzmann-like relationship, which included the membrane
potential in the lipid phase and the peptide concentration in the bulk solution [21].
Moreover, knowing the substrate binding to the domain-inducing peptide, free
substrate can be calculated, and then the molar fraction of free substrate can be
taken into account into the deduced previous kinetic models (Eqs. 3 and 9).
As a result, if there is competition effect due to peptide binding substrate, in case
of the surface-binding model, the enzymatic activity will always diminish because the
substrate reordering has no effect in the enzyme activity. Instead, in case of the
phospholipid-binding model with peptide-induced breakage of substrate homogene-
ity the enzyme activity may either increase or decrease depending on the difference
between the competitive effect (diminishing the enzyme activity) and the substrate
distribution effect (increasing the enzyme activity) [19]. A theoretical estimation of
PLCβ, acting on PIP2 as substrate, and having enriched substrate domain induced
by pentalysine, has been shown in Figure 4 of Salinas et al. 2005 [19]. A maximum
for an enriched domain, with acute declination for others, are shown.
4. Lypolitic enzyme activity in lipid phases with multiple substrate
domains
The above kinetics expressions can be generalized to any amount of substrate
domains, even to infinite number of domains, and this latter is very useful for
modeling any kind of substrate distribution in the total lipid phase [22].
In this extended theoretical frame, we have the following:
In homogenous condition, f is the molar fraction of phospholipid substrate.
S reorders into n homogeneous domains, with the ith domain (i = 1, 2,…, n) with
normalized area ai and molar fraction fi of S.
The total conservation equation is given as:
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The cross-sectional areas of any lipid molecules in any phases are equal and






Thus, again, it can be demonstrated that the enzyme activity for the surface
kinetic model does not depend on the substrate ordering, and it is equal to the
enzyme activity for the completely homogenous substrate distribution case (Eq. 2).
For the phospholipid-binding model, the enzyme activity even depends on the
reordering of the substrate on the lipid phase, such that some terms in Eq. 1 must be
replaced by more general ones, even more than in Eq. 3. Thus, in case of multiple
domains in the phospholipid-binding model, it has been demonstrated theoretically
that the enzymatic activity on n substrate domains is given as:






þ km f þ  f 2Si
  (16)
where f is defined in according to Eq. 15 and 〈 f 2Si〉 is the average of the square of
the substrate molar fraction weighted by the domain areas:
 f 2Si






Two abovementioned results can be represented by Eqs. 16 and 17: First, when
the lipid substrate distribution is completely homogeneous (n = 1), Eq. 1 is obtained.
Secondly, when there are only two domains of lipid substrate (enriched substrate
domain and nonenriched substrate domain; n = 2), Eq. 3 is obtained.
To calculate any V-value, 〈 f 2Si〉 must be calculated as a summation over the
whole surface of the lipid phase. Thus, minimum and maximum V-values are







2 ¼ f 2 ∑
n
i¼1
ai ¼ f 2 (18)




max ¼ f (19)
Thus, the minimum V-value as a function of substrate distribution was obtained
for a homogeneous distribution ( f Si ¼ f ). The maximum V-value was obtained for
one domain composed only by molecules of phospholipid substrate, and the other
one without substrate (e.g., f1 = 1 and f2 = 0). Then, the enzymatic activities are










þ km f þ f
(20)
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5. Effects of Poisson distribution of substrate on enzyme activity
following the phospholipid binding model
Since the extended theory shown above does not consider boundaries, the same
can be applied to a population of lipid particles (like vesicles or micelles), each one
as a substrate domain represented in a summation term in Eq. 17.
Frequently, data from in vitro kinetic studies of lipid metabolizing enzymes
have been interpreted as indicating cooperative phenomena [23–25]. Alterna-
tively, there is an explanation based on the idea that phospholipid substrate
molecules are not homogeneously distributed within a population of lipid
particles, although simultaneously we can suppose the substrate having homoge-
neous distribution within each particle. Then, modeling the nonhomogeneous
substrate distribution on the population of lipid particles, it is assumed that the
probability of finding a substrate molecule on a lipid particle does not depend on
the number of previous substrate molecules in the same lipid particle. A conse-
quence of this assumption is a Poisson distribution of the substrate on the mixture
of the lipid particles.
Defining α as the average number of lipid molecules per lipid particle (in micel-
lar case, this parameter is known as aggregation number), and according to Eq. 17
and Poisson-distributed substrate, it can be demonstrated that [22]
 f 2Si




We consider a lipolytic enzyme following the phospholipid-binding model in a
system of multiple domains of substrate, and such that the lipid phase is composed
by a mixture of lipid particles, each one with homogeneously distributed substrate,
but Poisson distributed over the same population of particles. Then, the 〈 f 2Si〉 value







þ kmf þ f 2 1þ 1fα
  (22)
That is, Eq. 22 is an expression of the rates of enzyme activity on Poisson-
distributed phospholipid substrates. Applying this equation to published kinetic
parameters for PLC acting on PIP2 in Triton X-100 micelles (CL = 200 μM,
km = 0.13, and ks = 170 μM) [23], the ratio between “the enzyme activity on micelles
with Poisson-distributed substrate” (Eq. 22) and “the enzyme activity on micelles
with homogeneously distributed substrate” (Eq. 1) was calculated. Assuming a
range of f from 10�1 to 10�3 (as in published work [12, 13]), activity ratios between
1.0 and 6.0 (α ¼ 200) and between 1.1 and 11.0 (α ¼ 100) were obtained. We can
see that without considering cooperative effects, a simple explanation for a very
high departure from the homogeneous standard model may be that the increases in
enzyme activity are due to Poisson distribution of the substrate.
5.1 Substrate-distribution dependence of PLA2 activity in mixed micelles
The mentioned kinetic theory applied to Poisson-distributed substrate on lipid
particles has been verified with experimental results, and their obtained parameters
have been compared with those of the canonical phospholipid-binding model
originally developed for homogeneously distributed substrate on mixed micelles
79






The cross-sectional areas of any lipid molecules in any phases are equal and






Thus, again, it can be demonstrated that the enzyme activity for the surface
kinetic model does not depend on the substrate ordering, and it is equal to the
enzyme activity for the completely homogenous substrate distribution case (Eq. 2).
For the phospholipid-binding model, the enzyme activity even depends on the
reordering of the substrate on the lipid phase, such that some terms in Eq. 1 must be
replaced by more general ones, even more than in Eq. 3. Thus, in case of multiple
domains in the phospholipid-binding model, it has been demonstrated theoretically
that the enzymatic activity on n substrate domains is given as:






þ km f þ  f 2Si
  (16)
where f is defined in according to Eq. 15 and 〈 f 2Si〉 is the average of the square of
the substrate molar fraction weighted by the domain areas:
 f 2Si






Two abovementioned results can be represented by Eqs. 16 and 17: First, when
the lipid substrate distribution is completely homogeneous (n = 1), Eq. 1 is obtained.
Secondly, when there are only two domains of lipid substrate (enriched substrate
domain and nonenriched substrate domain; n = 2), Eq. 3 is obtained.
To calculate any V-value, 〈 f 2Si〉 must be calculated as a summation over the
whole surface of the lipid phase. Thus, minimum and maximum V-values are







2 ¼ f 2 ∑
n
i¼1
ai ¼ f 2 (18)




max ¼ f (19)
Thus, the minimum V-value as a function of substrate distribution was obtained
for a homogeneous distribution ( f Si ¼ f ). The maximum V-value was obtained for
one domain composed only by molecules of phospholipid substrate, and the other
one without substrate (e.g., f1 = 1 and f2 = 0). Then, the enzymatic activities are










þ km f þ f
(20)
78
Extracellular Vesicles and Their Importance in Human Health
5. Effects of Poisson distribution of substrate on enzyme activity
following the phospholipid binding model
Since the extended theory shown above does not consider boundaries, the same
can be applied to a population of lipid particles (like vesicles or micelles), each one
as a substrate domain represented in a summation term in Eq. 17.
Frequently, data from in vitro kinetic studies of lipid metabolizing enzymes
have been interpreted as indicating cooperative phenomena [23–25]. Alterna-
tively, there is an explanation based on the idea that phospholipid substrate
molecules are not homogeneously distributed within a population of lipid
particles, although simultaneously we can suppose the substrate having homoge-
neous distribution within each particle. Then, modeling the nonhomogeneous
substrate distribution on the population of lipid particles, it is assumed that the
probability of finding a substrate molecule on a lipid particle does not depend on
the number of previous substrate molecules in the same lipid particle. A conse-
quence of this assumption is a Poisson distribution of the substrate on the mixture
of the lipid particles.
Defining α as the average number of lipid molecules per lipid particle (in micel-
lar case, this parameter is known as aggregation number), and according to Eq. 17
and Poisson-distributed substrate, it can be demonstrated that [22]
 f 2Si




We consider a lipolytic enzyme following the phospholipid-binding model in a
system of multiple domains of substrate, and such that the lipid phase is composed
by a mixture of lipid particles, each one with homogeneously distributed substrate,
but Poisson distributed over the same population of particles. Then, the 〈 f 2Si〉 value







þ kmf þ f 2 1þ 1fα
  (22)
That is, Eq. 22 is an expression of the rates of enzyme activity on Poisson-
distributed phospholipid substrates. Applying this equation to published kinetic
parameters for PLC acting on PIP2 in Triton X-100 micelles (CL = 200 μM,
km = 0.13, and ks = 170 μM) [23], the ratio between “the enzyme activity on micelles
with Poisson-distributed substrate” (Eq. 22) and “the enzyme activity on micelles
with homogeneously distributed substrate” (Eq. 1) was calculated. Assuming a
range of f from 10�1 to 10�3 (as in published work [12, 13]), activity ratios between
1.0 and 6.0 (α ¼ 200) and between 1.1 and 11.0 (α ¼ 100) were obtained. We can
see that without considering cooperative effects, a simple explanation for a very
high departure from the homogeneous standard model may be that the increases in
enzyme activity are due to Poisson distribution of the substrate.
5.1 Substrate-distribution dependence of PLA2 activity in mixed micelles
The mentioned kinetic theory applied to Poisson-distributed substrate on lipid
particles has been verified with experimental results, and their obtained parameters
have been compared with those of the canonical phospholipid-binding model
originally developed for homogeneously distributed substrate on mixed micelles
79
Effects of Vesicular Membranes Reordering on the Activity of Lipid Metabolizing Enzymes
DOI: http://dx.doi.org/10.5772/intechopen.85972
[12, 13]. Both models (“nonhomogeneous model” and “homogeneous model,”
respectively) can be represented simultaneously by the following general equation:






f þ f 2
(23)
where
Ff ,α ¼ 1, (24)
in a homogeneous model (Eq. 1), and
Ff ,α ¼ 1þ 1αf , (25)
in a nonhomogeneous model (Eq. 22).
In micelles, it has been found that α, the average number of lipid molecules per
mixed micelle (i.e., the aggregation number), depends on the molar fraction of
phospholipid (but not on total detergent concentration [26]) within the concentra-
tion range of Triton X-100 and phospholipid used in Hendrickson et al.’s study [13].
Therefore, in order to find the parameters for modeling, the functional dependence
of α from f must be taken into account in micellar experiments [22].
In Table 1, all the values of parameters km and kS obtained for homogeneous and
nonhomogeneous substrate distributions are compared. The differences indicate
that the values of these kinetic parameters can depend critically on the distribution
of the substrate.
6. Discussion
To understand the effect of lipid substrate reordering on their metabolizing
enzymes, theoretical results are shown. A simple kinetic model considers a
nonhomogeneous membrane with the lipid substrate reordered in two domains
with different molar fractions. The results are included in a more general extended
theory considering substrate multidomains on either lipid surface of vesicles.
Because the calculations do not regard any domain boundaries, the same models
obtained from this theory (Eqs. 2 and 16) can be applied on a mixture of lipid







Kinetic parameters for PLA2
activity on Triton X-100/thio-
PC mixed micelles
km = 0.0532 0.0216
kS = 1.9168 mM 6.2170 mM
Kinetic parameters for PLA2
activity on Triton X-100/thio-
PE mixed micelles
km = 0.1379 0.0942
kS = 0.1132 mM 0.4107 mM
Parameter values are taken from Table II in Salinas et al. 2011 [14].
Table 1.
Values for fitting kinetic parameters for PLA2 activity on Triton X-100 mixed micelles regarding either
homogeneous substrate distribution or Poisson substrate distribution, with adjustable εTt parameter (the molar
concentration of detergent that is not kinetically active, a proposed parameter that enhance the fitting).
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Here, only two kinetic models have been considered, but similar theoretical
framework could be applied on other ones. The general mathematical expression for
the surface-binding model does not depend on whether the substrate distribution is
homogeneous or nonhomogeneous (Eq. 2). Thus, in this kinetic model, any sub-
strate distribution changing has no kinetic effect.
On the contrary, considering the phospholipid-binding model, the calculations
predict how the substrate distribution may affect the activity of the lipid metabo-
lizing enzyme. In particular, the enzyme activity is increased by the transition
from the homogeneous substrate distribution to any nonhomogeneous one
(Eqs. 16 and 17).
Concordantly, in erythrocytes, the Ca2+-induced domains increase the activity of
PLA2 [27], an enzyme that follows the phospholipid-binding model [12, 13]. The
increased activity agrees with an observed enzyme reordering, which may be due to
formed enriched-substrate domains. Then, there will be more enzyme molecules
binding to areas of higher substrate molar fraction, causing a larger local enzyme
activity. On the other hand, PLCβ kinetic data from micellar experiments have
fitted to the phospholipid-binding model using Hill coefficients [28–30], but the
usage of this type of coefficients was not useful in monolayers having with large
increases in enzyme activity after small increases in the PIP2 fraction [31]. The
analysis of pressure versus area isotherm of the monolayers suggested a
nonhomogeneous distribution of the lipids and was proposed that the PIP2 mole-
cules get together into enriched lateral domains, favoring the PLCβ activity, an
enzyme following the phospholipid-binding model. This agrees with what is expected
from the theory presented here.
In other cases, since basic molecules can induce formation of acidic phospholipid
domains in membranes, the increased activity of PLC δ1 and PLC δ3 by addition of
polyamines or basic proteins such as spermine, protamine, histone, and melittin
[32] also can be explained by substrate redistribution. Differently, PLCβ activity
decreases in experiments with vesicles containing acidic phospholipid domains
induced by the basic molecules, pentalysine, spermine, and MARCKS (151–175)
[17]. However, assuming that PLCβ is a phospholipid-binding enzyme, the decrease
in enzyme activity may be due to a high competitive effect of the substrate-domain-
inducing peptide. Such competitive effect overcomes the rise in activity that sub-
strate redistribution would produce. Finally, the importance of each effect is
dependent on the used amount of domain-inducing molecule and this could explain
the apparent contradictory results of the activities of lipid-metabolizing enzymes,
such as PLC (an enzyme following the phospholipid-binding model [24, 29, 30]
upon addition of domain-inducing molecules [17, 23, 32, 33]).
Substrate distribution also must be considered in in vitro kinetic experiments of
enzymes following the phospholipid-binding model. In this sense, the application of
the theory developed here is useful for kinetic experiments with mixed lipid parti-
cles (i.e., liposomes or micelles, instead of lipid domains). We assumed that each
one of the particles will have a homogeneous molar fraction, which follows a
Poisson distribution on the lipid particles [34, 35].
If the average of substrate molecules per lipid particle in suspension ( fα) is very
large ( fα ≫ 1), then Eq. 22 predicts that the enzymatic activity tends to the value
obtained for a homogeneously distributed substrate (Eq. 1, or its equivalent, Eqs. 23
and 24). However, in case of decreased average of substrate molecules per lipid
particle in suspension ( fα≪ 1), Eq. 22 predicts that the enzyme activity will be
larger than in the homogeneous case at equal f value. Concordantly, some PLC
isoenzymes [24, 29, 30] and PLA2 [13] have an increased activity in cases of small
substrate molar fractions, similar to cooperative phenomena. However, if these
kinetic data could be fitted to Eq. 22, they will contribute to a more simple
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domains in membranes, the increased activity of PLC δ1 and PLC δ3 by addition of
polyamines or basic proteins such as spermine, protamine, histone, and melittin
[32] also can be explained by substrate redistribution. Differently, PLCβ activity
decreases in experiments with vesicles containing acidic phospholipid domains
induced by the basic molecules, pentalysine, spermine, and MARCKS (151–175)
[17]. However, assuming that PLCβ is a phospholipid-binding enzyme, the decrease
in enzyme activity may be due to a high competitive effect of the substrate-domain-
inducing peptide. Such competitive effect overcomes the rise in activity that sub-
strate redistribution would produce. Finally, the importance of each effect is
dependent on the used amount of domain-inducing molecule and this could explain
the apparent contradictory results of the activities of lipid-metabolizing enzymes,
such as PLC (an enzyme following the phospholipid-binding model [24, 29, 30]
upon addition of domain-inducing molecules [17, 23, 32, 33]).
Substrate distribution also must be considered in in vitro kinetic experiments of
enzymes following the phospholipid-binding model. In this sense, the application of
the theory developed here is useful for kinetic experiments with mixed lipid parti-
cles (i.e., liposomes or micelles, instead of lipid domains). We assumed that each
one of the particles will have a homogeneous molar fraction, which follows a
Poisson distribution on the lipid particles [34, 35].
If the average of substrate molecules per lipid particle in suspension ( fα) is very
large ( fα ≫ 1), then Eq. 22 predicts that the enzymatic activity tends to the value
obtained for a homogeneously distributed substrate (Eq. 1, or its equivalent, Eqs. 23
and 24). However, in case of decreased average of substrate molecules per lipid
particle in suspension ( fα≪ 1), Eq. 22 predicts that the enzyme activity will be
larger than in the homogeneous case at equal f value. Concordantly, some PLC
isoenzymes [24, 29, 30] and PLA2 [13] have an increased activity in cases of small
substrate molar fractions, similar to cooperative phenomena. However, if these
kinetic data could be fitted to Eq. 22, they will contribute to a more simple
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explanation based on the substrate distribution. In other case, in experiments with
PLA2, increase in enzyme activity has been associated with decrease of the size of
lipid vesicles, suggesting that PLA2 activity happens in areas with structural defects
[36]. Again, here our approach based on substrate distribution provides a simple
alternative explanation: if the substrate molar fraction in the mixture of lipid parti-
cles is Poisson distributed, then Eq. 22 could be applied. Considering that substrate
is fixed ( f fixed), the decreasing vesicle sizes (α decrease) produces decreasing
average of substrate molecules per vesicle ( fα). Therefore, in according to Eq. 22, at
low values of fα and for Poisson-distributed substrate, the relative enzyme activity
must increase more notoriously, regarding the case of homogeneous distribution of
substrate as reference.
The application of the theoretical model (Eq. 22) in published results of the
PLA2 activity on Triton X-100 mixed micelles of phospholipids [13], considering
Poisson-distribution substrate, allows a very good fit to the data. Interestingly, the
estimated values of the kinetic parameters strongly depend on whether the sub-
strate distribution used in the fitting is distributed either homogeneously or
according to Poisson.
On the other hand, detergent-based micelles are not capable to mimic the lipid
environment of membranes. In such case, the activities of most membrane protein
could be affected. As a solution, liposomes or high-density apolipoprotein particles
have been proposed [2]. However, compared with those experimental models, the
EVs offer a number of potential benefits, such as providing a more adequate mem-
brane environment for membrane proteins, in terms of both dynamics and stability.
In summary, depending on the enzyme model, the lipid substrate reordering can
regulate the enzyme activity, giving to the membrane organization a topological
role in the control of cell process. In order to a good estimation of kinetic parameters
in phospholipase enzymology, in vitro kinetic experiments must consider the sub-
strate distribution effects. Also, many complex metabolic effects of substrate-
domain-inducing molecules can be explained by a result of the balance between the
competitive effects of the substrate domain inducers and substrate redistribution.
All these considerations should be taken into account even in case of EVs, in relation
to their formation, functionality, and action on membrane targets.
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explanation based on the substrate distribution. In other case, in experiments with
PLA2, increase in enzyme activity has been associated with decrease of the size of
lipid vesicles, suggesting that PLA2 activity happens in areas with structural defects
[36]. Again, here our approach based on substrate distribution provides a simple
alternative explanation: if the substrate molar fraction in the mixture of lipid parti-
cles is Poisson distributed, then Eq. 22 could be applied. Considering that substrate
is fixed ( f fixed), the decreasing vesicle sizes (α decrease) produces decreasing
average of substrate molecules per vesicle ( fα). Therefore, in according to Eq. 22, at
low values of fα and for Poisson-distributed substrate, the relative enzyme activity
must increase more notoriously, regarding the case of homogeneous distribution of
substrate as reference.
The application of the theoretical model (Eq. 22) in published results of the
PLA2 activity on Triton X-100 mixed micelles of phospholipids [13], considering
Poisson-distribution substrate, allows a very good fit to the data. Interestingly, the
estimated values of the kinetic parameters strongly depend on whether the sub-
strate distribution used in the fitting is distributed either homogeneously or
according to Poisson.
On the other hand, detergent-based micelles are not capable to mimic the lipid
environment of membranes. In such case, the activities of most membrane protein
could be affected. As a solution, liposomes or high-density apolipoprotein particles
have been proposed [2]. However, compared with those experimental models, the
EVs offer a number of potential benefits, such as providing a more adequate mem-
brane environment for membrane proteins, in terms of both dynamics and stability.
In summary, depending on the enzyme model, the lipid substrate reordering can
regulate the enzyme activity, giving to the membrane organization a topological
role in the control of cell process. In order to a good estimation of kinetic parameters
in phospholipase enzymology, in vitro kinetic experiments must consider the sub-
strate distribution effects. Also, many complex metabolic effects of substrate-
domain-inducing molecules can be explained by a result of the balance between the
competitive effects of the substrate domain inducers and substrate redistribution.
All these considerations should be taken into account even in case of EVs, in relation
to their formation, functionality, and action on membrane targets.
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Abstract
Extracellular vesicles (EVs) represent a generic term for all the secreted vesicles, 
which include exosomes, microvesicles, and apoptotic bodies. EVs are key partners 
in the intercellular communication and play an essential role in multiple physi-
ological and pathological conditions. EVs are shuttles for cargo molecules, such as 
RNA (mRNA, microRNA, and other noncoding RNAs), DNA, proteins (receptors, 
transcription factors, enzymes, and extracellular matrix proteins), and lipids. In 
pathological states, including cancer, EVs might represent either useful biomarkers 
or can be used for therapeutic purposes. Moreover, in cancer, it was demonstrated 
that EVs play an essential role in drug resistance. Here, we review the role played by 
EVs in the most common forms of cancer, with a special focus on ovarian and breast 
cancers.
Keywords: extracellular vesicles, cancer, biomarker, cargo, therapy
1. Introduction
Extracellular vesicles (EVs) are cell-derived membranous vesicles (from normal 
or cancerous cells) bearing packages of information within or on their surface. 
Their content can influence neighboring or remote cells, and therefore, EVs are 
considered to play an important role in intercellular communication [1]. Different 
functional molecules (proteins, mRNA, and microRNAs) are transferred between 
cells with the aid of EVs. The content of EVs is highly variable and dependent of 
the cell of origin. The EVs in human blood originate from platelets, leukocytes, 
erythrocytes, endothelial cells, vascular smooth muscle cells, and cancer cells (for 
review see [2]). It is now widely accepted that extracellular vesicles also represent a 
potential resource for biomarkers.
The first study suggesting the existence of extracellular vesicles was carried 
out in 1946 [3]. In a 1967 report, membrane particles derived from activated 
platelets, termed “platelet dust,” were commonly considered as a waste product or 
cellular debris directly budded from the plasma membrane [4]. Both prokaryotes 
and higher eukaryotes can release EVs. Different terms are used to describe EVs 
due to varying methods of isolation and due to the biogenesis mechanism. The 
terminologies of EVs include microvesicles, dexosomes, texosomes, archaeosomes, 
argosomes, prostasomes, epididymosomes, and oncosomes [5]. Gradually, while 
building up knowledge about EVs, a need for its classification emerged and the 
International Society for Extracellular Vesicles (ISEV) was founded [6]. This society 
89
Chapter 5
Extracellular Vesicles in Cancer
Andrei-Dennis Voichitoiu, Beatrice Mihaela Radu, 
Luciana Pavelescu, Dragos Cretoiu, Antonia Teona Deftu, 
Nicolae Suciu and Sanda Maria Cretoiu
Abstract
Extracellular vesicles (EVs) represent a generic term for all the secreted vesicles, 
which include exosomes, microvesicles, and apoptotic bodies. EVs are key partners 
in the intercellular communication and play an essential role in multiple physi-
ological and pathological conditions. EVs are shuttles for cargo molecules, such as 
RNA (mRNA, microRNA, and other noncoding RNAs), DNA, proteins (receptors, 
transcription factors, enzymes, and extracellular matrix proteins), and lipids. In 
pathological states, including cancer, EVs might represent either useful biomarkers 
or can be used for therapeutic purposes. Moreover, in cancer, it was demonstrated 
that EVs play an essential role in drug resistance. Here, we review the role played by 
EVs in the most common forms of cancer, with a special focus on ovarian and breast 
cancers.
Keywords: extracellular vesicles, cancer, biomarker, cargo, therapy
1. Introduction
Extracellular vesicles (EVs) are cell-derived membranous vesicles (from normal 
or cancerous cells) bearing packages of information within or on their surface. 
Their content can influence neighboring or remote cells, and therefore, EVs are 
considered to play an important role in intercellular communication [1]. Different 
functional molecules (proteins, mRNA, and microRNAs) are transferred between 
cells with the aid of EVs. The content of EVs is highly variable and dependent of 
the cell of origin. The EVs in human blood originate from platelets, leukocytes, 
erythrocytes, endothelial cells, vascular smooth muscle cells, and cancer cells (for 
review see [2]). It is now widely accepted that extracellular vesicles also represent a 
potential resource for biomarkers.
The first study suggesting the existence of extracellular vesicles was carried 
out in 1946 [3]. In a 1967 report, membrane particles derived from activated 
platelets, termed “platelet dust,” were commonly considered as a waste product or 
cellular debris directly budded from the plasma membrane [4]. Both prokaryotes 
and higher eukaryotes can release EVs. Different terms are used to describe EVs 
due to varying methods of isolation and due to the biogenesis mechanism. The 
terminologies of EVs include microvesicles, dexosomes, texosomes, archaeosomes, 
argosomes, prostasomes, epididymosomes, and oncosomes [5]. Gradually, while 
building up knowledge about EVs, a need for its classification emerged and the 
International Society for Extracellular Vesicles (ISEV) was founded [6]. This society 
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provided some criteria to classify EVs into three groups: microvesicles (MVs), 
exosomes, and apoptotic bodies (for details visit www.isev.org). These vesicles are 
secreted by both normal cells and cancerous cells as means of cell-to-cell communi-
cation. Alternatively, they may be prepared artificially from the engineered artifi-
cial lipid vesicles called liposomes in which EVs’ features, components, or cargos are 
incorporated and are the most likely to be useful for drug delivery [7].
EVs are actively involved in cell-to-cell communication, inflammation, chronic 
disease development and progression, pre-metastatic niche formation, and the 
metastatic organotropism of different tumor types [8]. Tumor-derived EVs (TEVs) 
have been reported to play major roles in the onset, progression, and metastasis of 
cancer, including ovarian [9], breast [10], colorectal [11, 12], prostate cancer [13], 
and melanoma [14–16].
Here, we review knowledge about EVs in cancer, with a focus on breast and ovar-
ian cancers. We discuss the importance of the content of EVs (e.g., nucleic acids, 
and proteins) in cancer development, metastasis, and drug resistance.
2. The variety of extracellular vesicles
Replacing EVs includes a heterogeneous population of membrane vesicles 
categorized depending on the mechanism by which they are released from cells. 
According to their size and mechanisms of biogenesis, EVs can be categorized 
into three classes: (a) exosomes, (b) ectosomes or shedding microvesicles, and (c) 
apoptotic bodies [17, 18]. Differentiation criteria are based on their size, content, 
and by a certain combination of markers (Figure 1 and Table 1). Cancerous cells 
have been described to release exosomes and ectosomes and some other additional 
subpopulations of EVs [19].
2.1 Exosomes
Exosomes are EVs with multivesicular endosomal origin released by all cell 
types [33]. Exosomes are found in physiological fluids such as blood and plasma 
[34, 35], urine [36], cerebral fluid [37], saliva [38, 39], seminal fluid [40], breast 
milk [41, 42], and amniotic fluid [43, 44]. The presence of EVs has been reported 
in interstitial spaces since they are released by B cells [45], T cells [46], dendritic 
cells [47], platelets [48], Schwann cells [49], tumor cells [50], cardiomyocytes [51], 
endothelial cells [52], stem cells [50], and telocytes [53–55]. Exosomes are able to 
influence cells from the local environment and also distant target cells, thus regulat-
ing intercellular signaling [56]. Their size varies between 30 and 100 nm, and as 
membrane vesicles, they are delineated by a specific lipid bilayer similar to that of 
the cells they originate from [57]. Studies have shown that while normal human 
blood contains about 2000 trillion exosomes, the blood of cancer patients contains a 
double amount, about 4000 trillion exosomes [57]. In noncancerous cells, exosome 
secretion was suggested to play a role in cellular homeostasis by removing harmful 
cytoplasmic DNA of normal cells and in preventing viral hijacking of host cells by 
excreting viral DNA from cells as shown by Takahashi et al. [58].
The plasma of cancer patients contains different types of exosomes, some 
released by normal cells and others released by cancerous cells, explaining the 
heterogeneity in size (30–150 nm) of the exosomal population [59]. Exosomes can 
be isolated from cancer patients’ plasma with a variety of methods [60]. They are 
based not only on classical techniques such as ultracentrifugation, but also on some 
modern ones such as size exclusion chromatography [61].
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Tumor cell-derived exosomes are able to promote inflammation and are able 
to compromise innate immunity by delivering different signals, which affect the 
proliferation, apoptosis, cytokine production, and reprogramming of T cells [62].
2.2 Ectosomes
Ectosomes are a heterogeneous vesicle population, ranging in diameter between 
100 and 1000 nm. Discovered in approximately the same time as exosomes, in 
1990s, ectosomes did not attract the same interest as the study of exosomes. While 
the interest in exosomes reached the maximum between 2008 and 2010, the ecto-
somes had its peak in 2012 [20, 63].
Ectosomes are known under different names, which might be misleading 
(Table 1), while ecto is a prefix that means outwardly, externally, and is therefore 
suggestive of their way of forming. The mechanism of formation of ectosomes 
differs greatly from that of exosomes, as well as their cargo molecules. Ectosome 
formation does not require exocytosis. Ectosomes are formed by direct outward 
Figure 1. 
Classification of EVs based on their diameter (expressed in nm) (A) or on their mechanism of biogenesis (B).
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budding of the plasma membrane in specialized microdomains of the plasma-
lemma, the phenomenon known as microvesicle shedding [29]. They are released 
both by cells in normal resting state and by cells upon stimulation. Ectosome fusion 
with the plasma membrane of a recipient cell is followed by changes in antigens, 
enzymes, and other proteins in a specific site of plasmalemma, while their content 
release into the cytoplasm can alter the recipients’ cell gene expression [64, 65]. 
Tumor-derived ectosomes were shown to have immunosuppressive properties by 
inducing the chemotaxis of granulocytes, lymphocytes, and monocytes due to 
several chemokines (e.g., particularly IL-8) transported in ectosomes [66].
Oncosomes are a particular type of ectosomes, excessively large, which can 
even reach 1000 nm, characteristic to advanced cancers. There is a confusion in 
the use of these terms in the literature and that is why we thought to treat onco-
somes as a particular category of ectosomes. The generic name of ectosomes can 
include oncosomes, while the name of oncosomes excludes ectosomes released 
from normal cells. Oncosomes content is adapted to serve cancer metabolism, 
so they will contain enzymes involved in glucose, glutamine, and amino acid 
metabolism. Furthermore, oncosomes are enriched in proteins, which have a 
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role in cell migration, angiogenesis, and cancer progression and metastasis [28]. 
Oncosomes allow intercellular transfer of oncogenes, hence the motivation to 
be considered as existing biomarkers in the blood or plasma of patients for the 
detection of cancer [67].
2.3 Apoptotic bodies
Apoptotic bodies (ApoBDs) are the largest type of extracellular vesicles (typi-
cally 1–5 μm in diameter) visible during an apoptotic process. Kerr in 1972 proposed 
the term “apoptotic body” [68]. ApoBDs are released as blebs of cells undergoing 
apoptosis and consist of cytoplasm, organelles with or without a nuclear fragment. 
It has also been shown that ApoBDs can harbor proteins, lipids, DNA, rRNA, organ-
elles, and cytosol [18]; this is the reason why the disassembly of an apoptotic cell 
into ApoBDs can mediate intercellular communication and may contribute to the 
development of various disease states [69]. These bodies are then phagocytosed by 
macrophages or neoplastic cells and degraded within phagolysosomes. Their forma-
tion has been proposed to play an important role in the clearance of apoptotic cells 
by phagocytes. Different cell types can generate ApoBDs via different mechanisms 
[70]. These ApoBDs can be classified based on cell-type-specific surface markers 
and content. Jiang et al. showed that ApoBDs share the same surface markers as 
their cell of origin; this is the reason why apoptotic bodies are very different and can 
be divided into specific subclasses [70].
ApoBD occurs spontaneously in untreated malignant neoplasms, and is impli-
cated in both physiological involution and atrophy of various tissues and organs. 
Pathological settings include inflammation [71], autoimmunity [72–74], viral 
infection [75], and tumorigenesis because they participate in the horizontal transfer 
of oncogenes due to their nuclear material content from the dying cells [76].
3. Extracellular vesicles and tumor microenvironment
Tumor masses are composed of cancer cells and stromal cells, in which one 
include mesenchymal cells, fibroblasts and immune cells, and extracellular matrix 
(ECM) components. All these cells emit EVs and participate in the creation of a 
unique tumor nanoenvironment. EVs are capable of horizontal transfer of bioactive 
content to interact with cells in the tumor microenvironment. These interactions 
can include fusion of the EV with the plasmalemma of the recipient cell or endo-
cytosis of the EVs [77]. EVs represent the bidirectional way of interaction between 
stromal and cancer cells as a mean to exchange information and modify the tumor 
microenvironment. Therefore, the content of these vesicles is of great significance 
in the evolution of the cancer, since it was shown to modulate the complex signaling 
networks that facilitate tumor progression [78].
3.1 Nucleic acids
Circulating DNA can be found in free form or contained in EVs and is thought 
to be the future in cancer diagnosis and treatment monitoring. This will be pos-
sible because the DNA fragments contained in EVs are relatively intact (average 
15 kbp) by comparison with the circulating cell-free one (average 130 bp) due 
to the protection offered by the lipid bilayer [79]. Vagner et al. showed in a very 
recent study that the majority of the extracellular DNA is contained in large onco-
somes, rather than in exosomes, both in vitro and in the patients’ plasma and has 
all cancer-specific genomic alterations [80]. The majority of the DNA contained 
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in tumor-derived exosomes is double stranded and represent the whole genomic 
DNA, suggesting its usefulness in identifying mutations present in parental tumor 
cells, as it was indicated by Thakur et al. [81]. Wyatt et al. showed that cancer-
derived DNA is sufficient to identify the DNA alterations from metastatic tissue 
and is very important because it integrates somatic information from more than one 
metastatic lesion [82].
The presence of retrotransposons, cDNAs, and ncRNAs has also been reported 
in EVs and appears to be a unique feature of tumor cells [83]. Several studies 
reported a correlation between increased retrotransposon activity and tumorigen-
esis [84]. For example, LINE-1 hypomethylation in various human cancers was 
intensively studied since it is considered to be an early event in tumorigenesis and 
to be linked with the induction of proto-oncogenes [85]. Loss of LINE-1 methyla-
tion was found to associate with more aggressive progression of colorectal cancer 
[86]. Moreover, LINE-1 hypomethylation level can be considered as an important 
epigenetic process, which became a potential prognostic factor for ovarian multi-
step carcinogenesis [87].
miRNAs represent potential candidates responsible for influencing the tumor 
microenvironment; however, little is known about the mechanism by which they 
produce changes in the transcriptome of target cells [88].
3.2 Proteins
Proteins exported in EVs are signaling molecules that interfere in a whole series 
of processes such as cell metabolism, cell invasion and growth, angiogenesis, and 
mRNA processing [89]. Among these, it is worth mentioning that the epidermal 
growth factor receptor vIII (EGFRvIII), mutant Ras family members, or c-Met have 
been proposed as cancer biomarkers [90, 91]. Other proangiogenic regulators, such 
as VEGF and bFGF, are harbored in EVs shed from cancerous cells promoting new 
blood vessel formation [92].
Moreover, EVs also transfer proteases such as MMP-2, MMP-9, and MT1-MMP 
and become responsible for the partial degradation of the extracellular matrix [93]. 
The content is released in an acidic environment after the vesicle is stabilized in the 
extracellular matrix with the aid of β1 integrin adhesion molecules [94].
3.3 Lipids
Naturally, EVs also contain a lipid component, which consists of the main mem-
brane lipids: sphingomyelin, phosphatidylserine, and glycosphingolipids and cho-
lesterol, but they also carry polyunsaturated fatty acids PUFAs, mainly arachidonic 
acid and linoleic acid [95, 96]. Sphingomyelin, as a component of the EVS, was 
firstly reported by Kim et al. who described its angiogenic properties [97] . In addi-
tion, it has been shown that the lipid content of exosomes suppresses critical cancer 
survival pathways such as notch leading to cancer cell death of human pancreatic 
tumoral SOJ-6 cells [98]. Moreover, other important signaling mediators, such 
as prostaglandins, arachidonic acid, phospholipase A2, and phospholipase C and 
D, are also found in EVs [99]. The prostaglandins found in breast-cancer-derived 
exosomes, such as PGE2, are responsible for promoting tumor growth by inducing 
the release of pro-inflammatory cytokines such as IL-6 and VEGF, which induce 
the accumulation of myeloid-derived suppressor cells capable to differentiate into 
macrophages in the tumor microenvironment [100, 101]. PGE2 indeed makes the 
connection between cancer and macrophages and can promote tumorigenesis 
by enhancing the expression of programmed cell death protein ligand 1 (PD-L1) 
responsible for tumor escape from immune system during cancer progression [102].
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Cancer stem cells (CSCs) are held directly responsible to promote cancer initia-
tion and progression. Also, there are several studies showing their importance in 
therapy resistance, recurrence, and metastasis [103]. CSCs themselves do not exist 
as a static population, their stemness being supported by the mesenchymal stem 
cells, endothelial cells, fibroblasts, or immune cells by paracrine signaling [104]. 
For example, in breast cancer, the overexpression of the chemokines CXCL14 and 
CXCL12 in myoepithelial cells and myofibroblasts favors the metastasis [105]. 
Cancer-associated fibroblasts (CAF) release exosomes, which induce the stem-
ness of breast cancer cell lines, developing an aggressive cancer cell phenotype 
[106]. Also, the ECM molecules are relevant for breast cancer colonization, which 
contribute to the control of CSC. In this sense, tenascin C, a protein in the ECM, 
contributes in the formation of the stem niche by protecting CSC from immune sur-
veillance [107]. In breast cancer, high levels of tenascin C are associated with poor 
clinical outcome in breast cancer due to lung cancer metastasis [108].
4. Role of extracellular vesicles in tumorigenesis
The role of EVs in tumorigenesis was described in various types of cancer, 
including ovarian [109–111] and breast cancers [112, 113]. EVs undergo several 
alterations in tumorigenesis, including changes in their biogenesis, release rate and/
or protein content, incorporation of oncogenic and mutant macromolecules, medi-
ated release of genomic DNA, and uptake of tumoral cells [114]. The transfer of 
DNA between apoptotic tumoral cells and other cells is important in tumorigenesis. 
In vitro, it was shown that apoptotic bodies derived from cancer cells are respon-
sible for triggering the expression of oncogenes in fibroblasts due to the information 
contained in tumor-derived EVs [76].
In ovarian or breast cancer, investigating the content of EVs might give important 
informations on tumorigenesis. To detail, exosomes released by IGROV1 ovarian 
cancer cells (with high content of RNA-binding proteins, such as LIN28A or LIN28B), 
but not by OV420 ovarian cancer cells, were taken up by HEK293 cells, contributing 
to the tumor development [109]. Moreover, in hypoxia conditions, SKOV3 human 
epithelial ovarian cancer cells release exosomes with high content of miR-940 that 
stimulate the M2 macrophage phenotype, and in turn, M2 subtype macrophages 
stimulate the tumor cell migration and proliferation [111]. The majority of circulat-
ing miRNA, packed in EVs, can be used as biomarkers in ovarian cancer, but their use 
is not only limited for diagnosing the existence of the cancer, but also being reliable 
markers for monitoring the tumor histology, stage, or the patient outcome [110].
The content of EVs released from two human breast cancer cell lines, MCF-7 
(less invasive) and MDA-MB-231 (more invasive), was analyzed, and approxi-
mately, 270 proteins were identified [113]. In circulating EVs, epidermal growth 
factor-like repeats and discoidin I-like domains 3 (EDIL3) are the extracellular 
matrix (ECM) protein that was described to play a critical role in tumorigenesis 
by the activation of integrin-focal adhesion kinase (FAK) signaling cascade [113]. 
Breast-cancer-derived EVs (e.g., exosomes) present a cell-independent microRNA 
biogenesis from pre-miRNAs (like Dicer, AGO2, or TRBP) to mature miRNAs [112]. 
In particular, exosomes detected in the cells and sera of patients affected by breast 
cancer were shown to stimulate tumorigenesis in nontumoral epithelial cells by 
a Dicer-dependent mechanism [112]. It was also demonstrated that in the breast 
tumor microenvironment, there is a downregulation of the tumor suppressor p85α, 
which is clinically relevant in tumorigenesis, and the mechanism involves the loss of 
p85α expression in stromal fibroblasts promoting breast cancer progression by the 
epithelial-to-mesenchymal transition [111].
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matrix (ECM) protein that was described to play a critical role in tumorigenesis 
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5. Extracellular vesicles and metastatic niches
Tumor microenvironment was described to undergo series of molecular and 
cellular changes to form the metastatic-designated sites, called pre-metastatic niche 
[115, 116]. The formation of pre-metastatic niche requires the cross talk between 
primary tumor-derived components, and the microenvironment of the host stro-
mal components and of the tumor-mobilized bone-marrow-derived cells [117].
Interestingly, the role of EVs in metastatic niches can be exploited in novel 
therapeutic approaches. Indeed, technologies based on exosomes, separated from 
the ascitic fluid of ovarian cancer patients, embedded in a 3D scaffold metastatic 
trap, were successfully tested in murine models of ovarian metastasis in order to 
improve survival [118]. Numerous studies indicated that tumor-derived exosomes 
might play a role in promoting angiogenesis and modulation of the immune system  
[119, 120]. Moreover, exosomes derived from cancerous tumor are capable of 
remodeling the surrounding parenchyma, thus supporting tumor progression and 
the generation of the pre-metastatic niche [121, 122].
6. Role of extracellular vesicles in metastasis
EVs have been described to play an essential role in the local and distant 
communication between cancer cells and their environment and in contributing 
to the progression of metastasis [123]. Although the function of EVs in metastasis 
is not completely understood, studies show that miRNAs isolated from EVs are 
actively involved in complex metastatic processes, including local invasion, 
angiogenesis, immune modulation, metastatic niche preparation, colonization, 
and dormancy [123].
EVs play an essential role in the tumor metastasis by ensuring the cross talk 
between tumor and the adipose tissue, and obesity was described to influence 
the metastatic behavior of tumors, especially in melanoma, breast, and ovarian 
cancers [124].
In breast cancer, metastatic exosomes creating a facilitating local environment 
for metastasis was demonstrated, and annexin II contained in these exosomes 
contributes to this process by promoting angiogenesis [125].
7. Tumor-derived extracellular vesicles in ovarian cancer
Nawaz et al. have recently done an extensive review on the role of EVs in ovarian 
cancer and concluded that the gaining of new insights into these mechanisms would 
contribute to the identification of new biomarkers among the ovarian-cancer-
derived EVs and to the development of efficient EVs-based immunotherapies [126]. 
Proteomic analysis of exosomes derived from two human ovarian cancer cell lines 
(i.e., OVCAR-3 and IGROV1) indicated the presence of 2230 proteins, 1017 proteins 
being common for both cell lines, 380 proteins being newly reported compared to 
the ExoCarta database, and some of them being associated with tumorigenesis and 
metastasis and might represent promising biomarkers [127].
Additionally, matrix metalloproteinase-1 (MMP1) might be a very good bio-
marker for the ovarian cancer due to its overexpression in ascites-derived EVs in 
correlation with the degree of malignancy and the low prognosis for the ovarian 
cancer patients [128]. Moreover, the peritoneal dissemination of ovarian cancer is 
facilitated by malignant EVs containing MMP1 derived from the ascites of patients, 
and EVs were demonstrated to induce apoptosis in mesothelial cells [128].
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The mechanisms of drug resistance development also involve the release of 
EVs from ovarian cancer cells upon exposure to drug (i.e., cisplatin) and induce 
invasiveness [129].
8. Breast-cancer-derived extracellular vesicles
In breast cancer, EVs can play two essential roles “diagnosis biomarkers” or 
“therapeutic targets.” Thus, breast cancer induces the release of exosomes from 
salivary glands, being potential markers for early diagnosis [130]. Interestingly, 
EVs serve as a cargo not only for nucleic acids and proteins, but also for anticancer 
drugs. Considering the critical contribution of EVs in facilitating tumorigenesis, 
metastasis, and drug resistance [130], they could be considered as potential thera-
peutic targets in breast cancer.
Moreover, the analysis of EVs can help to distinguish the “degree of aggressive-
ness” in breast cancer. To detail, EVs derived from the aggressive human breast 
cancer MDA-MB-231 cell line, but not from the less invasive human breast cancer 
MCF-7 cell line, were demonstrated to induce platelet activation and aggregation 
by tissue factor-independent and tissue factor-dependent procoagulant activi-
ties [131]. EVs have been demonstrated to be involved in the cross talk between 
neighboring cancer cells and to transmit phenotypic aggressive traits from one cell 
to another. To date, EVs released by Hs578Ts(i)8 triple-negative breast cancer cells 
were able to increase the invasion, proliferation, and migration characteristics of 
Hs578T cells [132].
9. Extracellular vesicles as biomarkers—new diagnostic tools
In different body fluids, especially plasma and serum, EVs biomarkers have been 
detected with great clinical value in various types of cancer, Table 2.
The protein content of the EVs can be potentially used in the early detection 
of cancer as suggested in a pilot study by Smalley et al. [151]. The plasma levels of 
exosomal proteins represents an important biomarker that discriminates between 
ovarian cancer patients and normal ones, and their values correlate with the stage 
of the disease [119]. Among exosomal proteins, TGF-β1 and MAGE3/6 can be 
used as reliable biomarkers to discriminate between benign and malignant ovarian 
tumors, or to ascertain the efficacy of chemotherapy [119]. Although epithelial cell 
adhesion molecule (EpCAM) was demonstrated to promote epithelial-mesenchy-
mal transition in advanced stages of endometrial cancer [152], studies indicated 
that EpCAM is not a robust biomarker to classify exosomes derived from benign 
and malignant ovarian tumors [134] or to detect early stages of the pathology [153]. 
Besides EpCAM, several exosomal proteins were identified to be overexpressed 
in ovarian cancer, including proliferation cell nuclear antigen (PCNA), tubulin 
beta-3 chain (TUBB3), epidermal growth factor receptor (EGFR), apolipoprotein 
E (APOE), claudin 3 (CLDN3), fatty acid synthase (FASN), ERBB2, and L1CAM 
(CD171) [127]. Additionally, claudin-4, but not claudin-3, is a valuable biomarker 
in the peripheral blood of ovarian cancer patients with almost 98% specificity 
[133]. Exosomal proteins can also represent important biomarkers for the evalua-
tion of efficacy of therapies. Thus, annexin A3 can be employed for early detection 
of the resistance to platinum-based therapy in ovarian cancer patients [135, 136].
In breast cancer, several studies identified various exosomal miRNAs as poten-
tial biomarkers correlated with tumor malignancy degree and prognosis. Indeed, 
exosomal miR-21 and miR-1246 had higher levels in plasma of breast cancer 
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patients compared to control patients [138]. Additionally, high levels of exosomal 
miR-939 were associated with low outcome in patients with triple-negative breast 
cancer [139], and high levels of exosomal miR-373 were identified in triple- 
negative, estrogen–receptor- and progesterone-receptor-negative, breast cancer 
patients [58]. Moreover, an extensive proteomics analysis identified alpha1-
antitrypsin and haptoglobin precursors as novel biomarkers in the serum of patients 
with infiltrating ductal breast carcinomas [137].
The release of EVs has a calcium-dependent mechanism, and alterations in 
calcium signaling have been described in tumorigenesis, metastasis, or drug 
resistance in various types of cancer, including breast and ovarian cancers [154, 
155]. Therefore, more attention should be paid to the calcium-dependent signal-
ing cascades in different cancer stages in direct relationship with the cell-to-cell 
communication mechanisms of EVs in order to identify novel specific and reliable 
biomarkers.
10. Therapeutic roles of extracellular vesicles in cancer
EVs have a big potential for cancer therapy monitoring (Table 3). These are 
described as secreted lipid bilayer-enclosed lumens and are claimed to be valu-
able reservoirs of liquid biopsy biomarker [156]. EVs (mainly EVs-associated 
proteins and microRNAs) are proved to be the biomarkers in breast cancer 
diagnosis [157, 158].
Biomarkers of EVs Sample Types of cancer Reference
TGF-beta1, MAGE3/6, and 
Claudin-4
Plasma Ovarian cancer [119, 133]
EpCAM and annexin A3 Serum [134–136]
Alpha-1-antitrypsin and 
haptoglobin precursors
Serum Breast cancer [137]
miR-21, miR-939, miR-373, and 
miR-1246
Plasma [58, 138, 139]
miR-1290 and miR-375
Survivin, CD9+, CD63+, and 
alpha-1-antitrypsin
Plasma Prostate cancer [140–144]
IL-8 and TGF-beta mRNAs Plasma Glioma [60]
miR-21 CSF [145]
miR-1246, miR-4644, miR-3976, 
and miR-4306
CD44v6, Tspan8, EpCAM, and 
CD104
Serum Pancreatic cancer [146]
Alpha-1-antitrypsin, and histone 
H2B1K
Urine Urothelial carcinoma [147]
long coding RNA CRNDE-h Serum Lymph node and distant metastasis of 
colorectal cancer
[148]
miR-21 Plasma Esophageal cancer [149]
miR-19a l Serum Colorectal cancer [150]
Table 2. 
Biomarkers contained in EVs relevant in different types of cancer.
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11. Integrative overview
EVs play an essential role in cellular communication both in physiological and 
pathological conditions. In pathological conditions, EVs have been implicated in 
cancer, spreading of viruses or other pathogens, altered immune response, devel-
opment of neurodegenerative diseases, etc. In cancer, EVs ensure the cross talk 
between tumoral cells or between tumoral cells and nontumoral cells, and enable 
the development of multiple processes, including tumorigenesis, pre-metastatic 
niche formation, metastasis, and drug resistance. In ovarian and breast cancers, 
the involvement of EVs in all these processes of tumor evolution has been described 
and the analysis of EVs content is particularly useful for identifying biomark-
ers of the disease per se and, moreover, for the stage of the pathology evolution. 
However, there are still technical limitations for separation and/or analysis of EVs, 
and in clinical practice, the standardization of EVs-based reproductible protocols is 
required urgently. Considering the presence of EVs in such a variety of body fluids 
and tissues, an important conclusion is to consider EVs both as biomarkers and 
potential therapeutic targets (especially for immunotherapies) and to exploit them 
in the next future to improve the outcome of cancer patients.
Source of EVs Therapeutic effect Reference
Tumor peptide-loaded dendritic
cells-derived exosomes
Immunotherapy—because they suppress 
tumor growth
[159]
EVs from the rat pancreatic 
adenocarcinoma cell line BSp73ASML
Adjuvant therapy in immunotherapy [160]
Tumor antigen containing EVs Activates an antitumor response against 
OVA-transfected BL6–10 melanoma cells
[160]
EV vaccine derived from colorectal cancer 
(NB4 cell—a human acute promyelocytic 
leukemia cell line)
Activates CTLs through self-derived 
dendritic cell activation
[161]
EVs from self-derived dendritic cells Immunotherapy in cases of unresectable 
nonsmall-cell lung cancer
[162]
EVs from autologous self-derived dendritic 
cells
Metastatic melanoma patients [163]
EVs from ascites in combination with 
granulocyte macrophage colony-
stimulating factor
Immunotherapy in colorectal cancer [164]
miR-9 in mesenchymal stem cell-derived 
EVs
Chemosensitive in glioblastoma multiforme 
cells
[165]
iRGD-Exos-doxorubicin Suppressed breast tumor growth in an 
MDA-MB-231 tumor-bearing nude mouse 
model
[166]
Curcumin-primed EVs from a mouse brain 
endothelial cell line
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Extracellular vesicles (EVs) are particles released in the extracellular space from 
all cell types in physiological and pathological conditions and emerge as a new way 
of cell-cell communication by transferring their biological contents into target cells. 
The levels and composition of circulating EVs differ from a normal condition to a 
pathological one, making them real circulating biomarkers. EVs have a very com-
plex contribution in both health and disease, most likely in relationship between 
diabetes and cardiovascular disease. The involvement of EVs to the development of 
cardiovascular complications in diabetes remains an open discussion for therapists. 
Circulating EVs may offer a continuous access path to circulating information on 
the disease state and a new perspective in finding a correct diagnosis, in estimating 
a prognosis and also in applying an effective therapy. Besides their role as biomark-
ers and targets for therapy, EVs can be exploited as biological tools in influencing 
the different processes affected in diabetic cardiovascular diseases. This chapter 
will summarize the current knowledge about EVs as biological vectors modulating 
diabetic cardiovascular diseases, including atherosclerosis, coronary artery disease, 
and peripheral arterial disease. Finally, we will point out EVs’ considerable value 
as clinical biomarkers, therapeutic targets, and potential biomedical tools for the 
discovery of effective therapy in diabetic cardiovascular diseases.
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Lately, research has been increasingly focused on understanding of the biology 
of extracellular vesicles (EVs). Finding a more accurate name to define and classify 
EVs remains an open and, at the same time, a real challenge in the scientific world. 
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There are many reasons why it is difficult to find a very precise name for EVs: they 
are secreted by near all cell types in living organisms; the mechanisms through 
which they are released into the biological fluids are different and multiple; more-
over, they have different sizes (30–2000 nm in diameter) which make the methods 
of obtaining and analyzing them to be diverse, but at the same time, some of them 
are slightly controversial. Once released from the cells, EVs are not inert particles, 
but they have complex functions in both physiological and pathological processes 
due to their specific cargo and factors stimulating their secretion. Thus, EVs are now 
viewed as early noninvasive biomarkers for various disorders in order to establish 
a correct diagnosis, but they also can be real targets for an effective treatment and, 
at the same time, valuable tools for treating several diseases such as diabetic cardio-
vascular diseases.
2. Terminology and biogenesis pathways of extracellular vesicles
EVs are a large term used to define a variety of membrane-limited vesicles 
involved in the intercellular communication. A nomenclature has been pro-
posed but there are still numerous papers using different terms for EVs [1–3]. 
The EVs comprise different types of vesicles, and based on the size, morphol-
ogy, and mechanism of biogenesis, they are largely classified as: exosomes and 
ectosomes, also referred as shedding microvesicles (MVs) or microparticles 
(MPs) [4].
As for the apoptotic bodies, the researchers’ opinions are different; some 
of them think that they can be included in the EV category and others do not 
include them. Apoptotic bodies result from cells undergoing programmed cell 
death (apoptosis) and could be identified in EV probes [5]. The large cellular 
fragments resulted from apoptosis are phagocyted by neighboring cells and 
recycled; therefore, they should not be regarded as EVs involved in intercellular 
communication.
Exosomes (50–100 nm) have been described since 1980s as “exfoliated mem-
brane vesicles,” which may serve as a physiologic function occurring in many nor-
mal and neoplastic cells [6]. An ultrastructural study [7] showed that about 50 nm 
small vesicles are exocyted from multivesicular bodies (MVBs) after receptor- 
mediated endocytosis. For reticulocytes, exosomes’ exocytosis determines the loss 
of transferrin receptors during red cell maturation [8].
MVBs (Figure 1A–D) of 0.5–1 μm large vesicles containing 2–50 small intralu-
minal smaller vesicles belong to the endolysosomal compartment. This pleomorphic 
cellular compartment comprises early and late endosomes where a highly controlled 
molecular sorting mechanism drives MVBs to the lysosomes or to the extracellular 
space. During endosome maturation into late endosomes, inward budding from the 
limiting membrane of the endosome leads to the formation of intraluminal vesicles 
in MVBs [9]. Usually, MVBs fuse with lysosomes, the terminal compartment of the 
endocytic pathway, where they are digested and the final components are recycled. 
Some MVBs can fuse with the plasma membrane and their intralumenal vesicles 
are released from cells as exosomes. The process by which the fate of endosomal 
content is determined is not fully understood [10, 11]. Accumulating evidence 
suggests that the release of EVs often serves as an alternative disposal pathway to 
the overloaded lysosomes [12, 13]. This mechanism may be involved in a vascular 
calcification [14].
It is demonstrated that exosomes are not only cell specific but also they carry 
RNAs between cells and play major roles in intercellular communication [15]. How 
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RNAs reach the MVB vesicles is not clear, but it is supposed that cytosolic RNAs are 
taken up into intraluminal vesicles undergoing inward budding from the limiting 
membrane of the MVBs [9, 16].
Ectosomes (MVs or MPs) are slightly larger vesicles (100–500 nm) compared 
with exosomes and are also cell specific as they are released from plasma membrane 
by budding. Ectosomes do not require exocytosis as they are generated by outward 
budding of a plasma membrane domain, which enclose a cargo gathered at the 
cytosolic face. The detachment of the ectosomes from the donor cells involves 
contraction of cortical actin beneath the plasma membrane [17]. These plasma 
membrane-derived vesicles are also reported to carry RNAs and proteins as an 
effective mechanism for intercellular communication.
Multivesicular cargos (Figure 1A–D) have also been described as EVs with a 
particular appearance: clustered vesicles (80–200 nm) shielded by plasma mem-
brane [18]. This type of EVs has been described as mediating bone mineralization 
[19], vascular calcifications [20], or intercellular communication between telocytes 
[18], which often surround the vessels [21]. In our experience, endothelial cells 
(ECs) from diabetic kidney often release multivesicular cargos in the vascular 
lumen (Figure 1C). Possible mechanism of multivesicular cargo biogenesis based 
on electron microscopy images [18, 19] involves an initial aggregation of vesicles in 
the cortical cytoplasm which further will bulge a segment of the plasma membrane. 
Finally, gathered vesicles are released into the extracellular space as a cargo shielded 
by plasma membrane. The dissolution of the shielding membrane of the multive-
sicular cargo will release individual or grouped cytoplasmic-derived vesicles into 
the extracellular space.
Figure 1. 
Transmission electron microscopy of the extracellular vesicles in diabetic kidney. (A) Multivesicular body 
(MVB) with intraluminal vesicles in the cytoplasm of endothelial cell. (B) Numerous extracellular vesicles 
(square area) present between vascular smooth muscles cells (VSMCs) in vascular media. (C) Multivesicular 
cargos (MVCs) released by an endothelial cell (E) into the lumen of a peritubular capillary.  
(D) Multivesicular cargos (MVCs) released by a circulating lymphocyte (Ly).
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3. Function of extracellular vesicles in physiology
3.1 Physiological role of extracellular vesicles
EVs are connected to different physiological and pathological processes, such 
as tumor growth modulation, cytokine production, or cardiovascular disorders 
[22–24].
EVs contain lipids, and pools of proteins, some specific for the cell type 
generating them—MHC class I and II, and some which are present in most 
EVs—proteins from the plasma membrane, cytosol, and endosome. This latest 
feature suggests the shared biogenesis pathway for these EVs. On the surface 
of EVs, proteins similar with the ones from the originating cells can be found 
[25–28]. Different types of nucleic acids such as DNA, small RNA, ribosomal RNA 
(rRNA), microRNA (miRNA), long noncoding RNA (lncRNA), and mRNA are 
enclosed within the EVs, which transfer their content into recipient cells, induc-
ing transient or persistent phenotypic changes, which will modify their cellular 
functions.
According to Barros et al. [25], there are at least four mechanisms by which 
the EVs can influence the target cells: (1) direct contact between the proteins 
from the target cell and EV membrane, which changes the intracellular signal-
ing of the recipient cells; (2) cleavage of proteins on the EVs’ surface and further 
interaction between the protein fragments and receptor-proteins on the recipient 
cell; (3) fusion between EVs and target cell membrane, followed by EV content 
release within the recipient cell; and (4) internalization of EVs by phagocytosis or 
endocytosis.
3.2 Role of extracellular vesicles in immunological response
The immune response involves participation of innate and adaptive immune 
system to regulation of body homeostasis, defense, and surveillance, thus maintain-
ing the equilibrium between health and disease.
3.2.1 Activation of the helper T cells (CD4+)
Molecules of MHC class II complex are specific to antigen-presenting cells 
(APCs), such as dendritic cells (DC), macrophages, and B lymphocytes, which 
present internalized exogenous peptides for the activation of CD4+ T cells. B cells 
release functional EVs with increased amounts of MHC class II molecules coupled 
with peptides, which are able to generate T helper cell response. T cells are strong 
stimulators of the EVs’ synthesis by B cells due to activation of CD40, and IL-4 
receptors [29–31], and the B cell-derived EVs also contain molecules of MHC class I, 
components of B cell receptor (BCR)—CD19, immunoglobulins, and tetraspanins 
[30, 31]. Content of EVs derived from DC, with MHC class II—peptide complexes, 
contributes to amplification of adaptive immune response [32–34].
3.2.2 Activation of the cytotoxic T cells (CD8+)
Because all nucleated cells express MHC class I molecules, the nucleated cells-
derived EVs contain the MHC class I—endogenous/exogenous antigens complexes, 
thus giving the potential to activate the cytotoxic T cells [35]. These findings were 
confirmed for the first time by Admyre et al., who demonstrated that monocyte-
derived DC released exosomes capable of inducing antigen-specific immune 
response from peripheral blood-isolated CD8+ T cells [36].
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3.2.3 Immunomodulation induced by EVs
The production and release of EVs presenting on the surface factors which 
are capable of triggering apoptotic pathways, such as Fas ligand or galectin 9, can 
induce immunosuppression. On the other hand, platelet-secreted EVs can induce 
secretion of pro-inflammatory cytokines, such as IL-8, IL-1β, and IL-6, thus trig-
gering an inflammatory immune response [37].
4.  Extracellular vesicles as biological vectors modulating diabetic 
cardiovascular diseases
4.1 Role of extracellular vesicles in coronary artery disease
Individuals with type 2 diabetes mellitus develop cardiovascular disorders, 
including coronary artery disease, more frequently than healthy controls, mainly 
through the chronic, damaging exposure of the vascular system to hyperglycemia. 
Therefore, it is important to understand the exact mechanisms through which 
diabetes contributes to the development and severity of these complications.
EVs generated in patients with diabetes mellitus promote inflammation and 
contribute to the development of atherosclerotic lesions, stimulating monocyte 
adhesion and their infiltration in the subendothelial layer, promoting the migration 
and proliferation of vascular smooth muscle cells (VSMCs) and also the calcifica-
tion of the atherosclerotic plaque.
4.1.1 Extracellular vesicles and the coronary atherosclerotic plaque
Recent studies have shown that atherosclerotic lesions of all stages contain 
MVs. Higher levels of circulating MVs have been discovered in individuals with 
cardiovascular risk factors, such as smoking [38], dyslipidemia [39], diabetes 
mellitus [40], and arterial hypertension [41], probably through activation or from 
apoptosis of different cells being exposed to a damaging stimulus. Data extracted 
from in vitro studies suggest that MVs can have both pro-inflammatory and anti-
inflammatory effects, depending on the stimulus that induces their formation [42]. 
MVs increase the release of proinflammatory cytokines, mainly interleukin-6 and -8 
(IL-6 and IL-8), from ECs and leukocytes, promoting the adhesion of monocytes 
to the endothelium and their migration to the atherosclerotic plaque [42, 43]. Also, 
endothelial MVs can activate monocytes by transferring miR-10a and thus interfer-
ing with the nuclear factor-κB inflammatory pathway. Another effect of MVs is the 
decrease of the nitric oxide (NO) production by ECs, consequently impairing endo-
thelial vasodilating properties [44]. Endothelial-derived MVs and platelet-derived 
MVs increase endothelial permeability by delivering two enzymes (caspase 3 and 
Rho-kinase) to target cells and inducing apoptosis [45]. MVs promote adhesion 
of monocytes to the endothelium by increasing endothelial expression of adhe-
sion molecules, such as intercellular adhesion molecule-1 (ICAM-1), or adhesion 
molecule receptors, such as CD11a, on monocytes [46]. ICAM1 expression can also 
be regulated by miR-222 in MVs [42, 47].
Various MVs contribute to foam cell formation in the atherosclerotic plaque by 
stimulating lipid and cholesterol formation in macrophages. Macrophages and foam 
cells undergo afterward apoptosis, forming a core of extracellular lipids. Increased 
monocyte and macrophage apoptosis contributes to augmented MV release in the 
plaque. MVs of monocyte and macrophage origin are the largest population of MVs 
in human atherosclerotic lesions [48].
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inflammatory effects, depending on the stimulus that induces their formation [42]. 
MVs increase the release of proinflammatory cytokines, mainly interleukin-6 and -8 
(IL-6 and IL-8), from ECs and leukocytes, promoting the adhesion of monocytes 
to the endothelium and their migration to the atherosclerotic plaque [42, 43]. Also, 
endothelial MVs can activate monocytes by transferring miR-10a and thus interfer-
ing with the nuclear factor-κB inflammatory pathway. Another effect of MVs is the 
decrease of the nitric oxide (NO) production by ECs, consequently impairing endo-
thelial vasodilating properties [44]. Endothelial-derived MVs and platelet-derived 
MVs increase endothelial permeability by delivering two enzymes (caspase 3 and 
Rho-kinase) to target cells and inducing apoptosis [45]. MVs promote adhesion 
of monocytes to the endothelium by increasing endothelial expression of adhe-
sion molecules, such as intercellular adhesion molecule-1 (ICAM-1), or adhesion 
molecule receptors, such as CD11a, on monocytes [46]. ICAM1 expression can also 
be regulated by miR-222 in MVs [42, 47].
Various MVs contribute to foam cell formation in the atherosclerotic plaque by 
stimulating lipid and cholesterol formation in macrophages. Macrophages and foam 
cells undergo afterward apoptosis, forming a core of extracellular lipids. Increased 
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plaque. MVs of monocyte and macrophage origin are the largest population of MVs 
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Infiltration of LDL particles in the vascular wall during the atherosclerotic 
process can induce the formation and release of tissue factor-enriched MVs from 
the VSMCs, which in turn influence VSMC proliferation and migration [49].
EVs of different origins, with different miRNA content, contribute to VSMC 
proliferation and migration; for example, MVs with miR-223 induce a decrease in 
atherosclerotic plaque size by inhibiting VSMS proliferation and migration, while 
endothelial vesicles with miR-143 and miR-145 prevent VSMC dedifferentiation [50].
4.2 Role of extracellular vesicles in peripheral arterial disease
4.2.1 Atherosclerosis and vascular calcification in diabetes mellitus
Adipose tissue-derived EVs were shown to have immunomodulatory effects on 
macrophages which in turn, after contacting said EVs, secreted factors that inter-
fered with insulin signaling in human adipocytes [51]. Moreover, EVs released from 
adipocytes from obese individuals act in a paracrine manner on neighboring adi-
pocytes and impair insulin-mediated glucose transport [52]. In turn, the exosomes 
derived from insulin resistant adipocytes carry sonic hedgehog (SHH) protein that 
increases the expression levels of TNF-α, IL-1β, IL-6, VEGF-A, ICAM-1, MMP2, 
and MMP9 in the atheroma plaque and promotes vasa vasorum angiogenesis, 
leading to greater plaque burden and vulnerability [53]. Thus, EVs provide a link 
between obesity, low-grade inflammation, insulin resistance, and atherosclerosis 
progression.
EVs also play a key role in the cross talk between ECs and macrophages that 
can either act in the direction of vascular homeostasis or promote atherosclerosis, 
depending on their composition. It was shown that EVs secreted by Kruppel-like 
factor 2-treated ECs show anti-inflammatory actions, while oxidized-LDL-
treated ECs produce EVs with high levels of miR-155, directing macrophage 
differentiation toward pro-inflammatory M1 macrophages [54]. In M1, but not 
in M2 macrophages, the inflammasome is known to be activated [55] and the 
inflammasome signaling leads to the secretion of pro-inflammatory exosomes 
[56], further favoring atherosclerosis progression. Furthermore, atherosclerotic 
patients have high numbers of monocyte/macrophage-derived miR-150-rich EVs 
that enhance EC migration, a major component of atherosclerosis [57]. Thus, 
circulating endothelial microparticles (EMPs) were shown to be an independent 
risk factor for endothelial dysfunction which occurs early in atherosclerosis, and 
the fact that in type 2 diabetes mellitus their number is increased [58] and their 
miRNA composition is altered containing miRNAs mainly involved in angio-
genesis [59] proves the involvement of EVs in cardiovascular complications of 
diabetes mellitus.
However, exosomes from other sources can alleviate diabetes mellitus as shown 
at rats treated with exosomes from human umbilical cord derived multipotent mes-
enchymal stromal cells (MSCs) that have the ability to reverse peripheral insulin 
resistance and relieve β-cell destruction [60].
Atherosclerosis, old age, diabetes, and hyperphosphatemia induce VSMC trans-
differentiation to osteoblasts [61] characterized as loss of SM22a and SMA markers 
and gain of Runx2, SP7, osteopontin, osteocalcin, alkaline phosphatase (ALP), tran-
scription factor Sox9, collagen II, and collagen X [62]. These trans-differentiated 
cells secrete 50–150 nm calcium-phosphorus-rich exosomes that serve as calcifica-
tion nuclei, in the same manner that osteoblast-secreted matrix vesicles lead to bone 
mineralization [63]. However, extracellular calcium leads to Fetuin-A uptake in 
VSMCs mediated by annexins, and high Fetuin-A levels in secreted exosomes pre-
vent further calcification [64]. This control mechanism is affected when Fetuin-A 
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levels are low due to chronic dialysis [65] and higher than normal plasma Fetuin-A 
levels can lead to insulin resistance and diabetes through the direct inhibition of the 
insulin receptor [66], thus only worsening the cardiovascular diseases (CVDs).
EVs found in intima and media of calcified vascular wall (Figure 2A–D) [14] 
seem to be different of matrix vesicle with role in physiological and pathological 
calcification [19]. Vascular cell-derived EVs may serve as a continuous source of 
damaging microcalcifications in atherosclerotic plaques [20]. These vesicles have 
been described as exosomes from endosomal compartment, plasma membrane-
derived ectosomes, and vesicles shielded by a plasma membrane (multivesicular 
cargos) that are released into extracellular space as a cargo [14]. As the first two 
types are intense investigated and described, the last type derived from multive-
sicular cargos is less investigated.
4.3 Role of extracellular vesicles in insulin resistance
The prevalence of type 2 diabetes is rapidly increasing worldwide, in parallel 
with the current obesity epidemic, posing a major healthcare expenditure burden. 
Obesity increases the risk for development of diabetes, cancer, and CVDs. In the 
course of events leading from obesity to type 2 diabetes, several mechanisms are 
currently outlined. Among them, low-grade systemic inflammation in adipose 
tissue of obese persons has been proposed as a possible link between insulin resis-
tance and altered functions of vascular cells by increased cytokines production. 
Furthermore, it has been shown that the molecules that are released by adipose 
Figure 2. 
Transmission electron microscopy of the diabetic arteries in diabetic kidney. (A) Large spaces with vesicular 
content [square marked area in (A) is magnified in (B)] increase the vascular wall thickness. (B) Numerous 
extracellular vesicles accumulated between vascular smooth muscles cells (VSMCs) and small calcifications 
(c) may be seen. (C) Concentric amorphous deposits (d) are located between endothelium (E) and vascular 
smooth muscle cells (VSMCs). (D) Higher magnification of square marked area in (C) shows also numerous 
vesicles in the extracellular space (#) between vascular smooth muscle cells (VSMCs).
Extracellular Vesicles and Their Importance in Human Health
116
Infiltration of LDL particles in the vascular wall during the atherosclerotic 
process can induce the formation and release of tissue factor-enriched MVs from 
the VSMCs, which in turn influence VSMC proliferation and migration [49].
EVs of different origins, with different miRNA content, contribute to VSMC 
proliferation and migration; for example, MVs with miR-223 induce a decrease in 
atherosclerotic plaque size by inhibiting VSMS proliferation and migration, while 
endothelial vesicles with miR-143 and miR-145 prevent VSMC dedifferentiation [50].
4.2 Role of extracellular vesicles in peripheral arterial disease
4.2.1 Atherosclerosis and vascular calcification in diabetes mellitus
Adipose tissue-derived EVs were shown to have immunomodulatory effects on 
macrophages which in turn, after contacting said EVs, secreted factors that inter-
fered with insulin signaling in human adipocytes [51]. Moreover, EVs released from 
adipocytes from obese individuals act in a paracrine manner on neighboring adi-
pocytes and impair insulin-mediated glucose transport [52]. In turn, the exosomes 
derived from insulin resistant adipocytes carry sonic hedgehog (SHH) protein that 
increases the expression levels of TNF-α, IL-1β, IL-6, VEGF-A, ICAM-1, MMP2, 
and MMP9 in the atheroma plaque and promotes vasa vasorum angiogenesis, 
leading to greater plaque burden and vulnerability [53]. Thus, EVs provide a link 
between obesity, low-grade inflammation, insulin resistance, and atherosclerosis 
progression.
EVs also play a key role in the cross talk between ECs and macrophages that 
can either act in the direction of vascular homeostasis or promote atherosclerosis, 
depending on their composition. It was shown that EVs secreted by Kruppel-like 
factor 2-treated ECs show anti-inflammatory actions, while oxidized-LDL-
treated ECs produce EVs with high levels of miR-155, directing macrophage 
differentiation toward pro-inflammatory M1 macrophages [54]. In M1, but not 
in M2 macrophages, the inflammasome is known to be activated [55] and the 
inflammasome signaling leads to the secretion of pro-inflammatory exosomes 
[56], further favoring atherosclerosis progression. Furthermore, atherosclerotic 
patients have high numbers of monocyte/macrophage-derived miR-150-rich EVs 
that enhance EC migration, a major component of atherosclerosis [57]. Thus, 
circulating endothelial microparticles (EMPs) were shown to be an independent 
risk factor for endothelial dysfunction which occurs early in atherosclerosis, and 
the fact that in type 2 diabetes mellitus their number is increased [58] and their 
miRNA composition is altered containing miRNAs mainly involved in angio-
genesis [59] proves the involvement of EVs in cardiovascular complications of 
diabetes mellitus.
However, exosomes from other sources can alleviate diabetes mellitus as shown 
at rats treated with exosomes from human umbilical cord derived multipotent mes-
enchymal stromal cells (MSCs) that have the ability to reverse peripheral insulin 
resistance and relieve β-cell destruction [60].
Atherosclerosis, old age, diabetes, and hyperphosphatemia induce VSMC trans-
differentiation to osteoblasts [61] characterized as loss of SM22a and SMA markers 
and gain of Runx2, SP7, osteopontin, osteocalcin, alkaline phosphatase (ALP), tran-
scription factor Sox9, collagen II, and collagen X [62]. These trans-differentiated 
cells secrete 50–150 nm calcium-phosphorus-rich exosomes that serve as calcifica-
tion nuclei, in the same manner that osteoblast-secreted matrix vesicles lead to bone 
mineralization [63]. However, extracellular calcium leads to Fetuin-A uptake in 
VSMCs mediated by annexins, and high Fetuin-A levels in secreted exosomes pre-
vent further calcification [64]. This control mechanism is affected when Fetuin-A 
117
Part One: Extracellular Vesicles as Valuable Players in Diabetic Cardiovascular Diseases
DOI: http://dx.doi.org/10.5772/intechopen.85225
levels are low due to chronic dialysis [65] and higher than normal plasma Fetuin-A 
levels can lead to insulin resistance and diabetes through the direct inhibition of the 
insulin receptor [66], thus only worsening the cardiovascular diseases (CVDs).
EVs found in intima and media of calcified vascular wall (Figure 2A–D) [14] 
seem to be different of matrix vesicle with role in physiological and pathological 
calcification [19]. Vascular cell-derived EVs may serve as a continuous source of 
damaging microcalcifications in atherosclerotic plaques [20]. These vesicles have 
been described as exosomes from endosomal compartment, plasma membrane-
derived ectosomes, and vesicles shielded by a plasma membrane (multivesicular 
cargos) that are released into extracellular space as a cargo [14]. As the first two 
types are intense investigated and described, the last type derived from multive-
sicular cargos is less investigated.
4.3 Role of extracellular vesicles in insulin resistance
The prevalence of type 2 diabetes is rapidly increasing worldwide, in parallel 
with the current obesity epidemic, posing a major healthcare expenditure burden. 
Obesity increases the risk for development of diabetes, cancer, and CVDs. In the 
course of events leading from obesity to type 2 diabetes, several mechanisms are 
currently outlined. Among them, low-grade systemic inflammation in adipose 
tissue of obese persons has been proposed as a possible link between insulin resis-
tance and altered functions of vascular cells by increased cytokines production. 
Furthermore, it has been shown that the molecules that are released by adipose 
Figure 2. 
Transmission electron microscopy of the diabetic arteries in diabetic kidney. (A) Large spaces with vesicular 
content [square marked area in (A) is magnified in (B)] increase the vascular wall thickness. (B) Numerous 
extracellular vesicles accumulated between vascular smooth muscles cells (VSMCs) and small calcifications 
(c) may be seen. (C) Concentric amorphous deposits (d) are located between endothelium (E) and vascular 
smooth muscle cells (VSMCs). (D) Higher magnification of square marked area in (C) shows also numerous 
vesicles in the extracellular space (#) between vascular smooth muscle cells (VSMCs).
Extracellular Vesicles and Their Importance in Human Health
118
tissue cells into circulation are enclosed in vesicles. EVs derived from adipose tissue 
may play a role in the paracrine cross talk between adipocytes and macrophages in 
adipose tissue in obesity [51], and in endocrine manner for transmission of signals 
to other cells from cardiovascular system [67]. There are the studies that support 
the idea that EVs are important mediators for metabolic organ cross talk. Thus, it 
was hypothesized that insulin-secreting beta (β) cells and insulin-sensitive tissues 
release exosomes that can be transferred to other metabolic organs, or to immune or 
endothelial cells. In this way, in an autocrine or paracrine manner, exosomes influ-
ence glucose homeostasis and insulin resistance [68].
When circulating miRNA profile of lean and obese individuals was compared, 
those miRNAs differentially expressed were predicted to regulate inflammatory 
and fibrotic signaling pathways [69]. Moreover, in obesity, exosomes from adipose 
tissue-derived MSCs have reduced pro-angiogenic properties due to decreased 
content in miR-126, VEGF, and MMP-2. A differential EV proteomic profile has also 
been observed between obese diabetic and obese nondiabetic rats [70]. In a recent 
study, the lean mice treated with exosomes from obese mice developed glucose 
intolerance and insulin resistance. In addition, using exosomes transfected with a 
specific siRNA targeting PPARα, the phenotype induced by obesity-associated miR-
NAs was recapitulated. Importantly, it was demonstrated that obesity-associated 
exosomal miRNAs modulate glucose and lipid metabolism in mice [71].
In type 1 diabetes, the imbalances between effector T cells and regulatory T cells, 
as well as dendritic cell presentation of islet auto-antigens, play an important role in 
the destruction of islet β cells. It has been shown that MVs derived from endothelial 
progenitor cells (EPCs) combined with islets can activate angiogenesis, decrease 
leucocyte-endothelial interaction, and improve pancreatic β cell function [72]. 
Another study revealed that insulinoma-released exosomes or MPs are immunos-
timulatory and can activate autoreactive T cells spontaneously developed in non-
obese diabetic mice [73]. Exosomes could also serve as triggering factors for specific 
autoimmunity events leading to diabetes, as shown in another study where in NOD 
mice exosomes released by islet-derived MSCs trigger autoimmune responses [74]. 
Thus, specific biological roles of EVs are dependent on functional state and the type 
of cells from which the EVs are released.
5.  Extracellular vesicles as clinical biomarkers, therapeutic targets, and 
biomedical tools in diabetic cardiovascular diseases
5.1 Extracellular vesicles as clinical biomarkers
Early recognition of prediabetes and diabetes is critical for the prevention or the 
successful treatment of diabetes-induced cardiovascular complications.
The traditional markers used in clinical practice, such as glycated hemoglobin 
and glucose determinations, are detected only when diabetes is already established 
and cannot precisely predict an individual’s risk of developing diabetes [75].
Biomarkers for early detection of the disease and identification of individuals 
at risk of developing complications would greatly improve the care of diabetic 
patients.
The study of EVs is opening new horizons for their potential application not 
only as therapeutic tools but also as clinical biomarkers for monitoring disease 
progression. Even if most clinical data are derived from the studies of tumor 
patients, increased levels of EVs have been detected in body fluids in a variety of 
cardiovascular and inflammatory pathologies, obesity, atherosclerosis, diabetes, 
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and metabolic syndrome—biomarkers of both incidence and progression diabetic 
retinopathy in diabetic patients.
Owing to their association with the onset, progression, and pathogenesis of type 2 
diabetes, EVs are emerging as a new and attractive class of biomarkers for prognosis, 
diagnosis, progression/severity, and management of diabetes.
EVs are detectable in most of the body fluids, including blood, and their expres-
sion pattern appears to provide valuable information about the functional state of 
their parental cells [76].
In the study by Sun et al. [77], levels of urinary CD63-positive exosomes were 
found increased at the early stage of renal injury in diabetic nephropathic subjects.
On the other hand, circulating MPs, in particular platelet-derived microparticles 
(PMPs) and EMPs, have been found elevated in a wide range of thrombotic disor-
ders, with an interesting relationship between their levels and disease pathophysiol-
ogy, activity, or progression [78, 79]. EMP plasma levels have been associated with 
several CVDs and risk factors. Circulating PMPs are also shown to be involved in the 
progressive formation of atherosclerotic plaque and development of arterial throm-
bosis [80, 81], especially in diabetic patients [59]. Indeed, diabetes is characterized 
by an increased procoagulant state and by a hyperreactive platelet phenotype, 
with enhanced adhesion, aggregation, and activation. Elevated MP levels, such 
as TF-positive MPs, have been shown to be one of the procoagulant determinants 
in patients with type 2 diabetes mellitus [82]. Also, it was demonstrated that EVs 
participate in the transport of cytokines and angiogenic factors in diabetic patients 
with ocular complications [83]. Moreover, a recent study showed that distribution 
of pro- and anti-angiogenic miRNAs in patients with type 2 diabetes is in close 
touch with the upregulation or downregulation of miRNAs in the plasma fraction 
enriched in ectosomes (MVs or MPs) [84]. This topic has been widely discussed in 
a paper by Alexandru et al. [84], in which MPs and MPs-associated miRNAs were 
presented as active players in vascular complications in diabetes.
More than that, since urinary EVs (UEVs) have been described in diabetic 
nephropathy (DN), they immediately became to be proposed and a biomarker in 
kidney complication [85, 86]. Patients with DN have exceptionally high rates of 
cardiovascular morbidity and mortality; thus, there is an emerging need to find the 
link between the risk of DN and CVD progression.
Owing that urine is an easily accessible fluid sample, UEVs can be obtained in 
bulk, which make them emerging as a valuable source for disease stage-specific 
molecular signatures potentially useful in diagnostics. Therefore, UEVs has been 
proposed to be a novel biomarker in diagnostics, prognosis, and disease progression 
in diabetic kidney complications [87, 88].
Similar to CVDs, in DN, the profile and concentration of proteases and prote-
ases inhibitors is changing in UEVs. For example, Musante et al. [89] have found 
that cathepsins (A, C, D, L, and XZP) are significantly increased in UEVs isolated 
from DN patients. Cathepsins are included to the class of lysosomal proteases and 
their proteolytic activity is related to ECM remodeling [90]. The proteomic study 
confirmed that in diabetic UEVs, serine proteases and their inhibitors, including 
SERPINA1 and SERPINA3, are present [90].
Besides protein cargo, also miRNA UEVs content have some specific features, 
strongly related to CVD pathomechanism. Barutta et al. showed a differential 
expression of 22 exosomal miRNAs between micro- and normoalbuminuric 
patients with DN [91]. Among them, miR-130a has been found to play a critical role 
in cardiac fibrosis by directly targeting peroxisome proliferator-activated receptor-γ 
(PPAR-γ) [91]. Interestingly, miR-155 was significantly reduced in UEVs from DN 
patients. This miR is significantly expressed and secreted in Krüppel-like factor 5 
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SERPINA1 and SERPINA3, are present [90].
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strongly related to CVD pathomechanism. Barutta et al. showed a differential 
expression of 22 exosomal miRNAs between micro- and normoalbuminuric 
patients with DN [91]. Among them, miR-130a has been found to play a critical role 
in cardiac fibrosis by directly targeting peroxisome proliferator-activated receptor-γ 
(PPAR-γ) [91]. Interestingly, miR-155 was significantly reduced in UEVs from DN 
patients. This miR is significantly expressed and secreted in Krüppel-like factor 5 
Extracellular Vesicles and Their Importance in Human Health
120
(KLF5)-overexpressing VSMCs and it is considered as a potent regulator of endo-
thelium barrier function through regulating endothelial targeting tight junction 
protein expression. In murine model of atherosclerosis, VSMCs-derived exosomes 
mediated the transfer of miR-155 from VSMCs to ECs, which led to an increased 
endothelial permeability and enhanced atherosclerotic progression [92]. These data 
suggest the possible role of UEVs in kidney remodeling, which can bring the new 
insight into vascular complications and vascular risk in diabetes.
5.1.1 Therapeutic potential of extracellular vesicles
According to results from studies from the last 5 to 10 years, EVs could play an 
important role in different cardiac regenerative therapies and could also be used as 
therapeutic targets and vectors in cardiovascular medicine.
Platelet-derived vesicles induce vascular endothelial growth factor (VEGF)-
dependent angiogenesis and stimulate postischemic revascularization after chronic 
ischemia [93]. Also, plasma-derived exosomes activate Toll-like receptor 4 on 
cardiomyocytes and thus protect the myocardium from ischemia-reperfusion injury 
[94]. MSCs-derived EVs could be an alternative to stem cell transplantation after 
myocardial ischemia by transfer of specific miRNAs through embryonic stem cell 
EVs [95].
Different cardiovascular medications can influence the level of circulating MVs. 
Antiplatelet agents (ticlopidine and abciximab) inhibit platelet activation and 
also the release of platelet-derived MVs [96–98]. Antihypertensive agents (such as 
angiotensin II receptor inhibitors, beta blockers, and calcium channel blockers) 
lower the circulating levels of platelet- and monocyte-derived MVs [99]. The effects 
of statin treatment on circulating MVs of platelet and endothelial origin are still 
unclear [100, 101].
Statins and antihypertensive medication are able to modify the properties of 
in vivo-generated endothelial MVs and their effect on the expression of endothelial 
adhesion molecules, inhibiting the adhesion of monocytes to ECs and improving 
endothelial function [102].
In other words, MVs are now regarded as novel therapeutic targets to monitor 
the therapeutic response to treatments in diabetic macrovascular complications. 
The beneficial effects of several drugs, such as statins, antiplatelet agents, anti-
oxidants, angiotensin II receptor blockers, and calcium-channel blockers, have 
been reported to be partially due to their effects on reduction of both MV numbers 
and/or procoagulant factors [103]. Moreover, the cardiovascular benefits of anti-
hyperglycemic drugs used to treat type 2 diabetic patients, such as, glibenclamide 
[104], acarbose [105], miglitol [106], and gliclazide [107], might be at least partially 
attributed to the anti-atherothrombotic effects of medication, through the decrease 
of procoagulant MV levels and platelet-activating factors. Pioglitazone treatment 
reduced the level of circulating endothelial-derived-MVs and increased the level 
of EPCs and the endothelial-derived MVs/EPCs ratio, improving the imbalance 
between endothelial damage and repair capacity [108]. Moreover, in our studies on 
atherosclerotic animal model and patients with hypertension and dyslipidemia, we 
showed that administration of irbesartan, an AT1 receptor antagonist, decreases 
the levels of circulating MVs, and also of specific MVs (endothelial-, platelet-, and 
leukocyte-derived MVs), and increases EPC levels, preventing the appearance of 
vascular endothelial dysfunction [78]. The mechanisms underlying this response 
include the reduction/increase of a number of specific membrane receptors 
exposed by MPs (TF, P-selectin, E-selectin, PSGL-1, Rantes), respectively, by EPCs 
(β2-Integrins and α4β1-integrin), the augmentation of endothelium-mediated 
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vasodilation and the reduction of protein expression of VEGF/stromal cell-derived 
factor-1α (SDF-1α) [109].
In addition to their role as drug targets, EVs are an attractive drug delivery 
vehicle. The use of EVs as therapeutic vectors could be done through bioengineer-
ing, either by modifying the cytosolic content of the vesicles which could be 
transferred to the target cells in order to influence cell metabolism, or by loading of 
EVs with molecules to be delivered to target cells. Studies regarding the use of EVs as 
therapeutic vectors in CVDs are few and are only on animal models.
EVs present some individual features, which make them promising therapeutic 
tools, and emphasize EV-based therapies as a promising alternative to cell therapy 
in cardiovascular medicine. Using EV-based therapeutics avoids biological issues 
associated with cell-based strategies, such as stress-induced necrosis or aberrant 
differentiation [110].
Thus, EVs have a particular stability over time conferred by their membranous 
structures that make them real “off-the-shelf” tools allowing careful maintenance 
of stability, integrity, and biological activity during their manufacture, storage, 
and subsequent administration [111]. Moreover, EV lipid bilayer coat protects their 
bioactive cargo from degradation when they circulate from one cell to another. 
The small size of EVs, compared to whole cells, also offers therapeutic benefits, 
such as decreased macrophage phagocytosis and vascular occlusion, and easier 
injection [110]. Additionally, EVs have innate biocompatibility, low toxicity and 
immunogenicity, and selective uptake that make them an excellent delivery vehicle 
for therapeutics [112].
With all these features, at this time, EVs represent attractive nanocarriers for 
drugs as well as therapeutic small molecules, nucleic acids, and proteins.
In order to enhance the EVs’ therapeutic capabilities and applicability, meth-
odologies have been developed for loading them with non-native cargo and also, 
several targeting strategies for systemically delivery. The two main categories of 
current strategies are: (i) approaches focused on cellular modification and  
(ii) methods focused on direct EV alteration [113].
The most common therapeutic approaches that have used EVs are: (i) to deliver 
small RNAs attempting to reverse pathological miRNA-based communication with 
anti-miRNA oligonucleotides or (ii) to stimulate protective communication with 
synthetic miRNA mimics [114, 115]. More specific delivery of anti-miRNAs or 
miRNA mimics to target cells is realized by engineering vesicles with cell-selective 
surface proteins [116], which should reduce off-target effects. The ability to load 
EVs with miRNAs suggests the possibility of using EVs to deliver miRNA-based 
therapeutics in CVDs. The field of miRNA-based therapies is advancing rapidly, 
and research focused on circulating EVs and their miRNA content has revealed 
diverse and important roles [112].
However, not many studies have focused their objective in the use of EVs 
as therapeutic tools against CVDs. In this regard, in a mouse model of type 1 
diabetes, it was shown that MSCs-derived EVs delayed the onset of type 1 dia-
betes through modulation of IL-1β-mediated pancreatic B-cell damage [117]. 
Moreover, EVs secreted by induced pluripotent stem cells deliver cardioprotec-
tive miR-21 and miR-210, preventing cardiomyocyte apoptosis in the ischemic 
myocardium [118].
More information exists in the literature concerning the individual subsets of 
EVs: exosomes and MVs as therapeutic targets and biomedical tools. For instance, 
it was reported that cardiomyocytes exert an anti-angiogenic function in type 
2 diabetic rats through exosomal transfer of miR-320 into ECs [119]. Further 
research showed that exosomes derived from cardiomyocytes overexpressing 
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(KLF5)-overexpressing VSMCs and it is considered as a potent regulator of endo-
thelium barrier function through regulating endothelial targeting tight junction 
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heat shock protein 20 (Hsp20) protect against in vitro high glucose-triggered cell 
death as well as in vivo diabetes mellitus-induced cardiac adverse remodeling, 
suggesting that Hsp20-engineered exosomes might be a novel promising therapy 
[120]. Exosomes from human fibrocytes stimulated with platelet-derived growth 
factor-BB for 7 days and transforming growth factor-β for the following 3 days 
displayed both, in vitro and in vivo, wound healing properties in diabetic db/db  
mice [121]. Although it has been shown that this pharmacological treatment 
of human fibrocytes increased expressions of miR-126, miR-130a, miR-132, 
miR124a, miR-125b, and miR-21 into exosomes, the exact mechanism implicated 
in these effects is still unknown. In addition, administration of mouse brain endo-
thelial cell-derived exosomes, loaded with miR-146a by chemical transfection 
method, into the brain’s ventricle attenuates dementia-like pathology in diabetic 
db/db mice [122].
Several experimental data and preclinical models have demonstrated the 
excellent potential of stem cell-derived exosomes to be used as therapeutic tools 
in CVDs [111]. Thus, exosomes enriched with miR-22 secreted by MSCs follow-
ing ischemic preconditioning was reported to have a significant benefit in cardiac 
recovery after myocardial infarction, by targeting the methyl CpG binding protein 
2 [123]. Exosomes derived from human MSCs, carrying miR-21-5p, mediates effects 
on cardiac contractility and calcium handling, likely via PI3K signaling, opening 
new research ways in optimizing future stem cell-based cardiotherapies [124]. 
Furthermore, it was shown that exosomes secreted by human cardiosphere-derived 
cells enriched in miR146a inhibited apoptosis and promoted proliferation of cardio-
myocytes, improving in this way angiogenesis. In another study, it has been showed 
that in cardiomyocytes cultured in a hypoxic environment, GATA-4 overexpressing 
MSCs-derived exosomes contribute to increased cardiomyocyte survival, reduced 
cardiomyocyte apoptosis, and preserved mitochondrial membrane potential [125]. 
Importantly, the use of exosomes isolated from MSCs for the reduction of inflam-
matory state during type 1 diabetes mellitus is mentioned into an Egyptian clinical 
trial (phase II-III, NCT02138331) [126].
In addition, it has been demonstrated that abnormal miRNA expression in MVs 
is involved in neoangiogenesis: (i) diminished expression of miRNA-200b reduces 
VEGF levels [127] and (ii) augmented expression of miR-29b regulates certain 
apoptotic genes and increases VEGF levels [128]. These data suggested that acting 
on these miRNA levels in MVs may control cell proliferation in diabetic retinopathy. 
Likewise, MVs cargo with miR-126 play an important role in angiogenesis and 
vascular integrity [129], while administration of the miR-126-enriched MVs to 
ApoE−/− mice could reduce the development of aortic plaques of atherosclerosis 
[130]. Importantly, it has been shown that MVs derived from EPCs, carrying spe-
cific miRNAs, activate angiogenesis through phosphatidylinositol 3 kinase/protein 
kinase B signaling pathway [129]. MVs derived from human acute monocytic leuke-
mia cell line (THP-1 cells) treated by inflammatory factors contain miR-150 which 
may be involved in EC migration [226]. In a recent study, we showed that MVs of 
healthy origins promote EPC proliferation, adhesion, and migration, supporting 
reestablishment of EPC ability to incorporate in damaged endothelium and working 
in concert with existing ECs to form blood vessels [131]. These beneficial effects 
of MVs on late EPC dysfunctionality in atherosclerosis could be explained by the 
ability of MVs to transfer specific miRNA (miR-10a, miR21, miR-126, miR-146a, 
and miR-223) into recipient cells and by insulin-like growth factor- 1 expression 
activation [228].
Data summary concerning exosome and MV charge and their therapeutic effects 
are presented in the Table 1.
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6. Progress and challenges in extracellular vesicle field
Although research into EV field is gaining ground, some challenges need to be 
overcome before using them in the clinic, such as: (i) optimization of EV isolation 
procedures, especially the time of protocols, decrease of amount of samples, and 
the selective isolation of distinct EV subtypes; (ii) the large-scale production in 
good manufacturing conditions; and (iii) increase of the specificity of engineered 
EVs vis-à-vis target cells to avoid the possible side effects [126].
Additionally, much still remains to be revealed regarding the role of EVs in 
cell-cell communication both in health and diabetic cardiovascular disorders. 
Specifically, understanding the effects of the chronic inflammatory environment 
in diabetes on the packaging and release of endothelial-EVs and their following 
interactions with cardiomyocytes could be useful [112]. Advancing the knowledge 
regarding the cellular source and destination of EVs in CVDs will allow exploration 
of the specific cellular interactions, while understanding EV organ-tropism will 
help to target specific tissues, improving the efficiency of miRNA-based therapies.
Even so, with many problems remaining to be resolved, as we mentioned above, 
prior EV-based therapeutics might be clinically used to treat CVDs. Anywise, the 
many studies underline their potential as successful therapeutic targets in combat-
ting the heavy millstone of metabolic disease [112].
7. Conclusions
Overall, our chapter strongly suggests that EVs may function as significant 
regulators of both physiological and pathological conditions and demonstrates their 
universal role in the relationship between diabetes and cardiovascular disease. Their 
unique properties as biological vectors modulating diabetic cardiovascular diseases, 
including atherosclerosis, coronary artery disease, and peripheral arterial disease, 
are also highlighted.
Undoubtedly, elucidation of terminology, biogenesis, biological content, and 
function of EVs contributes to better understanding of the complexity of their role 
in influencing the different processes affected in diabetic cardiovascular diseases. 
Consequently, we envisage that for EVs used as clinical biomarkers, therapeutic 
targets, and biomedical tools in diabetes and associated complications, there is a 
need for developing a molecular system of EVs based on their lipidomic, metabo-
lomic, and miRnomic signature. Once these issues are clarified, preventative and 
therapeutic strategies can be implemented and further developed.
Despite the fact that existing literature discussed in this chapter describes the 
EV importance in diabetic cardiovascular diseases, it also leaves some significant 
questions unanswered. Thus, it becomes increasingly complicated to establish an EV 
structure either beneficial or harmful, to clarify their role either good or bad, in both 
health and disease. Incontestably, more research evaluating such properties is neces-
sary to establish EVs’ value as clinical biomarkers, therapeutic targets, and biomedical 
tools based on concrete scientific results for diabetic cardiovascular disease treatment.
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Abstract
Extracellular vesicles (EVs) involved in the intercellular communication hold 
cell-specific cargos that contain proteins, various species of RNA and lipids. EVs 
are emerging as powerful tools for diagnosis and therapy in most diseases but 
little is known about their role in central nervous system (CNS) physiology or 
disease. Considering the extraordinary intricated cytoarchitecture of the brain, 
the implication of EVs in its pathophysiology is difficult to establish. Blood circu-
lating EVs derived from local or distant vascular cells or EVs released from brain 
into the cerebrospinal fluid (CSF) may influence the brain activity. EVs released 
in the blood stream from various tissues may influence the brain by passing 
through the blood-brain barrier (BBB) or through choroid plexus. Since the cho-
roid plexus has also a clearance role, it might be possible that EVs carrying brain 
abnormal proteins to pass into the blood can be detected. Thus, considering that 
EVs are specialized cargos bearing combined signals between cells, they might be 
an interesting therapy target in the future for both regulating neurogenesis and 
abnormal protein clearance. We present here data gathered about EVs that may 
influence the CNS functionality and be involved in most common neurodegen-
erative diseases.
Keywords: extracellular vesicles, exosomes, intercellular communication,  
brain barriers, neurodegenerative diseases
1. Introduction
Extracellular vesicle (EV) is a term used to define a heterogeneous group of 
vesicles isolated from biological fluids or tissues. EVs seem to mediate complex 
cell-to-cell communication over long distances or nearby through various 
macromolecules: polypeptides, various species of RNAs, and/or lipids.  
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The classification of EVs is based on their size and mechanism of biogenesis and 
includes: exosomes, less than 100 nm small vesicles released from multivesicu-
lar bodies after endocytosed materials have been sorted in the endolysosomal 
compartment [1, 2]; ectosomes, up to 500 nm larger vesicles budding from the 
plasma membrane [2, 3]; and multivesicular cargos, consisting of numerous 
vesicles, about 150 nm, enclosed in a plasma membrane-derived shield [4]. 
Although many medical fields experienced real progress with newly discovered 
diagnostic tools or treatments for several diseases, smaller steps are taken in the 
field of cerebrovascular and neurodegenerative diseases. Age-related changes, 
cardiac diseases, and atherosclerosis are known to contribute to the pathogenic 
mechanism of cerebrovascular and neurodegenerative diseases affecting the 
elderly.
2. Biological content of extracellular vesicles
An increasing body of evidence proves that EVs are not only involved in the 
waste disposal system, but, more importantly, they function as membrane-bound 
carriers for intercellular communication [5, 6]. This type of intercellular com-
munication was proven to modulate cellular functions both in homeostatic and 
pathological conditions [6, 7]. High concentrations of EVs were detected in culture 
supernatants and biological fluids [8, 9]. For example, EVs have been isolated from 
CSF and proved to contain overrepresentation of brain-specific proteins derived 
from cerebral white mater and choroid plexus [10]. Several studies demonstrated 
that the level and composition of circulating EVs are altered in disease states, neu-
rodegenerative diseases included [10–12]. Endothelial cells (ECs) and platelets have 
been most studied as sources for EVs [13, 14], but circulating cells as monocytes or 
lymphocytes may also be a source for EVs.
Protein composition of the EV-enclosing membrane, mainly different types of 
integrins, cell adhesion molecules, and tetraspanins, guides the interaction with 
the recipient cells, the targeting, or recruitment once EVs are released into the 
extracellular environment [15]. Specific molecules allow EVs either to interact 
with surface receptors on recipient cells to activate signaling cascades, or to 
promote their docking and uptake. One potential mechanism is direct membrane 
fusion with direct transfer of the cargo molecules into the recipient cytosol [16]. 
Endocytosis, including clathrin-dependent endocytosis, lipid raft-dependent 
pathways, phagocytosis, and even micropinocytosis, was more frequently 
considered [15].
A recent quantitative proteomic analysis allowing comparison of different EV 
subpopulations [17] proved that several classic exosome markers such as flotillin-1, 
heat-shock 70-kDa proteins, actin, and MHC I and II are present in all EV fractions 
obtained by successive centrifugation. Moreover, classic exosomal tetraspanins 
CD9, CD63, and CD81 were unreached in the exosomal fraction but also detected 
in different amounts in larger EVs. The study suggests a further classification of EV 
pelleting at high speed into four subcategories: (a) EVs enriched in all tetraspanins 
and endosome markers (bona fide exosomes); (b) EVs devoid of CD63 and CD81 
but enriched in CD9 (associated with plasma membrane and an early endocytic 
signature); (c) EVs devoid of CD63/CD9/CD81; and (d) EVs enriched in extracel-
lular matrix (ECM) or serum-derived factors. They also propose five categories of 
proteins with different relative distributions in different EV populations that relate 
them to their intracellular source [17]. Thus, exosomes contain ECM proteins, 
receptors, heparin-binding, phospholipid-binding, integrins, immune response, 
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and cell adhesion molecules, while ectosomes are enriched in endoplasmic reticu-
lum proteasome and mitochondrial proteins [9].
The amounts of different lipid classes in EVs have been determined in several 
studies [23, 34], and the enrichment of EV membranes for cholesterol, sphingo-
myelin, glycosphingolipids, and phosphatidylserine compared with their cellular 
sources was proved. However, differences in lipid composition were reported 
between vesicle type and cellular source. Generally, exosomes seem to be enriched 
in glycolipids, phosphatidylserine, and free fatty acids, while ceramides and sphin-
gomyelins were consistently enriched in ectosomes. Still, phosphatidylcholines were 
depleted in exosomes but unchanged or enriched in ectosomes [9].
EVs contain not only proteins and lipids, but several classes of RNAs. Most of 
the recent in vitro studies have proved that EVs contain functional RNA molecules 
that reflect the cellular status and are involved in intercellular crosstalk [18, 19]. 
Different species of RNA have been reported to be enclosed in EVs derived from 
various sources—mRNA, rRNA, and tRNA fragments and especially microRNA 
(miRs) [5]. Several mechanisms for RNA selection, loading into EVs, and their 
uptake by various target cells have been proposed [5, 20]. Packing into EVs protects 
the molecules from RNase degradation once released into the extracellular envi-
ronment. Thus, RNA molecules can be transferred to distant recipient cells, their 
protein production can be modulated [8, 21], or they may be used as predictive bio-
markers for the occurrence of cardiovascular events as demonstrated by the study 
of EVs containing miR-199a and miR-126 in patients with stable coronary artery 
disease [22]. In atherosclerotic disease, miR-containing circulating EVs and apop-
totic bodies, along with other bioactive molecules, are released by proinflammatory 
stimulated monocytes and T cells; ECs and activated platelets initiate hyperplasia 
of vascular smooth muscle cells (VSMCs) which leads to phenotype switching from 
contractile to synthetic and activates their proliferation and migration [23].
Besides membrane proteins and RNA cargo, EVs may contain cytosolic proteins, 
such as cytokines, chemokines, growth factors, enzymes or transcription fac-
tors, functional organelles, and other bioactive molecules such as lipid mediators, 
derived from arachidonic acid [5]. Also, some EVs seem to retain the capacity to 
synthesize eicosanoids using their phospholipid content both by enzymatic and 
nonenzymatic processes [24].
All neural cells from rodent [25, 26] and human [25, 27], even immortalized 
human brain microvascular ECs [25, 28], release EVs which contain mRNA and 
miRs for epigenetic reprogramming of neural cells or post-transcriptional control 
of specific genes [25]. In vitro studies of brain angiogenesis revealed that EVs 
deliver proangiogenic protein, mRNAs, and miRs from cultured glioblastoma cells 
into cerebral ECs [25, 29], especially increased VEGFR-B from immortalized mouse 
cerebral ECs stimulated with LPS and cytokines into targeted cerebral vascular 
pericytes [25, 30]. In vitro and in vivo studies showed that neuronal exosomes 
containing miR-132 could mediate neuronal regulation of brain vascular integrity. 
Thus, in zebrafish larvae and cultured rodent brain cells, it has been shown that 
neurons transfer miR-132, a highly conserved and neuron-enriched miR, via secret-
ing exosomes to ECs to maintain brain vascular integrity. Following translocation to 
ECs through exosome internalization, miR-132 regulates the expression of vascular 
ECs cadherin (VE-cadherin), an important adherens junction protein, by directly 
targeting eukaryotic elongation factor 2 kinase [31]. In addition, two proteins found 
in peripherally circulating plasma EVs, cystatin C and CD14, have been linked to the 
development of brain atrophy and to cerebral white matter lesions, a small vessel 
disease within the brain [32]. Because exosomes contain transferrin and insulin 
receptor [25, 28], which mediate macromolecular passing through the blood-brain 
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The classification of EVs is based on their size and mechanism of biogenesis and 
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with surface receptors on recipient cells to activate signaling cascades, or to 
promote their docking and uptake. One potential mechanism is direct membrane 
fusion with direct transfer of the cargo molecules into the recipient cytosol [16]. 
Endocytosis, including clathrin-dependent endocytosis, lipid raft-dependent 
pathways, phagocytosis, and even micropinocytosis, was more frequently 
considered [15].
A recent quantitative proteomic analysis allowing comparison of different EV 
subpopulations [17] proved that several classic exosome markers such as flotillin-1, 
heat-shock 70-kDa proteins, actin, and MHC I and II are present in all EV fractions 
obtained by successive centrifugation. Moreover, classic exosomal tetraspanins 
CD9, CD63, and CD81 were unreached in the exosomal fraction but also detected 
in different amounts in larger EVs. The study suggests a further classification of EV 
pelleting at high speed into four subcategories: (a) EVs enriched in all tetraspanins 
and endosome markers (bona fide exosomes); (b) EVs devoid of CD63 and CD81 
but enriched in CD9 (associated with plasma membrane and an early endocytic 
signature); (c) EVs devoid of CD63/CD9/CD81; and (d) EVs enriched in extracel-
lular matrix (ECM) or serum-derived factors. They also propose five categories of 
proteins with different relative distributions in different EV populations that relate 
them to their intracellular source [17]. Thus, exosomes contain ECM proteins, 
receptors, heparin-binding, phospholipid-binding, integrins, immune response, 
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and cell adhesion molecules, while ectosomes are enriched in endoplasmic reticu-
lum proteasome and mitochondrial proteins [9].
The amounts of different lipid classes in EVs have been determined in several 
studies [23, 34], and the enrichment of EV membranes for cholesterol, sphingo-
myelin, glycosphingolipids, and phosphatidylserine compared with their cellular 
sources was proved. However, differences in lipid composition were reported 
between vesicle type and cellular source. Generally, exosomes seem to be enriched 
in glycolipids, phosphatidylserine, and free fatty acids, while ceramides and sphin-
gomyelins were consistently enriched in ectosomes. Still, phosphatidylcholines were 
depleted in exosomes but unchanged or enriched in ectosomes [9].
EVs contain not only proteins and lipids, but several classes of RNAs. Most of 
the recent in vitro studies have proved that EVs contain functional RNA molecules 
that reflect the cellular status and are involved in intercellular crosstalk [18, 19]. 
Different species of RNA have been reported to be enclosed in EVs derived from 
various sources—mRNA, rRNA, and tRNA fragments and especially microRNA 
(miRs) [5]. Several mechanisms for RNA selection, loading into EVs, and their 
uptake by various target cells have been proposed [5, 20]. Packing into EVs protects 
the molecules from RNase degradation once released into the extracellular envi-
ronment. Thus, RNA molecules can be transferred to distant recipient cells, their 
protein production can be modulated [8, 21], or they may be used as predictive bio-
markers for the occurrence of cardiovascular events as demonstrated by the study 
of EVs containing miR-199a and miR-126 in patients with stable coronary artery 
disease [22]. In atherosclerotic disease, miR-containing circulating EVs and apop-
totic bodies, along with other bioactive molecules, are released by proinflammatory 
stimulated monocytes and T cells; ECs and activated platelets initiate hyperplasia 
of vascular smooth muscle cells (VSMCs) which leads to phenotype switching from 
contractile to synthetic and activates their proliferation and migration [23].
Besides membrane proteins and RNA cargo, EVs may contain cytosolic proteins, 
such as cytokines, chemokines, growth factors, enzymes or transcription fac-
tors, functional organelles, and other bioactive molecules such as lipid mediators, 
derived from arachidonic acid [5]. Also, some EVs seem to retain the capacity to 
synthesize eicosanoids using their phospholipid content both by enzymatic and 
nonenzymatic processes [24].
All neural cells from rodent [25, 26] and human [25, 27], even immortalized 
human brain microvascular ECs [25, 28], release EVs which contain mRNA and 
miRs for epigenetic reprogramming of neural cells or post-transcriptional control 
of specific genes [25]. In vitro studies of brain angiogenesis revealed that EVs 
deliver proangiogenic protein, mRNAs, and miRs from cultured glioblastoma cells 
into cerebral ECs [25, 29], especially increased VEGFR-B from immortalized mouse 
cerebral ECs stimulated with LPS and cytokines into targeted cerebral vascular 
pericytes [25, 30]. In vitro and in vivo studies showed that neuronal exosomes 
containing miR-132 could mediate neuronal regulation of brain vascular integrity. 
Thus, in zebrafish larvae and cultured rodent brain cells, it has been shown that 
neurons transfer miR-132, a highly conserved and neuron-enriched miR, via secret-
ing exosomes to ECs to maintain brain vascular integrity. Following translocation to 
ECs through exosome internalization, miR-132 regulates the expression of vascular 
ECs cadherin (VE-cadherin), an important adherens junction protein, by directly 
targeting eukaryotic elongation factor 2 kinase [31]. In addition, two proteins found 
in peripherally circulating plasma EVs, cystatin C and CD14, have been linked to the 
development of brain atrophy and to cerebral white matter lesions, a small vessel 
disease within the brain [32]. Because exosomes contain transferrin and insulin 
receptor [25, 28], which mediate macromolecular passing through the blood-brain 
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barrier (BBB), peripherally infused modified exosomes containing specific RNA 
were used to knockdown a specific gene in mouse brain [32–34]. Considering the 
extraordinary intricate cytoarchitecture of the brain, the presence of EVs in the 
adult brain is hard to be documented. Fetal brain and neurospheres contain cells 
which seem to release vesicles into the extracellular space (Figure 1). EVs are easier 
to be seen near ependymal cells floating in the ventricles from where they can be 
isolated [11].
3. Methods of isolation and analysis of extracellular vesicles
Minimal experimental requirements for definition of EVs and their functions 
have been proposed [35], and isolated EVs should be characterized, and the mor-
phology, protein composition, and functionality should be tested before any new 
enquiries are pursued. Whether the chosen isolation technique for the experiment 
consists in ultracentrifugation or any other technique, after collecting the sample it 
is necessary to perform two low-speed centrifugations as soon as possible after the 
sample collection [36]. The first low-speed centrifugation (300–800×g) removes 
cells, lipid droplets, and macromolecules from the sample, while the second 
low-speed centrifugation (2.500×g) removes platelets and apoptotic bodies. Cell 
removal is an important step; otherwise, the following high-speed centrifugations 
break the cells, leading to EV release and sample contamination [37].
Differential ultracentrifugation is the most widely used method for EV 
isolation [36], which involves multiple centrifugations at increasingly higher 
speeds obtaining a particle separation based on the sedimentation coefficient [38]. 
Establishing the appropriate speed and duration of centrifugation is a very impor-
tant step in EV isolation [36]. Several inconveniences can occur using this technique 
such as the loss of certain subpopulations of EVs or simultaneous isolation of lipo/
protein aggregates [39, 40].
Density gradient ultracentrifugation is a method that isolates the particles 
by size and mass density [41], and its usefulness lies in the fact that it can isolate 
several subpopulations of EVs which are lost using differential ultracentrifugation; 
therefore, it increases the purity of the isolated EVs [42].
Size exclusion chromatography is an easy handling method by which a size-
based separation is achieved [43]. It allows the electron microscopy to be per-
formed immediately after isolation and the proteins and lipoproteins are removed 
Figure 1. 
Transmission electron microscopy of the isolated extracellular vesicles: (A) negative staining and  
(B) cryo-electron microscopy.
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from the sample without losing any subpopulation, thus achieving a high-yield 
separation [44].
Precipitation kits gained a lot of attention during the last years involving a 
concentration method based on the use of polyethylene glycol polymers. The price 
for the kits is low, the protocol is easy to perform, it is compatible with both low 
and high volumes of samples, and the method can be applied on large scale [45]. It 
must be taken into account that the precipitation kits are not the best method for 
EV isolation, having a low-yield purification because of the co-precipitations [37]. 
Anyway, for validating the results, it is recommended to use one of the ultracentri-
fugation methods in parallel with this method.
After the isolation step, a general description of the protein composition 
should be made even though there are no specific EV markers discovered yet. EVs 
are enriched in certain proteins such as tetraspanins (CD63, CD81, and CD9) and 
TSG 101 for exosomes, annexin V for ectosomes, etc. [46]. To exclude a contamina-
tion, the presence or absence of proteins that are not expected to be found in EVs, 
intracellular proteins like calnexin, cytochrome C, histones, GRP94, and Argonaute 
complex must be detected [35]. Western blot, flow cytometry, or mass spectroscopy 
can be used for this protein characterization step.
The next step consists in individual characterization of the EVs using at least 
two methods: electron microscopy [35, 45], atomic force microscopy [47], or 
nanoparticle tracking analysis [48]. Transmission electron microscopy (TEM) 
is the most used method for visualization of EVs considering their nanoscale 
size (Figures 1 and 2). Negative staining [49], TEM on thin section from plastic 
Figure 2. 
Transmission electron microscopy: (A) ependymal cells (EC) facing the ventricular system of the mouse 
brain control the communication between cerebrospinal fluid and brain parenchyma; C—capillary. (B) 
Higher magnification of the square-marked area in (A) shows extracellular vesicles (arrows) close to cilia 
and microvilli of the ependymal cell (EC). Volume transmission may be mediated by multivesicular cargoes 
(encircled) which could be seen released from neurons in fetal mouse brain (C) or neurons from neurospheres 
generated from stem cells (D).
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barrier (BBB), peripherally infused modified exosomes containing specific RNA 
were used to knockdown a specific gene in mouse brain [32–34]. Considering the 
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to be seen near ependymal cells floating in the ventricles from where they can be 
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Minimal experimental requirements for definition of EVs and their functions 
have been proposed [35], and isolated EVs should be characterized, and the mor-
phology, protein composition, and functionality should be tested before any new 
enquiries are pursued. Whether the chosen isolation technique for the experiment 
consists in ultracentrifugation or any other technique, after collecting the sample it 
is necessary to perform two low-speed centrifugations as soon as possible after the 
sample collection [36]. The first low-speed centrifugation (300–800×g) removes 
cells, lipid droplets, and macromolecules from the sample, while the second 
low-speed centrifugation (2.500×g) removes platelets and apoptotic bodies. Cell 
removal is an important step; otherwise, the following high-speed centrifugations 
break the cells, leading to EV release and sample contamination [37].
Differential ultracentrifugation is the most widely used method for EV 
isolation [36], which involves multiple centrifugations at increasingly higher 
speeds obtaining a particle separation based on the sedimentation coefficient [38]. 
Establishing the appropriate speed and duration of centrifugation is a very impor-
tant step in EV isolation [36]. Several inconveniences can occur using this technique 
such as the loss of certain subpopulations of EVs or simultaneous isolation of lipo/
protein aggregates [39, 40].
Density gradient ultracentrifugation is a method that isolates the particles 
by size and mass density [41], and its usefulness lies in the fact that it can isolate 
several subpopulations of EVs which are lost using differential ultracentrifugation; 
therefore, it increases the purity of the isolated EVs [42].
Size exclusion chromatography is an easy handling method by which a size-
based separation is achieved [43]. It allows the electron microscopy to be per-
formed immediately after isolation and the proteins and lipoproteins are removed 
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from the sample without losing any subpopulation, thus achieving a high-yield 
separation [44].
Precipitation kits gained a lot of attention during the last years involving a 
concentration method based on the use of polyethylene glycol polymers. The price 
for the kits is low, the protocol is easy to perform, it is compatible with both low 
and high volumes of samples, and the method can be applied on large scale [45]. It 
must be taken into account that the precipitation kits are not the best method for 
EV isolation, having a low-yield purification because of the co-precipitations [37]. 
Anyway, for validating the results, it is recommended to use one of the ultracentri-
fugation methods in parallel with this method.
After the isolation step, a general description of the protein composition 
should be made even though there are no specific EV markers discovered yet. EVs 
are enriched in certain proteins such as tetraspanins (CD63, CD81, and CD9) and 
TSG 101 for exosomes, annexin V for ectosomes, etc. [46]. To exclude a contamina-
tion, the presence or absence of proteins that are not expected to be found in EVs, 
intracellular proteins like calnexin, cytochrome C, histones, GRP94, and Argonaute 
complex must be detected [35]. Western blot, flow cytometry, or mass spectroscopy 
can be used for this protein characterization step.
The next step consists in individual characterization of the EVs using at least 
two methods: electron microscopy [35, 45], atomic force microscopy [47], or 
nanoparticle tracking analysis [48]. Transmission electron microscopy (TEM) 
is the most used method for visualization of EVs considering their nanoscale 
size (Figures 1 and 2). Negative staining [49], TEM on thin section from plastic 
Figure 2. 
Transmission electron microscopy: (A) ependymal cells (EC) facing the ventricular system of the mouse 
brain control the communication between cerebrospinal fluid and brain parenchyma; C—capillary. (B) 
Higher magnification of the square-marked area in (A) shows extracellular vesicles (arrows) close to cilia 
and microvilli of the ependymal cell (EC). Volume transmission may be mediated by multivesicular cargoes 
(encircled) which could be seen released from neurons in fetal mouse brain (C) or neurons from neurospheres 
generated from stem cells (D).
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embedded EVs [49], can also be used to confirm the presence of the lipid bilayer 
of the isolated EV membrane and an election method to investigate EVs in tissue. 
Cryo-TEM [50] is a high resolution method to visualize the lipid bilayer. Electron 
tomography [4, 51] allows 3D reconstruction of the EVs with a very good imaging 
of the different types. For surface protein recognition, immuno-EM [52, 53] allows 
imaging of EV-specific markers.
Flow cytometry is a method based on measuring the signal of the light scatter-
ing from a structure passing through a laser beam. The smaller the particles, the less 
the light scattering, and therefore, conventional cytometry has a detection limit of 
approximately 200 nm [54]. Fluorescence-based detection is used to overcome this 
inconvenience [45, 55], the background noise being higher than the EV signal.
Nanoparticle tracking analysis involves the passing of a laser beam through a 
suspension that contains EVs and the scattering light is captured by a camera [48]. 
The Brownian movement of the EVs in the suspension is recorded, and according to 
their movement, the size can be measured [48].
The last step to fulfill the minimal experimental requirements involves the 
functional assays [35]. Multiple in vitro models can be designed for this step; 
co-incubating EVs with different culture cells and migration, proliferation, coagula-
tion, and fibrinolysis may be quantified depending on the chosen model [45].
There is no gold-standard method yet, but researchers are encouraged to explore 
and to standardize their methods of isolation with the hope that someday, easy EV 
isolation will be possible.
4. Extracellular vesicles and cardiovascular risk for brain pathology
All cells are capable of secreting specific arrays of EVs. Furthermore, the same 
cells may produce EVs by different biogenesis pathways, with different intracellular 
origins, of various sizes, with diverse composition and consequently, different 
functional properties [17]. Crucial feature for the normal functionality of the CNS 
and brain microenvironment homeostasis is sustained by vascular integrity which is 
highly dependent on the systemic status.
Several studies of patients with stable coronary artery disease have reported 
increased levels of circulating EVs which may influence the BBB integrity. Specific 
EV subpopulations, especially those of ECs origin, characterized by CD144+, 
CD131+/annexin A5+, or EVs containing miR-199a and miR-126, are currently 
researched as interesting biomarkers for cardiovascular risk and mortality in these 
patients [22, 56, 57].
Calcifications present in the atherosclerotic plaque [58] have a destabilizing 
effect in early lesions, favoring the rupture, but gain a potential protective effect in 
advanced lesions with heavy calcium deposits [59]. As several studies have shown, 
atherosclerotic plaque calcifications are associated with EVs of ECs, VSMCs, and 
macrophage origin. VSMCs can release EVs with low levels of calcification-inhibit-
ing enzymes and annexin A6/phosphatidylserine nucleation complexes. Exposure 
of VSMCs to proinflammatory cytokines can stimulate the release of EVs that can 
mineralize when inhibitors of calcification are missing [60]. Also, ECs exposed to 
proinflammatory stimuli can release EVs rich in bone morphogenetic protein 2, pro-
moting calcification in VSMs [61]. Alterations in local homeostasis of calcium and 
phosphate lead to the formation of macrophage-derived exosomes which stimulate 
mineralization, through an annexin-dependent mechanism [62].
Recent studies have also noted that in humans, advanced atherosclerotic plaques 
have a high content of procoagulant EVs, originating form leukocytes, erythro-
cytes, and VSMCs [63, 64]. In opposition to ectosomes, exosomes have shown 
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antithrombotic effects. In animal studies, platelet-derived exosomes suppressed 
platelet aggregation and occlusive thrombosis by inhibiting platelet CD36 and 
decreasing CD36-dependent oxidized LDL binding and macrophage cholesterol 
loading [65]. EVs influence the different mechanisms that lead to plaque destabili-
zation and rupture. Intraplaque hemorrhages are produced by neovascularization 
originating from adventitial tissue, stimulated by plaque EVs, such as CD40+ 
vesicles of macrophage origin. Hemorrhages are also favored by leukocyte and 
ECs-EVs with fibrinolytic activity [66, 67]. Fibrous cap weakening is associated 
with VSMC apoptosis, induced by the presence of EVs, released in some pathologi-
cal conditions [100]. Moreover, EVs can influence breakdown of matrix structural 
proteins through metalloproteinase interactions [68].
Circulating levels of procoagulant EVs are higher in patients with acute coronary 
syndromes compared to healthy controls or patients with stable coronary artery 
disease [57, 69]. Circulating EVs alter endothelial-dependent NO mediated vasodila-
tion, and endothelial EVs increase ECs thrombogenicity [70, 71]. Circulating EVs 
have also been investigated as prognostic markers in secondary prevention, in order 
to identify patients at high cardiovascular risk [56, 57]. Increased levels of CD11b+/
CD66+ leukocyte-derived EVs could be useful in identifying asymptomatic patients 
at high risk for plaque rupture [72], while CD3+/CD45+ EVs could identify individu-
als who will develop a major cardiovascular event [73].
All these circulating EVs associated with coronary disease [74] may affect 
the vascular bed of the brain and disrupt the functionality of BBB. Aging and 
cardiovascular-associated disease are associated with BBB alteration [75] and blood 
circulating EVs may mediate early dysfunctions or progression of cerebral associ-
ated pathology. EVs associated with hypercholesterolemia [76] and atherosclerosis 
[77, 78] may have an impact on BBB function, and reducing the proinflammatory 
cytokines enrolling in EVs [79] may be beneficial.
Different neuronal cell types and molecules concur to regulate the improvement 
of brain vasculature [31, 80–82]. Each cell, including neurons and astrocytes [32, 
83], is able to produce EVs enriched in specific proteins, lipids, and RNAs. EVs can 
stimulate targeted neural cells and surrounding neural tissues, which are impor-
tant elements of vascular integrity preservation. The brain pathological condition 
changes the EV content profile of proteins and miRs [84]. A number of studies have 
shown that EVs regulate arterial stiffness [32, 85] which is linked to small vessel 
[32, 86–88], and platelet-derived EVs seem to be important players in the formation 
of cerebral microthrombi which lead to brain atrophy and consequent cognitive 
degeneration. It is believed that the prothrombotic nature of an elevated number of 
platelet-derived EVs reported in the acute phase of cerebral infarction may conduct 
to infarct progression [32, 84, 89, 90]. EV proteins cystatin C and CD14 have been 
shown to be related to cerebral white matter lesions and the progression of brain 
atrophy in patients with manifest vascular disease, suggesting a role for EVs in the 
etiology of structural brain changes [32].
The role of cardiovascular disease risk factors in the occurrence and progression 
of cognitive impairment is widely accepted. There is a link between elevated levels 
of cholesterol and amyloid deposition in the brain, and the relationship between 
atherosclerotic injury and sporadic Alzheimer’s disease is investigated.
5. Extracellular vesicles in neurodegenerative diseases
The pathology of Alzheimer’s disease (AD) consists in the extracellular amyloid 
plaques formed by aggregated amyloid beta peptides and in the intraneuronal 
neurofibrillary tangles made of hyperphosphorylated tau proteins [91]. The 
Extracellular Vesicles and Their Importance in Human Health
142
embedded EVs [49], can also be used to confirm the presence of the lipid bilayer 
of the isolated EV membrane and an election method to investigate EVs in tissue. 
Cryo-TEM [50] is a high resolution method to visualize the lipid bilayer. Electron 
tomography [4, 51] allows 3D reconstruction of the EVs with a very good imaging 
of the different types. For surface protein recognition, immuno-EM [52, 53] allows 
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ing from a structure passing through a laser beam. The smaller the particles, the less 
the light scattering, and therefore, conventional cytometry has a detection limit of 
approximately 200 nm [54]. Fluorescence-based detection is used to overcome this 
inconvenience [45, 55], the background noise being higher than the EV signal.
Nanoparticle tracking analysis involves the passing of a laser beam through a 
suspension that contains EVs and the scattering light is captured by a camera [48]. 
The Brownian movement of the EVs in the suspension is recorded, and according to 
their movement, the size can be measured [48].
The last step to fulfill the minimal experimental requirements involves the 
functional assays [35]. Multiple in vitro models can be designed for this step; 
co-incubating EVs with different culture cells and migration, proliferation, coagula-
tion, and fibrinolysis may be quantified depending on the chosen model [45].
There is no gold-standard method yet, but researchers are encouraged to explore 
and to standardize their methods of isolation with the hope that someday, easy EV 
isolation will be possible.
4. Extracellular vesicles and cardiovascular risk for brain pathology
All cells are capable of secreting specific arrays of EVs. Furthermore, the same 
cells may produce EVs by different biogenesis pathways, with different intracellular 
origins, of various sizes, with diverse composition and consequently, different 
functional properties [17]. Crucial feature for the normal functionality of the CNS 
and brain microenvironment homeostasis is sustained by vascular integrity which is 
highly dependent on the systemic status.
Several studies of patients with stable coronary artery disease have reported 
increased levels of circulating EVs which may influence the BBB integrity. Specific 
EV subpopulations, especially those of ECs origin, characterized by CD144+, 
CD131+/annexin A5+, or EVs containing miR-199a and miR-126, are currently 
researched as interesting biomarkers for cardiovascular risk and mortality in these 
patients [22, 56, 57].
Calcifications present in the atherosclerotic plaque [58] have a destabilizing 
effect in early lesions, favoring the rupture, but gain a potential protective effect in 
advanced lesions with heavy calcium deposits [59]. As several studies have shown, 
atherosclerotic plaque calcifications are associated with EVs of ECs, VSMCs, and 
macrophage origin. VSMCs can release EVs with low levels of calcification-inhibit-
ing enzymes and annexin A6/phosphatidylserine nucleation complexes. Exposure 
of VSMCs to proinflammatory cytokines can stimulate the release of EVs that can 
mineralize when inhibitors of calcification are missing [60]. Also, ECs exposed to 
proinflammatory stimuli can release EVs rich in bone morphogenetic protein 2, pro-
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antithrombotic effects. In animal studies, platelet-derived exosomes suppressed 
platelet aggregation and occlusive thrombosis by inhibiting platelet CD36 and 
decreasing CD36-dependent oxidized LDL binding and macrophage cholesterol 
loading [65]. EVs influence the different mechanisms that lead to plaque destabili-
zation and rupture. Intraplaque hemorrhages are produced by neovascularization 
originating from adventitial tissue, stimulated by plaque EVs, such as CD40+ 
vesicles of macrophage origin. Hemorrhages are also favored by leukocyte and 
ECs-EVs with fibrinolytic activity [66, 67]. Fibrous cap weakening is associated 
with VSMC apoptosis, induced by the presence of EVs, released in some pathologi-
cal conditions [100]. Moreover, EVs can influence breakdown of matrix structural 
proteins through metalloproteinase interactions [68].
Circulating levels of procoagulant EVs are higher in patients with acute coronary 
syndromes compared to healthy controls or patients with stable coronary artery 
disease [57, 69]. Circulating EVs alter endothelial-dependent NO mediated vasodila-
tion, and endothelial EVs increase ECs thrombogenicity [70, 71]. Circulating EVs 
have also been investigated as prognostic markers in secondary prevention, in order 
to identify patients at high cardiovascular risk [56, 57]. Increased levels of CD11b+/
CD66+ leukocyte-derived EVs could be useful in identifying asymptomatic patients 
at high risk for plaque rupture [72], while CD3+/CD45+ EVs could identify individu-
als who will develop a major cardiovascular event [73].
All these circulating EVs associated with coronary disease [74] may affect 
the vascular bed of the brain and disrupt the functionality of BBB. Aging and 
cardiovascular-associated disease are associated with BBB alteration [75] and blood 
circulating EVs may mediate early dysfunctions or progression of cerebral associ-
ated pathology. EVs associated with hypercholesterolemia [76] and atherosclerosis 
[77, 78] may have an impact on BBB function, and reducing the proinflammatory 
cytokines enrolling in EVs [79] may be beneficial.
Different neuronal cell types and molecules concur to regulate the improvement 
of brain vasculature [31, 80–82]. Each cell, including neurons and astrocytes [32, 
83], is able to produce EVs enriched in specific proteins, lipids, and RNAs. EVs can 
stimulate targeted neural cells and surrounding neural tissues, which are impor-
tant elements of vascular integrity preservation. The brain pathological condition 
changes the EV content profile of proteins and miRs [84]. A number of studies have 
shown that EVs regulate arterial stiffness [32, 85] which is linked to small vessel 
[32, 86–88], and platelet-derived EVs seem to be important players in the formation 
of cerebral microthrombi which lead to brain atrophy and consequent cognitive 
degeneration. It is believed that the prothrombotic nature of an elevated number of 
platelet-derived EVs reported in the acute phase of cerebral infarction may conduct 
to infarct progression [32, 84, 89, 90]. EV proteins cystatin C and CD14 have been 
shown to be related to cerebral white matter lesions and the progression of brain 
atrophy in patients with manifest vascular disease, suggesting a role for EVs in the 
etiology of structural brain changes [32].
The role of cardiovascular disease risk factors in the occurrence and progression 
of cognitive impairment is widely accepted. There is a link between elevated levels 
of cholesterol and amyloid deposition in the brain, and the relationship between 
atherosclerotic injury and sporadic Alzheimer’s disease is investigated.
5. Extracellular vesicles in neurodegenerative diseases
The pathology of Alzheimer’s disease (AD) consists in the extracellular amyloid 
plaques formed by aggregated amyloid beta peptides and in the intraneuronal 
neurofibrillary tangles made of hyperphosphorylated tau proteins [91]. The 
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accumulation of the proteins induces an apoptotic response with neuronal loss and 
occurs especially in the cerebral cortex [92].
It has been observed that the pathological findings in AD have a typical spatial 
distribution suggesting a neuron-to-neuron spread of the amyloid and hyper-
phosphorylated tau proteins, which promote aggregation, acting as “seeds” [93]. 
Therefore AD is considered to have a prion-like model of propagation [94]. The 
immediate question that rises is: what is the mechanism of the propagation?
Amyloid beta is mainly formed extracellularly from the cleavage of APP by 
beta and gamma secretases, which are found at the level of the plasma membrane 
[95]. But in some degree, the secretases are present in endoplasmic reticulum and 
Golgi apparatus, and there is a certain intracellular production of amyloid beta 
[96]. It is removed from the cell via exosomes embedded in a multivesicular body 
as an alternative pathway to lysosomal degradation [97]. A new study suggests that 
exosomes containing amyloid beta are present in higher concentrations in the AD 
brain compared to the healthy brain [98]. Moreover, the study shows that exosomes 
are the carriers of the toxic amyloid beta from one neuron to another [98]. Also, 
it is thought that exosomes mediate the intercellular transfer of hyperphosphory-
lated tau protein, and the exosome-mediated tau protein induces the formation of 
neurofibrillary tangles [99].
The evolution of AD is insidious with an asymptomatic stage that lasts several 
years [100]. Although asymptomatic, the pathological changes in the brain are 
present in this stage [93]. These findings suggest the value of discovering biomark-
ers that can anticipate the onset of the clinical symptoms or can facilitate a window 
for the possibility of a future therapy that could stop the progression. Amyloid beta 
and hyperphosphorylated tau proteins are of great value as biomarkers when dosed 
from the cerebrospinal fluid [101]. Nevertheless, performing lumbar puncture in a 
wide population is almost impossible. Thereby, the discovery of new biomarkers is a 
valuable research theme.
Several types of miRs isolated from cerebrospinal fluid are differentially 
expressed in AD, such as miR-100, miR-146, miR-505, and miR-1274a [102]. The 
presence of several types of exosomal miRs isolated from serum (miR-361-5p, 
miR-93-5p, miR-335-5p, and miR-30e-5p) correlates with the neuropsychological 
evaluation and brain imaging [103]. It is to be mentioned that exosome-containing 
proteins like tau, apolipoprotein E, cystatin E, and HSP-90 alpha were isolated in 
the cerebrospinal fluid and were present in patients with AD [104]. This evidence 
proposes both miRs and protein-containing exosomes as a promising source of 
biomarkers for AD.
Parkinson’s disease (PD) is a neurodegenerative disease that consists in the loss 
of dopaminergic neurons localized in the substantia nigra [105]. The pathology of 
the disease implies the deposition of Lewy bodies in the neurons which are mostly 
made of misfolded and aggregated alpha-synuclein protein [105]. The Braak staging 
explains the spatio-temporal dissemination of Lewy bodies into the neurons from 
caudal to rostral, starting in the medulla oblongata and spreading to the level of 
the cerebral cortex, damaging various structures on this way [106]. The starting 
point is thought to be either the enteric nervous system or the olfactory bulb [106]. 
Thereby, it is suggested that PD has a prion-like propagation [94]. Are exosomes 
responsible for carrying alpha-synuclein from neuron to neuron? The mechanism 
could be similar to the one described in AD, but there are fewer studies to draw 
certain conclusions regarding the involvement of exosomes in the pathogenesis of 
PD. Excessive intracellular alpha-synuclein is thought to be transported out of the 
cell via multivesicular body containing exosomes in a similar manner as in AD in an 
attempt to clean the intracellular space [107].
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Studies of neuronal cell cultures expressing alpha-synuclein noticed that the 
protein is released by the cell free in the extracellular space but also incorporated 
in the exosomes [108]. Furthermore, neighboring cells take up the exosomes, and 
the transferred alpha-synuclein acts as seed for the formation of the aggregate 
[109]. Evidence to prove that in vivo alpha-synuclein is transferred by exosomes is 
not available yet, but it can be speculated that exosomes play an important role as 
in vitro.
The use of EVs as a biomarker tool in PD is a promising field too [110]. Several 
miRs carried by exosomes were increased in the CSF of PD patients, such as miR-
10a-5p, miR-153, and miR-409-3p, while some miRs such as miR-19b-3p and miR-1 
were significantly reduced [111]. Exosomes containing alpha-synuclein and LRRK 
proteins were also isolated in the CSF of PD patients [109, 112].
6. Extracellular vesicles’ perspective use in brain pathology
The discovery of the EV involvement in several biological processes gave hope 
that some questions regarding neurodegenerative diseases will be answered. First of 
all, it is important to clarify which are the cellular mechanisms involved in the pro-
gression of the disease and if exosomes play any role. Based on the spatio-temporal 
spreading of the pathological proteins in the brain, an appealing theory is the prion-
like propagation theory [113]. It is presumed that exosomes play an important role 
by facilitating the interneuronal transport of the proteins [114]. As well, there is a 
critical need in finding accessible biomarkers that can diagnose a neurodegenerative 
disease in the asymptomatic stage [115]. Dosing certain free proteins in biofluids 
can be an option, but several problems are experienced because of their low concen-
trations [115]. Therefore, a new approach is being attempted consisting in finding 
the proteins encapsulated in extracellular vesicles [116]. Micro-RNAs and different 
proteins carried by exosomes are attractive options for finding new biomarkers in 
several diseases as well as in neurodegenerative diseases [117].
Recently, it was discovered that an important player in the field of neural 
diseases is EV derived from stem cells [118], mainly in the case of stroke [118–120]. 
In stroke pathophysiology, inflammation plays a significant role, circulating 
EV-activating immune cells. Neurons quickly depolarize and die, being next phago-
cytosed by infiltrating circulating macrophages and microglia [84, 121].
Because of their β1 and α2b integrin-enriched content, human neural stem 
cell-derived EV administration recovers both tissue and sensorimotor function and 
may protect the BBB integrity, in the preclinical mouse thromboembolic model 
of stroke [122, 123]. Similarly, multipotent mesenchymal stromal cells (MSCs), 
through their capacity to secrete soluble factors, play an important role in brain 
repair. It was demonstrated that MSC cargos modulate cell signaling in ischemic 
stroke by PI3K/Akt pathway activation [123, 124] and EVs facilitated secretion of 
miRs sustaining MSC neuroprotective effects in ischemic stroke as well. Previous 
research demonstrated that intravenous administration of bone marrow-MSCs 
containing exosomes transferred miR-133b to astrocytes and neurons into the 
ischemic boundary zone [120, 123], and MSCs cultured in the presence of extracts 
from rat ischemic brain induced increased expression of exosomal miR133b [123, 
125]. Also, EVs released by human MSCs seem to have an anti-inflammatory effect 
on mast cells, by increased prostaglandin E2 (PGE2) synthesis and up-regulation of 
EP4 receptor which might prevent the rupture of intracranial aneurysms [126]. All 
these data suggest that EVs from various sources may contribute to the neurogenesis 
and angiogenesis during brain repair processes in cerebral diseases.
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7. Conclusion
The EVs emerge as a powerful tool for early diagnosis and subsequent preven-
tion of pathologies with high risk for the brain dysfunction. Still, EVs investigation 
as biomarkers and therapeutic agents is in its infancy. There is increasing evidence 
that EVs have an important role in brain pathophysiology. Thus, their potential 
application as prognostic and diagnostic biomarkers and targeted therapeutic tools 
relies on their subsequent isolation for molecular and functional characterization 
that can relate them with the cellular source and cellular mechanisms in both health 
and disease.
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